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General Hypothesis 
 
 The essential roles of insulin and serotonin in the hypothalamic regulation of energy 
balance have been well established. When insulin resistance occurs, in the case of type 2 
diabetes for example, the stimulation of the PI3K/Akt signaling pathway in the 
hypothalamus is attenuated, and the biological effects of this activation are altered. 
Serotonin can trigger this signaling cascade in the hippocampus and neuronal cell lines, 
as it has been shown by several studies.  However, it is yet to be investigated if serotonin 
activates this pathway in the hypothalamus too and if this activation is affected by insulin 
resistance. 
Therefore, we hypothesized that serotonin may activate the PI3K/Akt pathway in the 
hypothalamus and that a potential cross-talk between insulin and serotonin signaling exists in 
this brain region. 
The methodology used to address this hypothesis and the results obtained are described in 
details in the first research article included in this thesis. 
 
 Cumulative research studies indicate a bidirectional association between the metabolic 
syndrome, including type 2 diabetes, and depression. Serotonin deficiency and/or 
impaired action are considered among the main causes of depression. The main target 
for the treatment of this pathology is the serotonergic system especially in the 
hippocampus.   
Thus, we postulated that insulin and leptin resistance that occur in patients with metabolic 
syndrome could affect the efficiency of serotonergic function in the hippocampus most possibly 
via a cross-talk involving the PI3K/Akt/GSK3β signaling cascade. 
The methodology used to address this hypothesis and the results obtained are described in 
details in the second research article which is in preparation and included in this thesis. 
  
  
 
INTRODUCTION 
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CHAPTER 1 
 
Type II diabetes, obesity and depression 
 
1.1. Type 2 Diabetes Mellitus (T2D) 
Type 2 diabetes (T2D) (or non-insulin-dependent diabetes) is a major global 
epidemic that increased with a very high rate these last decades, and is predicted to be 
exacerbated in the decades to come (Chen et al., 2012a). In 2010, 285 million adults 
(6,4% of world population) were suffering from diabetes, 90% of them from T2D, and in 
2030 they are expected to reach the 439 million adults (7,7% of world population) (Shaw 
et al., 2010). The prevalence of T2D worldwide is a result of a variety of genetic, 
epigenetic (Drong et al., 2012), sociological (Stringhini et al., 2012), environmental and 
behavioral factors (Chen et al., 2012a).  
Unlike Type 1 diabetes which is caused by the deficiency of insulin production due to 
autoimmune degeneration of insulin-producing cells, the pancreatic β-cells, T2D is 
characterized by insulin resistance (decreased insulin production and efficacy). In T2D 
patients, insulin is unable to increase glucose metabolism and to inhibit liver glucose 
production leading to hyperglycemia and subsequent hyperinsulinemia (Kahn, 1994). 
Thus, insulin plays a crucial role in the regulation of glucose homeostasis through its 
action in various  organs (liver, muscle, adipose tissue, brain, heart) and the impairment 
of insulin efficiency leads to a wide and complex spectrum of physiological 
dysregulations as those observed in patients with T2D (Konner and Bruning, 2012; 
Stumvoll et al., 2005). Consequently, insulin resistance not only impedes energy 
homeostasis maintenance but also correlates with numerous comorbidities including 
obesity (Drong et al., 2012), cancer (Fantus, 2011), cardiovascular disease (Ferrannini and 
Cushman, 2012), neurodegenerative diseases (Craft and Watson, 2004), and depression 
(Pan et al., 2012). 
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1.2. Obesity 
Obesity is a worldwide epidemic with more than 200 million men and 300 million 
women over the limit of Body Mass Index [BMI=body weight (kg)/ height2 (m2)] for 
obese. Obesity (BMI>30 kg/m2) and overweight (BMI between 25 and 30 kg/m2) are fifth 
in the list with the major death risk factors globally (WHO, 2008). In addition, people with 
a BMI in the overweight or obese spectrum exhibit higher risk for other pathologies such 
as type 2 diabetes (Garber, 2012; Sung et al., 2012), cardiovascular disease (Bogers et al., 
2007), cancer (Bray, 2002; Renehan et al., 2006) and musculoskeletal disorders (Wearing 
et al., 2006). Obesity is a multifactorial disease involving epigenetic and/or genetic 
factors (Drong et al., 2012; Ramachandrappa and Farooqi, 2011), life style, and, 
environmental and social factors (Malik et al., 2013; Papas et al., 2007). 
Most cases of obesity are characterized by hyperleptinemia and leptin resistance, 
constituting a vicious cycle resulting in the impairment of leptin-dependent food intake 
inhibition (and leptin-dependent energy expenditure) leading to exacerbated body 
weight gain and stronger leptin-resistance (Konner and Bruning, 2012; Myers et al., 
2010).  
1.3. Depression (or Major Depressive Syndrome, MDS) 
Over 350 million people worldwide are suffering from depression, which is the 
leading cause of disability (WHO, 2012). Depression is a complex pathology and very 
difficult to characterize due to its highly variable course, inconsistent patient response to 
treatment and no clear established mechanism (Belmaker and Agam, 2008). The most 
convincing theory about the establishment of depressive behaviors is the monoamine-
deficiency theory. According to this theory insufficient neurotransmission or sensitivity of 
the monoamines serotonin and noradrenaline can cause depressive syndromes 
(Belmaker and Agam, 2008). Indeed, pharmacological increase of these monoamines at 
the synapse by selective reuptake inhibitors (SSRIs/SNRIs) improves depressive like 
symptoms (Mendels, 1987; Papakostas et al., 2007). In addition, polymorphisms on the 
gene that encodes serotonin transporter (SERT) (Caspi et al., 2003) and the gene that 
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encodes the principal enzyme for serotonin biosynthesis, the tryptophan hydroxylase-2, 
(Zhang et al., 2005) have been associated to depression. 
1.4. Type 2 Diabetes, Obesity and Depression  
Numerous studies have demonstrated the association between type 2 diabetes and 
obesity which is attributed primarily to the common signaling pathways of insulin and 
leptin (Belgardt and Bruning, 2010; Benomar et al., 2005a; Benomar et al., 2005b; Eckel et 
al., 2011; Kahn et al., 2006; Konner and Bruning, 2012). Moreover, the metabolic 
syndrome (which includes diabetes and obesity) and depression were shown to 
bidirectionally correlate in a meta-analysis of epidemiological studies (Pan et al., 2012). 
Another meta-analysis study gave strong evidence (80% of the studies) that obesity is 
associated with increased development of depression and a moderate possibility (53% of 
the studies) of depression being a risk factor of installation of obesity (Faith et al., 2011). 
Finally, other epidemiological studies reported that patients with T2D have 24% more 
risk of developing depression in comparison to healthy individuals (Nouwen et al., 2010). 
Taken together, these findings suggest a strong link between these pathologies. The 
cross-talk between insulin and leptin signaling pathways revealed many possible 
mechanisms that can explain the association between T2D and obesity. However, the 
mechanisms that underlie the connection between T2D and depression as well as obesity 
and depression are not clearly understood. Serotonin could be the missing component 
linking obesity/T2D and depression. Indeed, serotonin, a molecule that plays an 
important role in depression, has also been found to regulate body weight and glucose 
homeostasis by targeting similar neural circuits as insulin and leptin (Williams et al., 
2011). So far, no mechanism has been proposed on how serotonin interacts with the 
other two hormones to coordinate the overall regulation of energy homeostasis. 
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CHAPTER 2 
 Insulin 
2.1. General 
Insulin is a small peptide hormone (51 amino acids) which regulates glucose 
metabolism and many other physiological functions. The word “Insulin” derives from the 
latin word “insula”, which means island, and it is the English transfer of the first version in 
french “insulin”. 
Insulin was successfully extracted and functionally injected (in dogs) for the first time 
in 1921 by Banting and Best (Banting et al., 1922). The first injection of a human diabetic 
patient was performed the following year  (Roth et al., 2012). It was the first protein to 
have its sequence (1951) and tertiary structure (1969) discovered. Since its discovery, it 
has been a leading molecule for the establishment of many techniques such as 
radioimmunoassay. 
2.2. Production and Secretion 
Insulin is synthesized and secreted by the β-pancreatic cells of the islets of 
Langerhans. When β-cells are stimulated by circulating metabolites (mainly glucose and 
amino acids), hormones or by the vagus nerve, they secrete insulin into the portal vein 
and then to the general blood circulation (Goodman, 2009).   
Insulin production in the brain has been also demonstrated but it has been a subject 
of debate and controversy for a long time (van der Heide et al., 2006). A recent article 
showed that insulin is produced in neurons ending this long lasting debate (Mehran et 
al., 2012).  
2.3. Degradation 
Depletion of circulating insulin is an important biological step due to its role in the 
maintenance of blood glucose levels. Degradation of insulin is catalyzed by a protease, 
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the insulin-degrading enzyme (IDE). Although IDE is expressed in all insulin sensitive 
tissues, almost all insulin clearance occurs in liver and kidney (Duckworth et al., 1998).  
2.4. Gene, Biosynthesis and structure 
Human insulin is encoded by the INS gene located at the genetic locus 11p15.5 
(Harper et al., 1981) and its sequence was cloned in 1980 by Bell et al. (Bell et al., 1980). 
In rats there are two insulin genes ins1 and ins2 (Cordell et al., 1979).  
The product of this gene is preproinsulin, a 110 amino acid polypeptide. (Chan et al., 
1976; Steiner et al., 1967). This preliminary molecule undergoes cleavage of the 24 amino 
acid N-terminal signal-peptide by signal-peptidase enzymes and oxidative folding with 
the formation of disulfide bonds in the ER. These post-transcriptional modifications 
result in the more stable and main insulin precursor molecule, proinsulin (Eskridge and 
Shields, 1983). Finally, proinsulin molecules translocate to the Golgi apparatus where it 
get packed into secretory vesicles and subjected to maturation. The C-peptide is 
protease-cleaved by a prohormone convertase and carboxypeptidase E to produce 
mature insulin.(Docherty et al., 1989; Naggert et al., 1995).  
 
Figure 1: Protein sequence and structure of preproinsulin (Stoy et al., 2007). 
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Insulin is a globular protein/peptide and one of the smallest functional known 
proteins. This 51 amino acid peptide hormone has a molecular weight of 5.8 KDa and 
consists of two chains; A-chain (21 amino acids) and B-chain (30 amino acids). Three 
disulfide bonds contribute to the formation of the insulin molecule, two between A- and 
B-chains (A7-B7 and A20-B19) and one intra-A-chain (A6-A11). The crystal structure of 
this protein has been described as monomer, dimer or hexamer (Hua, 2010).  
2.5. Insulin Signaling 
2.5.1. Insulin Receptor (IR) 
Human insulin receptor cDNA was first cloned by two independent groups in 1985 
(Ebina et al., 1985; Ullrich et al., 1985) and the discovery of its sequence and promoter 
was published few years later (Seino et al., 1989). The insulin receptor gene (InsR) 
encodes 22 exons and 21 introns (Seino et al., 1989). Two different isoforms of insulin 
receptor, IRA (predominantly expressed in fetal and cancer tissues) and IRB, due to 
alternative splicing of exon 11 have been discovered, with IRA (which lacks exon 11) 
having higher affinity and dissociation rate to insulin (Knudsen et al., 2011) .  
Upon translation of the INSR gene the resulting precursor undergoes glycosylation 
and cleavage of a 27aa signal peptide in the ER (Ullrich et al., 1985). The occurring 
proreceptor gets further maturation by the chaperones calexin and calreticulin which 
includes glycosylation, folding and dimerization. Finally, it translocates to the Golgi 
apparatus and after proteolysis by furin-protease, a tetraheterotramer is formed 
consisting of two α and two β subunits (Bass et al., 1998).  
Insulin receptor along with insulin-like growth factor-I receptor (IGF-IR) receptor belong 
to the Class II Receptor Tyrosine Kinase (RTKs) family (van der Geer et al., 1994).  IR is a 
stable heterotetramer formed by two α (~130 kDa ) and two β  (~95-97 kDa) subunits 
linked by disulfide bonds (Sweet et al., 1987). The α subunits are extracellular and carry 
the two insulin binding sites, one on the carboxy-terminal α-chain (αCT) domain and one 
on the leucine-rich-repeat domain 1 (L1) domain of the receptor, which interact with the 
α and β chains of insulin respectively (Menting et al., 2013). The β subunits are 
 
7 
 
transmembrane and carry at their C-terminal an endogenous tyrosine kinase (De Meyts 
and Whittaker, 2002). In addition, several key tyrosine residues (Tyr1158/ Tyr1162/ Tyr1163) 
involved in initiating insulin signaling are located in the β subunits (Tavare et al., 1991; 
Zhang et al., 1991). IR mediates the ligand binding effects via activation of its 
intracellular related proteins whereas other RTKs directly interact with the intracellular 
signal transduction molecules (Ullrich and Schlessinger, 1990). One IR αβ-component 
can also couple with IGF-IR αβ-subunit and form a chimeric receptor where IGF-I binds 
with higher affinity then insulin (De Meyts and Whittaker, 2002; Soos et al., 1993). IGF-I 
and IGF-II can bind and activate IRA/IGF-IR and IRB/IGF-IR hybrids with high affinity to 
regulate cell proliferation and migration whereas insulin has very low affinity for both 
(Benyoucef et al., 2007). Overall, the formation of IR/IGF-IR hybrids favors the action of 
IGF-I and promotes proliferation- and development. In many types of cancer cells this 
type of hybrid receptor is the predominant form expressed (Belfiore et al., 2009).  
 
Figure 2: Insulin Receptor structure (De Meyts and Whittaker, 2002) 
a) left half: the 22 exons of the insulin-receptor gene, right half: protein modules 
b) supra-domain organization of the insulin receptor. 
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Insulin binding to IR induces a conformational change to the receptor which leads 
to trans autophosphorylation of the tyrosine kinase domains (Tyr1158/ Tyr1162/ Tyr1163) 
(Hubbard, 1997). The phosphorylated tyrosine residues of the insulin receptor serve as 
docking sites for PH domains and phosphotyrosine-binding domains (PTB domains) 
(Myers et al., 1995; Wolf et al., 1995). These interactions induce activation of the 
downstream proteins which in turn trigger respective signaling cascades, such as PI3K/ 
Akt and Ras/MAPK pathways (Taniguchi et al., 2006). 
 
Figure 3: Insulin interaction with Insulin receptor (Menting et al., 2013). 
 
2.5.2. Substrates  
a. Insulin Receptor Substrates (IRS) 
The IRS protein family contains 6 members (IRS1-6). IRS-1 and -2 are widely 
expressed in mammalian cells whereas the expression of IRS3, IRS4, IRS5 and IRS6 is 
limited to specific tissues (Taniguchi et al., 2006). Once the receptor is activated, IRS 
binds to the phospho-tyrosine residues of the JM domain and membrane phospholipids 
with the N-terminus PTB and PH domains respectively (Eck et al., 1996; He et al., 1996; 
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O'Neill et al., 1994). Consequently, phosphorylated tyrosine residues of IRSs serve as 
docking sites for downstream signaling molecules containing SH2 domains such as: the 
p85 regulatory subunit of PI3K (Myers et al., 1992) and growth-factor-receptor-bound 
protein-2 (Grb2) which interacts with son-of-sevenless (SOS) (Myers et al., 1994; Skolnik 
et al., 1993). Subsequently, these interactions promote the activation of the PI3K/Akt and 
the Ras/MAPK signaling pathways, respectively (Taniguchi et al., 2006).  
b. Src-homology-2-containing proteins (Shc) 
The Shc family contains four members Shc⁄ShcA, ShcB⁄Sli, ShcC⁄Rai⁄N-Shc, and 
ShcD⁄RaLP (Finetti et al., 2009). The three isoforms of ShcA p46, p52 and p66 (Pelicci et 
al., 1992), after binding to the PTB domain of IR, induce the triggering of Ras/MAPK 
pathway via Grb2 (Kim et al., 1998) or its inhibition (p66) (Xi et al., 2010). Upon its 
activation, Grb2 recruits and activates Ras which will subsequently induce the activation 
of the cascade Raf, MEK, ERK1/2 (Rozakis-Adcock et al., 1992). Shc proteins compete 
with IRS proteins for the PTB-binding domain of the IR (Gustafson et al., 1995; Wolf et al., 
1995). 
c. Other substrates and interacting proteins 
Other IR interacting proteins are GRB2-associated-binding protein 2 (GAB), 
downstream of kinases (DOKs), APS/SH2B, Cas-Br-M (murine) ecotropic retroviral 
transforming sequence homologue (Cbl) and CT10 regulator of kinase (Crk) (Siddle, 
2012). APS and Cbl form a complex which binds to the tyrosine phosphorylated IR via 
the PH domain of APS. This binding induces tyrosine phosphorylation of Cbl which leads 
to the recruitment of Crk and the guanine nucleotide exchange factor (GEF) C3G in 
proximity to the membrane, where C3G activates the TC10 and thus provokes the 
translocation of glucose transporter 4 (GLUT4) to the plasma membrane (Leto and 
Saltiel, 2012). Additional molecules that interact with IR but do not undergo tyrosine 
phosphorylation are JAK2, Grb7/10/14 adaptors, Receptor of activated protein kinase C 1 
(RACK1), integrins, β-arrestin and cytohesins (Siddle, 2012). 
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2.5.3. Negative regulators of Insulin Signaling 
In addition to regulation of the PI3K/Akt (Chapter One) insulin signaling can also 
be modulated at the level of IR and its substrates. IRS serine/threonine phosphorylation 
by downstream kinases (aPKC, AKT, mTOR, S6K1, ERK1/2, ROCK1, AMPK, GSK3, JNK, 
IKKβ)  feedback regulation induces inhibition of their function (Copps and White, 2012). 
a. Protein tyrosine phosphatase 1B (PTP1B)  
PTP1B is a 50 kDa phosphatase which contains a catalytic domain at the N-
terminal, a C-terminal ER targeting site and two proline rich domains (PRDs) which are 
important for protein-protein interactions (Yip et al., 2010). PTP1B is one of the main 
modulators of the insulin signaling pathway due to the ability to inhibit both IR and IRS 
(Goldstein et al., 2000; Salmeen et al., 2000). The catalytic domain of PTP1B binds with 
high affinity to the phosphorylated Tyr1162 residue of the activated IR and this interaction 
results in the dephosphorylation of this pY residue and inactivation of IR (Salmeen et al., 
2000). Dephosphorylation of IRS impairs its binding with Crk, GRB2, SHP-2, and the p85 
subunit of PI3K (Goldstein et al., 2000). Further, the action of PTP1B reduces the binding 
affinity of the complex Crk/C3G (Okada et al., 1998) and regulates GLUT4-mediated 
glucose transport induced by insulin (Chen et al., 1997). PTP-1B−/− and PTP-1B+/− mice 
have are more insulin-sensitive than wild type littermates and resistant to high fat diet-
induced obesity and insulin resistance (Elchebly et al., 1999). 
b. Suppressor of cytokine signaling-3 (SOCS3) 
SOCS3 is a member of the SOCS family which includes 8 members (SOCS1-7 and 
CIS) with similar structure containing a C-terminal SOCS-Box domain and a SH2 domain 
in the center. The SH2 domain serves as binding site to phosphotyrosine residues (Starr 
and Hilton, 1998). Insulin signaling activation induces SOCS3 expression (Emanuelli et al., 
2000) and activation (Peraldi et al., 2001). Suppressors of cytokine signaling (SOCS), 
SOCS1 and SOCS3, negatively regulate insulin signaling by blocking IRS tyrosine 
phosphorylation (Ueki et al., 2004), inducing IRS degradation (Rui et al., 2002) and 
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inhibiting IR kinase activity (Lebrun and Van Obberghen, 2008). Mice lacking SOCS3 in 
skeletal muscle are protected against high fat diet-induced hyperinsulinemia and insulin 
resistance(Jorgensen et al., 2013). Similarly, neuron-specific deletion of SOCS3 prevented 
the induction of hyperinsulinemia and insulin resistance by high fat diet consumption 
(Mori et al., 2004). 
 
 
 
Figure 4: Insulin signaling map. 
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2.6. Actions 
2.6.1. Periphery 
a. Liver 
Liver plays a crucial role in overall glucose homeostasis and the alteration of liver 
insulin responsiveness (as in insulin-resistant state or type 2 diabetes) leads to increased 
liver glucose production promoting hyperglycemia. It is well established that insulin 
plays a key role in liver glucose metabolism by balancing glucose input and output 
through the inhibition of gluconeogenesis and the activation of glycogen synthesis. 
Indeed, following meal, glucose is transported via GluT2 (an insulin-independent Glucose 
transporter) into hepatocytes to be stocked as glycogen or subjected to metabolic 
modifications to be exported as triglycerides exported into VLDL. Insulin regulates these 
processes mainly at the gene expression levels. The activation of insulin signaling 
pathways down-regulates PEPCK expression (key enzyme of gluconeogenesis). Insulin 
function in the liver mediates blood glucose regulation. Upon glycaemia increase, 
glucose uptake by the liver follows via the glucose transporter 2 (GLUT2). GLUT2 
mediates also glucose release from hepatocytes under hypoglycemic conditions. Insulin 
acts on the liver via its pathway to induce glucose metabolism. Concurrently, insulin 
inhibits hepatic glucose production. In addition, activation of the IR/IRS/PI3K/Akt 
pathway in the liver regulates activity and synthesis of intracellular enzymes. Besides 
glucose metabolism and glycogen synthesis, this action results to impairment of 
glycogenolysis, gluconeogenesis, lipolysis, ureogenesis, and ketogenesis and to 
promotion of lipogenesis and protein synthesis (Goodman, 2009).  
b. Muscle 
Insulin action in muscle promotes glucose uptake, phosphorylation and finally 
storage via transformation into glycogen. Glucose internalization in myocytes is 
facilitated by insulin induced GLUT4 membrane translocation. In addition, insulin 
decreases protein degradation by inhibiting protease expression and activity. Moreover, 
stimulation of the IRS/ PI3K/ Akt pathway augments protein synthesis by increasing 
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amino acid uptake from the blood via carrier  molecules and translation via activation of 
translation initiation factors 2 and 4 (eIF2, eIF4)  (Goodman, 2009).  
c. Adipose tissue 
Insulin action in adipocytes is multilateral including glucose uptake and 
transformation to long chain fatty acids or glycogen, esterification, lipolysis and fatty 
acid uptake from lipoproteins. As in muscle, glucose uptake in adipocytes is mediated by 
insulin-activated GLUT4 recruitment (Goodman, 2009). In adipocytes, insulin signaling 
pathway can also transcriptionally and post-transcriptionally regulate the production of 
leptin, a cytokine produced by this tissue (Lee and Fried, 2009).  
2.6.2. Central nervous system 
Once thought to be an insulin insensitive organ, the brain has been well 
demonstrated to be an essential target of insulin. After pancreatic secretion, this 
hormone reaches the brain by crossing the blood brain barrier and regulates a wide 
spectrum of cerebral and peripheral functions, the study of which has acquired excessive 
research attention for many decades now. In addition to glucose metabolism, energy 
homeostasis and food intake brain insulin action regulates also reproduction, behavior, 
mood, cognition, neuronal survival, synaptic plasticity, neuronal circuit formation and 
BBB function. As in hepatocytes, myocytes and adipocytes, insulin binds to IR expressed 
by neurons and triggers the activation of downstream signaling cascades.  Among the 
multiple cellular functions, glucose uptake and metabolism, protein synthesis and 
degradation, gene expression and translation are the most essential ones found to be 
largely regulated by insulin action. 
a. Insulin Receptor and signaling in the brain  
Insulin receptor is abundantly distributed in the mammal brain. However, the 
density of the receptor varies among different brain regions (Havrankova et al., 1978; 
Schulingkamp et al., 2000) and is reduced with ageing (Zhao et al., 2004). IR is more 
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predominantly expressed in the olfactory bulb, cerebellum, hippocampus, cortex, choroid 
plexus and the hypothalamus (Marks et al., 1990; Zhao et al., 1999). Both neurons and 
glial cells express IR (Lowe et al., 1986). Brain insulin receptor exhibits both structural and 
functional differences with the one found in peripheral organs. The molecular weight and 
carbohydrate composition of both α and β chains of the IR are found to be lower in the 
brain in comparison to the periphery (Heidenreich et al., 1983). Glial IR β subunit is 
bigger than the neuronal one and smaller than the one found in the liver (Lowe et al., 
1986). Moreover, unlike peripheral IR, brain IR is not down-regulated when exposed to 
chronic hyperinsulinemic conditions (Zahniser et al., 1984). 
The primary step upon IR activation is the tyrosine phosphorylation of its 
substrates IRS and Shc. In turn, PI3K/Akt and Ras/ERK signaling pathways are triggered 
transforming the insulin signal into cell process regulation (Kim and Feldman, 2012). 
b. Hypothalamus 
Insulin signaling in the hypothalamus is known to modulate hepatic glucose 
production (Obici et al., 2002b), food intake, fat mass, hepatic insulin sensitivity (Obici et 
al., 2002a), reproduction (Hill et al., 2010) and behavior (Grillo et al., 2011). Three 
neuronal subpopulations (POMC, Agrp/NPY, RIP) in the arcuate nucleus (ARC) and one 
(SF-1) in the ventromedial (VMN) hypothalamic nucleus are found to mediate the 
metabolic effects of hypothalamic insulin signaling (Grayson et al., 2012; Rother et al., 
2012). 
i. The Arcuate Nucleus (ARC) 
The arcuate nucleus is located at the mediobasal hypothalamus in proximity to the 
third ventricle and the median eminence, a circumventricular organ (Paxinos and 
Watson, 2005). The position of ARC is thus optimal for reception and integration of 
peripheral signals such as circulating hormones by the neurons situated in this area. 
Inside the ARC two principal neuronal populations that play an important role in the 
maintenance of energy homeostasis are targeted by insulin, the anorexigenic POMC and 
the orexigenic Agrp/NPY (Lin et al., 2010). More recently, another distinct subpopulation 
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of neurons in the ARC, the rat insulin promoter-expressing (RIP) neurons was reported to 
be targeted by insulin (Rother et al., 2012).  
The first population of neurons produces the 31-kD precursor protein 
proopiomelanocortin (POMC) (Mountjoy, 2010). The main product of this protein in the 
ARC, among many products, is the α-melanocyte-stimulating hormone (α-MSH), a 13 
amino-acid neuropeptide (Mountjoy, 2010). α-MSH acts as an agonist of the G protein 
coupled receptor (GPCR) melanocortin receptors types 3 and 4 (MC3R and MC4R) (Lu et 
al., 1994). Stimulation of MC4R by α-MSH in the brain leads to suppression of food 
intake (Balthasar et al., 2005) and increase of peripheral functions such as energy 
expenditure, hepatic and muscular insulin sensitivity and insulin production (Fan et al., 
2000; Mountjoy, 2010; Rossi et al., 2011). These effects are initiated via POMC projections 
to other hypothalamic nuclei such as PVN, VMN and the lateral hypothalamic area (LHA) 
as well as the preganglionic neurons of the spinal cord that express melanocortin 
receptors (Jacobowitz and O'Donohue, 1978; Mountjoy et al., 1994). Insulin binding to IR 
expressed by these neurons induces two parallel effects. Firstly, insulin action generates 
activation of the PI3K (Xu et al., 2005), which results in increased PIP3 levels and 
subsequent opening of ATP-dependent potassium (KATP) channels (Plum et al., 2006). 
Thus, insulin action on POMC neurons induces their hyperpolarization and inhibition of 
their excitability (Williams et al., 2010). Interestingly, upon insulin-induced activation of 
Akt, FOXO1 is phosphorylated and translocated from the nucleus to the cytoplasm. This 
effect prevents the FOXO1-mediated inhibition of POMC gene expression, increasing this 
way the intracellular levels of this protein and its derivative neuropeptides (Belgardt et 
al., 2008). However, deletion of IR from POMC neurons has no effect in energy 
homeostasis (Konner et al., 2007). Re-expression of IR in POMC neurons demonstrated 
that insulin action in these neurons increases hepatic glucose production (HGP) and 
energy expenditure (Lin et al., 2010). 
The second subgroup, Agrp/NPY, consists of neurons that co-express two 
anorexigenic peptides: the Agouti-related protein (Agrp) and the Neuropeptide Y (NPY) 
(Hahn et al., 1998). Agrp is an antagonist of MC3R and MC4R and thus antagonizes the 
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anorectic action of α-MSH, introducing the opposite effect which is hunger (Lu et al., 
1994; Ollmann et al., 1997; Rossi et al., 1998). NPY is a 36-amino-acid neuropeptide 
(Tatemoto, 1982) which initiates orexigenic action via activation of Y1 (Mullins et al., 
2001; Pedrazzini et al., 1998) and Y5 (Cabrele et al., 2000) receptors. Similarly to POMC 
neurons, insulin acts via its receptor to activate PI3K (Xu et al., 2005). This stimulation 
leads to hyperpolarization of these neurons via activation of KATP-channels, in a 
mechanism analogous to the one in POMC (Konner et al., 2007). FOXO1 promotes the 
expression of both Agrp and NPY and is blocked by insulin action via activation of the 
PI3K/Akt pathway (Kim et al., 2006). In addition, insulin signaling activation in this 
neuronal subgroup is necessary for the suppression of HGP (Konner et al., 2007; Lin et 
al., 2010). 
The RIP-expressing neurons have been recently identified as important regulators of 
energy homeostasis. They have been found to produce neither NPY nor POMC, but to 
exhibit orexigenic properties, since their ablation results in hypophagy and reduced body 
weight (Rother et al., 2012).  
i. The Ventromedial Nucleus (VMN) 
The ventromedial nucleus of the hypothalamus (VMN) comprises cluster of 
neurons which are located in the mediobasal hypothalamus, proximate to the third 
ventricle and above the ARC (Paxinos and Watson, 2005). In this brain area, there is one 
specific neuronal group that expresses the nuclear receptor Steroidogenic factor 1 (SF-1), 
which plays a significant role in the development and function of the VMN (Ikeda et al., 
1995; Zhao et al., 2008). Insulin-induced activation of PI3K in SF-1 neurons results in 
opening of KATP-channels and inhibition of excitability (Klockener et al., 2011). In 
addition, IR/PI3K signaling in these cells contributes to impairment of glucose 
metabolism and increased weight gain (Klockener et al., 2011).  
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Figure 5: Hypothalamic action of insulin, leptin and serotonin in the VMN SF1 neurons and the 
Arcuate POMC and NPY/Agrp neurons. Modified from (Williams et al., 2011). Modifications: a) 
insulin inhibits SF1 neurons firing rate via activation of KATP channels (Klockener et al., 2011) and b) 
the depolarization of POMC neurons by 5-HT2C is induced via activation of TrpC channels (Sohn et 
al., 2011) and K
+
channel-mediated M-current inhibition (Roepke et al., 2012). 
 
c. Hippocampus 
Hippocampal regions display a high mRNA expression and protein levels of IR 
and insulin signaling machinery (Bondy and Cheng, 2004; Folli et al., 1994; Zhao et al., 
1999). Insulin action on hippocampal neurons regulates synaptic plasticity (Zhao et al., 
2004) by modulating the function of GABAergic (Wan et al., 1997) and glutamatergic 
receptors (Man et al., 2000; Martin et al., 2012), inhibits pyramidal cell firing (Palovcik et 
al., 1984) and induces neuroprotective effects (Hui et al., 2005; Sun et al., 2010).  
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d. Insulin, Blood Brain Barrier (BBB) and glucose uptake 
Pancreatic insulin can reach the CNS by crossing the blood-brain barrier with a rate 
of 0.5 µl*g-1*min-1. This rate varies depending on numerous conditions such as fasting, 
obesity and ageing. Insulin transport across the BBB is under the control of a saturable 
mechanism, which limits the hyperinsulinemic contagion of the brain when blood insulin 
increases significantly. Less than 1o/oo of intravenously injected insulin is found to enter 
the mouse brain. A transporter molecule is hypothesized to perform insulin transfer 
across brain endothelial cells which is yet to be identified (Banks et al., 2012). Insulin 
uptake varies between different regions. The brain structures with the most elevated BBB 
crossing are pons-medulla, hypothalamus, hippocampus, striatum, cerebellum, frontal 
cortex and parietal cortex (Banks and Kastin, 1998). 
Insulin effects on BBB include amino acid uptake (tyrosine and tryptophan), 
hormones uptake (leptin) and protein degradation (amyloid beta 1-42). Glucose uptake 
in the brain is overall an insulin-independent function. The principal fuel of the CNS 
reaches the brain by transportation through the BBB. This process is potentiated by 
GLUT-1 in a process separated from insulin action. Internalization of glucose by brain 
cells can be facilitated by GLUT-4 after insulin-induced stimulation. However, glucose 
uptake by neurons and glial cells is primarily a result of insulin-independent procedures 
via the GLUT-1, GLUT-3 and GLUT-5  (Banks et al., 2012).  
2.7. Insulin Resistance 
Insulin resistance is generally determined by the loss of sensitivity of targeted tissues 
to circulating insulin. More precisely, insulin responsive cells’ ability to react upon ligand-
receptor binding is perturbed and as a result the insulin-induced effects are reduced or 
impaired. This condition is associated with a number of pathologies including type 2 
diabetes mellitus (T2DM), obesity, metabolic syndrome, Alzheimer’s disease, Parkinson’s 
disease, depression and cardiovascular disease. 
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CHAPTER 3 
Serotonin (5-HT) 
3.1. General 
Although its existence and action on smooth muscle contraction was known 
already during the 19th century, serotonin was isolated for the first time in 1948 by 
Rapport and colleagues and was given this name due to its source, serum, and its ability 
to cause vasoconstriction to organs when released (Rapport et al., 1948). Few years later, 
this molecule was identified to be 5-hydroxytryptamine (5-HT) (Reid and Rand, 1952).  
3.2. Brain Serotonin 
Brain 5-HT is the subject of excessive research due to its role as a 
neurotransmitter. It was first discovered in the brainstem in 1964 by Dahlström and Fuxe 
(Dahlstrom and Fuxe, 1964). Being the most widely distributed neurotransmitter in the 
brain, it regulates a wide range of functions including behavior, cycle/wake cycle, mood 
and food intake. As a consequence, impairment of serotonergic production or signaling 
leads to a large spectrum of pathologies such as anxiety, depression, obesity and 
schizophrenia.  
3.3. Production and secretion 
Serotonin amounts in the brain are mainly originated from neuronal clusters 
located in the midline of the brainstem tegmentum. More precisely, the somata of the 5-
HTergic neurons are found in the nine raphe nuclei (B1-9), which are grouped in three 
major formations: the dorsal raphe (B6, B7), the median raphe (B9, B8, and B5) and the 
caudal raphe (B1-3). The axons of rostral 5-HTergic neurons project towards the 
forebrain (ascending projections) and reach numerous regions such as hippocampus, 
frontal cortex, striatum, hypothalamus and amygdala. Caudal 5-HT producing cells 
project to the cerebellum and spinal cord (descending projections). Two distinct types of 
5-HT axon terminals are found in the rat brain: fine axons which have tiny varicosities 
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(less than 1 µm in diameter) that vary in shape, and beaded axons which have large, 
spherical varicosities (typically 2-3  µm in diameter) connected by thin intervaricose 
segments (Kosofsky and Molliver, 1987).  
Serotonergic neuron activity is feedback regulated by 5-HT-targeted regions via 
other transmitters including glutamate, acetylcholine, GABA, noradrenaline and 
neuropeptides (Lesch and Waider, 2012). Along with other amines (including 
noradrenaline and dopamine), 5-HT is thought to “modulate” rather than “mediate” 
information exchange. This notably relies on the observations that, in contrast with 
neurotransmitters such as glutamate and GABA, which transit in neurons exhibiting high 
variability in firing rates and emitting sharply focused projections, 5-HT is released in a 
more tonic way (Jacobs and Formal, 1999) in disparate targets. 
 
Figure 6: Projections of serotonergic neurons to the spinal cord and periphery (B1-B3) and 
to forebrain (B4-B9). From Lesch and Waider. (Lesch and Waider, 2012). 
Despite its significance, brain 5-HT is only a minority in terms of quantity (~5% of 
total 5-HT body content). The largest amounts (~90%) of 5-HT in the body of Mammals 
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are produced, stored and secreted by the enterochromaffin cells of the gastrointestinal 
mucosa (Gershon and Tack, 2007). Serotonin production is also found in the pineal 
gland, where it represents the precursor of melatonin during the night, the 
neuroepithelial bodies of the lungs, the parafollicular cells of the thyroid (Gaspar et al., 
2003) and the cells of the intestinal myenteric plexus (Gershon et al., 1965). 
3.4. Biosynthesis and structure 
Serotonin belongs to the family of monoamines. It is small indolamine (MW 176.2 
g/mol) that derives from the enzymatic conversion of the amino acid tryptophan in two 
steps. The first and rate limiting step, the hydroxylation of tryptophan, is catalyzed by 
tryptophan hydroxylase (TPH, TPH1 and TPH2, which is more brain-specific) and leads to 
the production of 5-hydroxytryptophan (5-HTP). Aromatic L-amino acid decarboxylase 
(AADC) performs the second step, which involves the decarboxylation of 5-HTP. 
Transcriptional regulation of these enzymes controls the production of 5-HT by 
serotonergic neurons (Deneris and Wyler, 2012).  
 
Figure 7: Biochemical pathway of the synthesis of serotonin from tryptophan and its 
metabolism to 5-OH-Indole Aldehyde (5-HIAA). From E.C. Azmitia (Müller and Jacobs, 
2010). 
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3.5. Degradation and uptake 
Membrane-bound mitochondrial flavoprotein monoamine oxidase A (MAO) is the 
main enzyme that catalyzes the oxidation, and thus the degradation, of 5-HT. This 
enzyme, via oxidative deamination, converts 5-HT into 5-hydroxyindoleacetic acid (5-
HIAA), which is quickly removed from the organism by the urines (Huszti and Borsy, 
1968).  
Serotonin re-uptake from extracellular fluid into 5-HT terminals mainly occurs via 
high affinity uptake mediated primarily by the serotonin transporter (5-HTT/SERT) (Blackburn 
et al., 1967; Blakely et al., 1991; Daws, 2009). Other proteins that exhibit lower affinity but a 
high capacity for 5-HT uptake, such as the extra-neuronal monoamine transporter (EMT) 
and the organic cation transporters (OCT1-3), can ensure 5-HT uptake in non-neuronal 
cells, probably contributing to the 5-HT homeostasis (Baganz et al., 2008; Feng et al., 
2005; Gasser et al., 2006; Grundemann et al., 2002; Schmitt et al., 2003).  
3.6. Serotonin signaling 
3.6.1. Serotonin Receptors 
Serotonin receptors are grouped in 7 classes according to their function, structure 
and intracellular signaling properties. The 6 of them (1, 2, 4, 5, 6, 7) belong to the α-
group of rhodopsin of GPCRs, in the amine receptor cluster. The 5-HT3 receptor is an 
exception since it is a ligand-gated ion channel that belongs to the nicotinic 
acetylcholine receptor superfamily (Berumen et al., 2012; Fredriksson et al., 2003). The 6 
GPCR groups are separated according to the G-protein they couple to. The first group of 
receptors (5-HT1A-F) couples to Gi/o proteins, the second (5-HT2A-C) couples to Gq 
proteins, the receptors 5-HT4, 5-HT and 5-HT7 couple to Gs proteins. Finally, it is not yet 
clear which G-proteins interact with the 5-HT5 receptors (Raymond et al., 2001). 
a. Class 1 
Class 1 comprises five members: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F which 
couple to Gi/o proteins to inhibit the enzyme adenylate cyclase (AC) and decrease the 
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production of cAMP. 5-HT1C was removed from this group and placed to the second 
class as 5-HT2C. 
5-HT1A receptors are distributed ubiquitously in the brain. Presynaptic auto-
receptors are detected in the cell bodies and dendrites of serotonergic neurons of the 
raphe nuclei (Sotelo et al., 1990), which inhibit firing by hyperpolarization via activation 
of the G-protein-coupled inwardly rectifying K+ channels (GIRK) (Penington et al., 1993; 
Sprouse and Aghajanian, 1987). Postsynaptic 5-HT1A receptors are located in the 
forebrain, with higher density in the hippocampus (granule cells of the dentate gyrus) 
and the septum using a specific ligand, 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-
DPAT) (Pazos and Palacios, 1985).  
5-HT1B receptor is expressed throughout the brain and is found in higher 
concentrations in the basal ganglia, striatum and frontal cortex. It serves as axon terminal 
auto- or heteroreceptors (Hoyer et al., 2002). In situ hybridization and Northern blot 
analysis revealed its expression in other regions such as the septum, the ventral 
tegmental area, the colliculi, the hypothalamus and the hippocampus (Doucet et al., 
1995). 5-HT1B in axon terminals activation inhibits 5-HT and other transmitter release 
(Riad et al., 2000).  
5-HT1D, 5-HT1E and 5-HT1F receptors are expressed at very low levels in 
comparison to 5-HT1A and 5-HT1B and their role is not very well defined due to lack of 
specific ligands. 
b. Class 2 
Class 2 comprises 5-HT2A, 5-HT2B and 5-HT2C receptors, which couple positively to 
Gq/11. Due to its structural, functional and signaling transmission properties that resemble 
more to the ones of 5-HT2 receptor subtypes, 5-HT1C was reclassified in this group. They 
all couple to Gq/11 proteins to activate phospholipase C and stimulate the hydrolysis of 
membrane phospholipids, increasing in parallel the formation of inositol phosphates and 
diacylglycerol (Bockaert et al., 2006). 
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5-HT2A receptors are distributed throughout the brain, mainly in the cortex, 
striatum, and hippocampus. Their location can be on the soma, the dendrites or the 
axons of pyramidal neurons, interneurons and monoamine releasing neurons (Polter and 
Li, 2011). 5-HT2A receptors action has been found to oppose to the effects of 5-HT1A in 
some cases (Li et al., 2004b). 
5-HT2B receptor has been detected in the rat CNS in the following regions: 
cerebellum, lateral septum, hypothalamus and medial amygdala (Duxon et al., 1997). This 
receptor is also expressed peripherally where it plays an important role in the function of 
the cardiovascular system (Launay et al., 2002), the liver (Ebrahimkhani et al., 2011) and 
the intestine (Wouters et al., 2009). 
5-HT2C receptors, in rats, are exclusively expressed in the brain, the choroid plexus 
and the spinal cord (Canton et al., 1996). They are present in the cellular membrane as 
homodimers (Herrick-Davis et al., 2012) and this dimerization is necessary for their 
function (Herrick-Davis et al., 2005). In addition, the mRNA of this receptor undergoes 
editing and results in the production of numerous isoforms with altered affinity to 5-HT 
and function (Burns et al., 1997). 
c. Class 3 
5-HT3 receptors, previously called M-receptor of Gaddum and Picarelli, are Cys 
loop ligand-gated ion channels, similar to nicotinic acetylcholine (nACh) receptors, and 
exhibit distinguished structure and functions compared to other six classes (Lummis, 
2012). The 5-HT3 receptors are ligand-gated ion channels that trigger rapid neuronal 
depolarization and excitatory neurotransmission (Derkach et al., 1989) through Ca2+ 
(Hargreaves et al., 1994), Na+ and K+ flow (Malone et al., 1991). The two 5-HT3 subunits 
(A and B) form homo- and hetero-pentameric receptors but only the 5-HT3A subunit is 
functionally present in the CNS (van Hooft and Yakel, 2003). The use of specific 
radioligand revealed higher levels of binding in the brainstem, mainly in the solitary tract 
nucleus. In the forebrain, medium density was found in the olfactory bulb and various 
subnuclei of the amygdala (Gehlert et al., 1993). 
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d. Classes 4-7 
5-HT4 receptors are mainly expressed in the olfactory tubercle, the caudate 
putamen, the ventral striatum, the medial habenula and the hippocampus. They are   
both somatodendritically and axonaly localized (Vilaro et al., 1996). 5-HT4 receptors 
activate AC and increase cAMP (Dumuis et al., 1988). 
The 5-HT5 receptor class includes two receptors, 5-HT5A and 5-HT5B which are 
detected in higher density in the hippocampus (5-HT5B only in the CA1) (Erlander et al., 
1993; Matthes et al., 1993). 5-HT5A is expressed in astrocytes where it inhibits AC (Carson 
et al., 1996). However the signaling pathways activated by these receptors have not been 
clearly demonstrated to date (Berumen et al., 2012). 
5-HT6 receptors activate AC and are predominantly expressed in the brainstem 
and to lower extend in forebrain, cerebellum, intestine and heart (Plassat et al., 1993). 
5-HT7 receptors induce the production of cAMP by activating AC and are 
expressed in limbic areas, including hippocampal pyramidal cells (Ruat et al., 1993). It 
regulates a number of function including mood, thermoregulation, memory and sleep 
(Hedlund and Sutcliffe, 2004). 
 
Figure 6: Main signaling pathways induced by the activation of different 5-HT receptors. 
Modified from Laura Cristina Berumen and colleagues (Berumen et al., 2012). 
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Table 1: Coupling patterns of multiple classes of 5-HT receptors(Millan et al., 2008). 
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3.6.2. Activation of PI3K/Akt pathway by 5-HT 
Ligand-binding to 5-HT1A can induce the activation of the PI3K/Akt/GSK3 pathway 
in primary cultures of hypothalamic (Cowen et al., 2005) or rhombencephalic neurons 
(Druse et al., 2005) and in the hippocampus in vivo (Polter et al., 2012). 5-HT1A-induced 
activation of Akt is dependent on coupling with Gi proteins (Cowen et al., 2005; Hsiung 
et al., 2005). Activation of PI3K/Akt pathway by 5-HT1B has been reported in transfected 
human neuroblastoma cells (Leone et al., 2000). Agonists of 5-HT2A and 5-HT7A receptors 
were reported to activate Akt in PC12 cells (Johnson-Farley et al., 2005). 
3.7. Functions of 5-HT in the Central Nervous System 
Brain serotonergic system is associated with the regulation of a variety of centrally 
controlled functions including feeding behavior (Breisch et al., 1976; Heisler et al., 2003; 
Leibowitz and Alexander, 1998), mood (Fernandez and Gaspar, 2012), social behavior 
(Kiser et al., 2012), sleep (Monti, 2011), thermoregulation (Cryan et al., 2000; Docherty 
and Green, 2010), cognition and memory (Buhot, 1997; Buhot et al., 2000), reward (Hayes 
and Greenshaw, 2011), locomotion (Jordan et al., 2008) and pain (Bardin, 2011). 
Additionally, impairment of serotonergic activity in the brain has been associated with a 
wide spectrum of psychiatric diseases including depression (Belmaker and Agam, 2008), 
schizophrenia (Remington, 2008) and anxiety (Fernandez and Gaspar, 2012).  
3.7.1. Hypothalamic regulation of food intake 
Serotonergic innervation from the median and/or dorsal raphe to the 
hypothalamus has been reported via several techniques many years ago (Azmitia and 
Segal, 1978; Beaudet and Descarries, 1979; Steinbusch, 1981). One of the principal 
actions of 5-HT in the hypothalamus is the regulation of food intake and energy 
homeostasis (Donovan and Tecott, 2013). Hypothalamic infusion of fenfluramine, a drug 
that increases the availability of 5-HT at the synapses (Rowland and Carlton, 1986), as 
well as 5-HT2C/1B receptor agonists, initiate a robust anorexigenic effect (Vickers et al., 
2000). The anorexigenic effect of 5-HT is primarily mediated by its action in the ARC 
(Donovan and Tecott, 2013). In addition, it has been demonstrated that microinjections 
 
28 
 
of 5-HT in the PVN, VMN and DMN nuclei induce suppression of food intake (Leibowitz 
and Alexander, 1998; Leibowitz et al., 1990; Paez and Leibowitz, 1993).  These effects 
require the orchestrated serotonergic action via activation of numerous receptors (1A, 
1B, 2B, 2C) in distinct neuronal subgroups, located in several hypothalamic nuclei 
(Sargent and Henderson, 2011; Vickers and Dourish, 2004). 
a. Arcuate Nucleus 
Serotonergic receptors are expressed in three neuronal subpopulations of the 
ARC, the orexigenic NPY/Agrp and RIP neurons, as well as the anorexigenic POMC 
neurons which receive and process peripheral and central signals in order to regulate 
energy homeostasis (Heisler et al., 2006; Hisadome et al., 2009; Rother et al., 2012; Xu et 
al., 2008; Yadav et al., 2009). Depending on the receptor that is stimulated, diverse 
cellular responses can occur, which can result in similar or opposed effects (Williams et 
al., 2011; Yadav et al., 2009). 
i. 5-HT2C  
The anorectic effects mediated via this receptor were suggested by studies 
involving treatments with the agonist m-chlorophenylpiperazine (mCPP) and/or 
antagonists of 5-HT2C (Kennett and Curzon, 1991; Kitchener and Dourish, 1994). The 
importance of this receptor in feeding suppression was further reported in 5-HT2C null 
mice which exhibited increased food intake and body weight in comparison to wild type 
littermates (Tecott et al., 1995). Further, the role of 5-HT2C in the regulation of energy 
balance was described in mice expressing a mutated form of the receptor. These animals 
displayed not only hyperphagia and obesity but also late onset leptin resistance, insulin 
resistance and glucose intolerance (Nonogaki et al., 1998). 
5-HT2C receptor is expressed in up to 80% of POMC neurons in the ARC (Heisler et 
al., 2002). The expression of 5-HT2C in POMC cells is required for the maintenance of 
energy homeostasis and the feeding suppression efficacy of dexfenfluramine (Heisler et 
al., 2002; Xu et al., 2008; Xu et al., 2010b). Moreover, hepatic insulin sensitivity is 
regulated by 5-HT2C activity in POMC neurons (Xu et al., 2010a). Stimulation of these 
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receptors by mCPP induces a PLC-dependent transient receptor potential C (TRPC) 
channel activation and inhibition of the K+ M-current, which result in depolarization and 
increased excitability of the POMC neurons (Roepke et al., 2012; Sohn et al., 2011) (see 
Chapter 2, figure 5).   
ii. 5-HT1B  
The involvement of 5-HT1B receptor in feeding behavior was first suggested after 
antagonist-induced reduction of the anorectic effects of dexfenfluramine (Grignaschi and 
Samanin, 1992). Mice with genetic deletion of this receptor were neither hyperphagic nor 
obese but they displayed insensitivity to the effects of dexfenfluramine on feeding 
behavior in comparison to wild type animals (Lucas et al., 1998).   
5-HT1B receptors are expressed in the orexigenic NPY/Agrp neurons of the ARC, 
which form somatic and dendritic synapses with serotonergic axons (Heisler et al., 2006). 
Activation of these Gi-coupled receptors with the selective agonists CP94253 and 
CP93129 induces hyperpolarization of NPY/Agrp neurons and inhibits their spontaneous 
firing and neurotransmitter release by an unknown yet mechanism (Heisler et al., 2006). 
Consequently, Agrp-mediated inhibition of MC4Rs is attenuated and leads to food 
intake suppression (Heisler et al., 2006) (see Chapter 2, figure 5). 
iii. 5-HT1A, 5-HT2B 
5-HT1A receptor is expressed in the ARC Agrp/NPY and POMC neurons (Collin et 
al., 2002) and its activation can initiate orexigenic effects as it has been demonstrated 
with the use of agonists such as 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT) 
(Cooper et al., 1988; Gilbert et al., 1988). Recently, it has been demonstrated that mice 
with a genetic deletion of the 5-HT1A receptor in POMC neurons exhibit hypophagia and 
reduced body weight, suggesting an orexigenic action of this receptor (Yadav et al., 
2011). Similarly, 5-HT2B deletion from POMC neurons resulted in feeding suppression, 
demonstrating an orexigenic effect of this receptor (Yadav et al., 2009). 
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iv. 5-HT1F 
A study reported that 5-HT reduces the excitability of RIP-Cre neurons in mice, 
and that this inhibition may be due to 5-HT1F receptors (Hisadome et al., 2009).  
b. Ventromedial Nucleus 
The VMN receives dense serotonergic innervation from the raphe (Steinbusch, 
1981; Willoughby and Blessing, 1987). 5-HT infusion inside the VMN induces a decrease 
in food intake and body weight (Fetissov and Meguid, 2010). Moreover, it was 
demonstrated that direct mCPP perfusion in the VMN suppresses food intake (Hikiji et 
al., 2004).  
3.7.2. Hippocampal action of 5-HT and depression 
a. The serotonin deficiency hypothesis of depression 
The serotonergic hypothesis of depression was first reported in the late 60’s, 
based on the role of serotonergic deficiency in the physiopathology of this disorder 
(Coppen, 1967). This theory relies on a wide range of biochemical studies regarding the 
brain serotonergic function of depressed patients (Cowen, 2008). Moreover, this notion 
is supported by the antidepressant effects of increased 5-HT synaptic bioavailability 
caused by MAO inhibitors (Feldstein et al., 1964) or tricyclic antidepressants (Reznik Off, 
1960), which decrease 5-HT oxidation and inhibit its neuronal uptake, respectively 
(Berton and Nestler, 2006). Additionally, the production and anti-depressive action of the 
selective serotonin reuptake inhibitors (SSRIs) reinforced even more the serotonergic 
theory of depression. 
More recent studies further confirmed this notion by using brain imaging 
techniques such as positron emission tomography (PET) (Dhaenen, 2001; Miller et al., 
2009; Sullivan et al., 2009).  
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 Table 2: Antidepressant drugs which target the serotonergic system. 
b. 5-HT innervation of hippocampal neurons 
Serotonergic projections that innervate dorsal hippocampus predominantly 
originate from the median raphe whereas the ventral hippocampal formation is 
innervated to greater extend by the median raphe (Mokler et al., 1999). Among the 
different areas of the dorsal hippocampus, the highest density of 5-HT axons was 
detected in Ammon's horn 3 (CA3), second highest in the dentate gyrus (DG) and the 
lowest in Ammon's horn 1 (CA1) (Mamounas et al., 1991). In the DG, fine serotonergic 
axons are found in the hilus and the molecular layer, but are almost absent from the 
granular area. However, beaded 5-HT terminals are extremely dense in the subgranular 
zone and less dense between the granule and molecular layers (Mamounas et al., 1991). 
The stratum radiatum and stratum oriens of the CA3 comprise intermingled beaded and 
fine serotonergic terminals whereas the layer of pyramidal cell bodies are almost lacking 
serotonergic axons (Mamounas et al., 1991). In the CA1, a network of fine 5-HT axon 
endings is detected in all areas except that of pyramidal cell bodies where the density is 
very low (Mamounas et al., 1991). 
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c. Hippocampal 5-HT signaling and depression 
Almost all the serotonin receptors are highly expressed in the hippocampus pre- and 
postsynaptically (Berumen et al., 2012) and, similarly, molecules that underlie its 
production (TPH) (Sakowski et al., 2006), uptake (SERT) (Owashi et al., 2004) and 
degradation (MAO) (Jahng et al., 1997) are present in this area. 
Among all the 5-HT receptors, 5-HT1A is the most extensively studied for its 
association with depressive and anxiety syndromes via its action in the hippocampus 
(Savitz et al., 2009). Presynaptic 5-HT1A autoreceptors induce an inhibitory effect in 
serotonergic neurons that innervate the hippocampus (Chaput et al., 1986).  
Postsynaptically, the 5-HT1A receptors are found in high densities in the CA1, CA3 and 
the DG (DG>CA1>CA3) (Barone et al., 1994; Verge et al., 1986). 5-HT action via these 
heteroreceptors induces hyperpolarization in CA1 and CA3 pyramidal neurons (Beck et 
al., 1992; Pugliese et al., 1998), LTP in the DG by GABAergic interneuron inhibition 
(Sanberg et al., 2006), cell proliferation, neurogenesis and survival in the subgranular 
zone of the DG (Huang and Herbert, 2005; Radley and Jacobs, 2002; Santarelli et al., 
2003) as well asneuroprotection (Shibata et al., 1992). Besides the canonical cAMP 
pathway, hippocampal 5-HT1A receptors can also activate other signaling pathways such 
as the PI3K/Akt/GSK3 and the MAPK pathways (Polter and Li, 2010). 5-HT1A receptor 
agonists 8-OH-DPAT and azapirones induce anti-depressive effects as reported by the 
forced swim test (Wieland and Lucki, 1990) and the tail suspension test (Miyata et al., 
2004), while the antagonists fail to affect depressive behaviors but block the 
antidepressant effects of desipramine and fluoxetine in the forced swim test (FST) and 
the tail suspension test, respectively (Detke et al., 1995; Miyata et al., 2004). Moreover, 
total 5-HT1A knockout mice (Ramboz et al., 1998) and mice lacking only 5-HT1A 
presynaptic autoreceptors (Bortolozzi et al., 2012) both display decreased depressive-like 
effects in the FST whereas over-expression of postsynaptic receptors had no effect in the 
FST immobility time but improved the antidepressant effects of the SSRI citalopram 
(Gunther et al., 2011). Thus a model of re-expression of this receptor only in the 
 
33 
 
serotonergic neurons of KO animals is needed in order to clearly understand the role of 
auto- and heteroreceptors in the antidepressant functions of 5-HT1A. 
Hippocampal action of 5-HT1B receptors plays an important role in depression 
despite its presence in low densities in this region (DG>CA1>CA3) (Verge et al., 1986). 
The effects of 5-HT1B autoreceptor activation involve the attenuation of 5-HT release in 
the ventral hippocampus as reported by SSRI treatment (e.g. paroxetine, fluoxetine) of 
KO mice for this receptor versus control mice (Gardier et al., 2003; Malagie et al., 2002). 
5-HT2A receptor function has been associated with major depressive syndrome in 
human studies (Mintun et al., 2004; Sheline et al., 2004) but there is a lack of substantial 
animal studies to describe the mechanism of action. 5-HT2A receptor localization in 
hippocampus is mainly identified in the pyramidal cell layer of CA1/3 and in the granular 
layer of the DG (Li et al., 2004a). 
5-HT2B receptor was recently reported to be necessary for both chronic and acute 
antidepressant effects of SSRIs (e.g. paroxetine and fluoxetine), with the use of agonists 
and KO mice for this receptor. It was suggested that these effects occur by increasing 5-
HT release in the brain, including the hippocampus, acting as an activating autoreceptor 
on the serotonergic neurons of the raphe, wherein the expression of the receptor was 
demonstrated for the first time (Diaz et al., 2012). In the hippocampus it is expressed in 
astrocytes and its activation by the agonist alpha-methyl 5-HT results in increased 
intracellular Ca2+ levels which is blocked by the antagonist of 4-(4-fluorobenzoyl)-1-(4-
phenylbutyl)-piperidine (Sanden et al., 2000). 
5-HT2C receptor is localized in higher density in the pyramidal layers of CA1 and CA3 
and the polymorph layer of the DG (Clemett et al., 2000). Antagonist infusion in the 
ventral hippocampus augmented the effect of the SSRI citalopram in the 5-HT release by 
an indirect mechanism which could involve GABAergic neurons (Cremers et al., 2007). 
Moreover, a selective 5-HT2C agonist administration results in reduced depressive-like 
behavior of rats as measured by the immobility time in the FST (Rosenzweig-Lipson et 
al., 2007). Isoforms that occur after alternative mRNA editing of the receptor introduce 
either more (isoleucine, asparagine, isoleucine, INI) or less (valine, glycine, valine, VGV) 
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depressive behavior in the FST, demonstrating the importance of the editing process in 
behavior (Mombereau et al., 2010). 
5-HT3 receptor in the rat hippocampus is expressed mainly in interneurons of the 
posteroventral CA1, in a region that receives significant serotonergic innervation (Tecott 
et al., 1993). 5-HT3 KO mice exhibit increased immobility time in the FST, suggesting an 
antidepressant action of the receptor (Bhatnagar et al., 2004).  
5-HT4 receptor agonists induce rapid antidepressant effects in rats measured by the 
decreased immobility time and sucrose consumption in the FST and the sucrose 
preference test (SPT), respectively. Further, agonist administration increases 
neurogenesis and CREB phosphorylation in the hippocampus (Lucas et al., 2007; Pascual-
Brazo et al., 2012). In situ hybridization revealed stronger expression in the granule layer 
of the DG, followed by the pyramidal cell layer of CA1 and CA2 areas (Vilaro et al., 2005). 
5-HT5 receptor is expressed in the rat hippocampus but it has not yet been clearly 
associated to depressive behavior (Oliver et al., 2000). 
5-HT6 receptor immunoreactivity is highly dense in the molecular layer of the DG and 
the strata oriens and radiatum of the CA1 (Gerard et al., 1997). Infusion of the 5-HT6 
receptor agonist EMD 386088 in the hippocampus of rats induces antidepressant-like 
effects such as decreased immobility time in the FST, an effect that is inhibited by the 
selective 5-HT6 receptor antagonist SB-399885 (Nikiforuk et al., 2011). 
5-HT7 receptor and its mRNA  are strongly detected in the pyramidal layers of CA1 
and CA3 and the subgranular zone of the DG, as shown by immunohistochemistry and in 
situ hybridization (Neumaier et al., 2001). Administration of the 5-HT7 receptor selective 
antagonist SB-258719 or the genetic deletion of the receptor induces antidepressant-like 
effects in the FST (decreased immobility time) (Guscott et al., 2005). Moreover, 5-HT7 
receptor heterodimerization with 5-HT1A receptor in hippocampal neurons attenuates 
the 5-HT1A-mediated activation of GIRK channels (Renner et al., 2012). 
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CHAPTER 4 
Leptin 
4.1. General 
Leptin, an adipocyte-secreted cytokine, regulates energy homeostasis and food 
intake, in addition to other physiological functions such as reproduction. It was named 
after the Greek word for thin, “λεπτός” (leptos), due to its role in acting against obesity.  
The characterization of two mouse strains at the Jackson Laboratory, the obese and 
hyperphagic  mice (ob/ob) by George Snell and his colleagues (Ingalls et al., 1950) and 
the diabetic (db/db) mice by Doug Coleman (Coleman, 1978), prepared the field for the 
discovery of leptin. The hypothesis of Douglas L. Coleman  that the mutated gene 
causing obesity in the ob/ob mice encodes a circulating hormone which regulates body 
weight and that the db gene encodes the receptor of this hormone (Grayson and Seeley, 
2012) was confirmed after cloning of these genes by the research group of Friedman 
(Zhang et al., 1994) and a group at Millennium Pharmaceuticals (Tartaglia et al., 1995) 
respectively . 
4.2. Production, Secretion and Degradation 
The adipocytes of the white adipose tissue are the main source of leptin production 
and secretion into the blood stream in levels which positively correlate to the body fat. 
Leptin secretion is regulated by hormones such as insulin, TNFα, NPY and 
glucocorticoids, by nutrients such as amino acids, lipids and glucose, and by 
neurotransmitters of the sympathetic nervous system  (Lee and Fried, 2009). Leptin 
mRNA has also been detected in brown adipose tissue, placenta, ovaries, stomach, 
skeletal muscle, pituitary gland, mammary epithelial cells and liver (Margetic et al., 2002).  
Depletion of leptin takes place also in adipocytes via proteasomal and lysosomal action 
and it is regulated by nutrient levels and insulin (Lee and Fried, 2006).  
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4.3. Gene, Biosynthesis and structure 
The human leptin is a 16 kDa (167 aa) protein which has a four-helix structure and 
belongs to the helical cytokine superfamily (Zhang et al., 1997). It is encoded by the gene 
Lep which is located at the genetic locus 7q31.3 (Zhang et al., 1994).   
4.4. Leptin Signaling 
4.4.1. Leptin Receptor (LepR/ObR) 
The leptin receptor (LepR) belongs to the super family of class I cytokine receptors 
which includes receptors such as IL6, glycoprotein 130 (gp130), the leukemia inhibitory 
factor receptor alpha (LIF-R) and the ciliary neurotrophic factor (CNTF) receptors 
(Tartaglia et al., 1995).  
The LepR gene is located at the genetic locus 1p31, 46.96 cM interval of chromosome 
4, 5q33 in human, mice or rats, respectively (NCBI-Gene Database). There are six 
isoforms that occur upon alternative splicing or ectodomain shedding in rats, five in mice 
and four in humans, identified as LepRa, LepRb, LepRc, LepRd, LepRe (not in humans) 
and LepRf (only in rats) (Figure X) (Ge et al., 2002; Lee et al., 1996; Wauman and 
Tavernier, 2011). LepRb, the isoform with the long cytoplasmic domain, is the main 
isoform for the transduction of leptin signaling pathways. In contrast to the short 
isoforms, LepRa,c,d,e,f, LepRb is detected in low concentrations in peripheral tissues 
including adipose tissue, liver and muscles. However, in the hypothalamus, LepRb is 
highly expressed whereas the levels of short forms are low (Harwood, 2012).  
During resting state, LepRb is present at the cellular membrane as a homodimer 
(Devos et al., 1997). The extracellular domain of the receptor contains two cytokine 
homology regions 2 (CHR2), an immunoglobulin-like domain (IgD) and two membrane-
proximal fibronectin type III (FNIII) domains. Leptin epitope II binds to the CRH2 of one 
LepR and epitope III binds to the IgD of another LepR. This suggests that a LepR 
homodimer binds with 2 leptin molecules to form a complex with a 2:2 stoichiometry. 
These interactions lead to a change in the conformation of membrane-proximal regions 
which promotes phosphorylation of intracellular substrates (Mancour et al., 2012).The 
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intracellular domain of LepR is constitutively associated with Janus kinase 2 (JAK2), JAK2-
binding protein SH2B and Src family kinases (SFKs) (Ghilardi and Skoda, 1997; Jiang et 
al., 2008).  
 
Figure 7: A. Leptin receptor isoforms in rats (from Wauman and Tavernier, 2011) B. 
Leptin/LepRb signaling architecture (from Mancour et al., 2012). 
 
4.4.2. Substrates  
i. Janus kinase 2 (JAK2) 
JAK2 belongs to the JAK family of non-receptor kinase of 120-130 kD which also 
includes JAK1, JAK3 and TYK2. JAK1,2 and TYK2 are ubiquitously expressed and JAK3 
expression is restricted to hematopoietic cells (Ihle, 1995).  
Leptin/LepR binding results in transphosphorylation and transactivation of JAK2. 
Upon activation, JAK2 phosphorylates three Tyr residues of the intracellular domain of 
LepR. Phosphorylated Tyr985, Tyr1077 and Tyr1138 residues serve as docking sites for 
SH2 domain-containing phosphatase 2 (SHP2), STAT5 and STAT3, respectively. Binding 
of these proteins to the receptor promotes their phosphorylation by JAK2 (Coppari and 
Bjorbaek, 2012). Tyr813/1007/1008 phosphorylation of JAK2 occurs by autophosphorylation 
or by SFKs and SH2B and leads to full activation of JAK2 (Jiang et al., 2008). 
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ii. Signal transducer and activator of transcription 3/5 (STAT3/5) 
STAT3 and STAT5 (750 to 850 amino acids) are members of the STAT family which 
contains seven  isoforms, namely STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and 
STAT6.  
Upon leptin/LepR binding, STAT3 undergoes Tyr705 and Ser727 phosphorylation, 
dimerizes and translocates into the nucleus as a homodimer where it regulates gene 
expression and mediates the effects of leptin (Santos and Costa-Pereira, 2011). 
Tyr1077 phosphorylation of LepR results in phosphorylation of both STAT5 
isoforms (A and B) at Tyr694 by JAK-2. Upon activation, STAT5 dimerizes and translocate 
to the nucleus in a mechanism similar to STAT3 (Gong et al., 2007). 
iii. SHP2 
SHP2 (or PTPN11) is a class 1 classical non-receptor PTP and contains 2 Src 
homology 2 domains in the N-terminal and one PTP domain in the C-terminal (Neel et 
al., 2003). Phosphorylated Tyr985 residue of LepR serves as docking site for SHP2 binding 
and activation. Mutation of Tyr985 to Phe blocks LepR/SHP2 binding and enhances STAT3 
activation by leptin (Carpenter et al., 1998).  
The knock-down of SHP2 in neurons enhances leptin-dependent JAK2/STAT3 
activation whereas ERK activation was impaired revealing a bidirectional role of SHP2 in 
leptin signaling regulation (Zhang et al., 2004).  
iv. Src family kinases (SFKs) 
SFK family comprises 11 members (Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, Src, Srm, 
and Yes). SFKs are also expressed in leptin-targeted tissues (Roskoski, 2004). Leptin-
dependent activation of SFKs contributes, at least partially, to the JAK2-independent 
effects of leptin. Besides, these kinases can activate JAK/STAT and MAPK/ERK pathways 
(Jiang et al., 2008). 
v. SH2B 
SH2B proteins are adaptor proteins that are involved in the signaling pathways of 
JAK kinases and many receptors such as insulin, IGF-I, nerve growth factor (NGF), brain-
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derived neurotrophic factor (BDNF). SH2B family comprises three members of 548-756 
amino acids:  SH2B1 (or PSM), SH2B2 (or APS) and SH2B3 (or Lnk). They all share similar 
protein regions consisting of SH2 domain, PH domain, several proline-rich regions and a 
dimerization domain (Maures et al., 2007). 
In the absence of stimulation, SH2B1 is constitutively associated with inactive 
JAK2 via the non-SH2 domains and inhibits its activity. The phosphorylation of JAK2 on 
Tyr813 in response to leptin promotes the binding of the pY residue to the SH2 domain of 
SH2B1 and critically increases the interaction between the two proteins (Li et al., 2007). 
The Tyr813/SH2B1 interaction enhances leptin-induced JAK2 activity. SH2B1 recruits IRS1 
and/or IRS2, creating a JAK2/SH2B1/IRS complex. This binding facilitates IRS tyrosine 
phosphorylation by JAK2 and prevents phosphatase-induced inactivation. IRS proteins  
phosphorylation in response to leptin activates the PI3K/Akt signaling pathways (Morris 
and Rui, 2009). 
4.4.3. Leptin Signaling Negative Regulation 
Leptin signaling is negatively regulated by the suppressor of cytokine signaling-3 
(SOCS3) and phosphatases which interact directly with LepR (PTP1B, TC-PTP, and RPTP 
epsilon) or downstream molecules (SHP2 and PTEN). 
a. Suppressor of cytokine signaling-3 (SOCS3) 
SOCS3 is a member of the SOCS family which includes 8 members (SOCS1-7 and 
CIS) with similar structure containing a C-terminal SOCS-Box domain and a SH2 domain 
in the center. The SH2 domain serves as binding site to phosphotyrosine residues (Starr 
and Hilton, 1998). Leptin signaling activation induces the expression of SOCS3 (Bjorbaek 
et al., 1999). SOCS3 binds to and inhibits JAK2 (Bjorbaek et al., 1999), LepR (by Tyr985 
phosphorylation) (Bjorbak et al., 2000). SOCS3 deletion (Howard et al., 2004) and LepR 
mutation of Tyr985 (Bjornholm et al., 2007) improve leptin sensitivity. 
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b. Protein tyrosine phosphatase 1-B (PTP1B) 
PTP1B interacts with JAK2 and inhibits its activity by dephosphorylation (Cheng et 
al., 2002). Similarly, STAT3 gets dephosphorylated by PTP1B (Lund et al., 2005). PTP1B  
null mice show increased leptin sensitivity (Zabolotny et al., 2002). 
c. T cell protein tyrosine phosphatase (TC-PTP) 
TC-PTP dephosphorylates STAT3 and blocks its activity (ten Hoeve et al., 2002). 
Neuronal inhibition of this protein improves leptin signaling and double deletion of 
PTP1B and TC-PTP appears to increase leptin sensitivity through an additive effect (Loh 
et al., 2011). 
d. Receptor protein tyrosine phosphatase epsilon (RPTPe) 
RPTPe belongs to the receptor subgroup of PTPs. Leptin signaling activation 
induces tyrosine phosphorylation of RPTPe and this activation leads to interaction with 
and inhibition of JAK2 (Rousso-Noori et al., 2011). 
 
Figure 8: Leptin signaling pathway map. 
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4.4.4. Actions 
a. Periphery 
Although the effects on regulation of body weight and energy homeostasis are 
mediated by the action of leptin in the brain, in peripheral tissues, leptin action is not 
redundant since it can induce various effects. (Guo et al., 2007). 
In adipocytes, leptin action promotes lipid oxidation and lipolysis and inhibits 
fatty acid synthesis (Wang et al., 1999). In addition, increased leptin signaling activation 
in the adipose tissue prevented from diet-induced obesity and revealed a negative 
feedback regulation of leptin production by leptin (Wang et al., 2005). In the liver, leptin 
action decreases lipid levels in a PI3K- dependent mechanism (Huang et al., 2004). 
Moreover, leptin receptor over-expression in hepatocytes is protective against high fat 
diet-induced hepatic steatosis and hypertriglyceridemia (Lee et al., 2001). In skeletal 
muscle, leptin mediates fatty-acid metabolism via activation of 5'-AMP-activated protein 
kinase (AMPK) (Minokoshi et al., 2002). In pancreatic β-cells, leptin inhibits insulin 
expression and secretion, cell proliferation, cell size and apoptosis (Marroqui et al., 2012). 
LepR deletion from pancreas improves insulin production, glucose tolerance and insulin 
signaling (Morioka et al., 2007). 
b. Central nervous system 
Leptin enters the CNS by crossing the BBB via a saturable transport system (Banks 
et al., 1996), which is facilitated by LepRa (Kastin et al., 1999), the most abundant leptin 
receptor isoform expressed in the BBB endothelial cells (Bjorbaek et al., 1998). On the 
other hand, the soluble receptor LepRe impairs the transport of circulating leptin in the 
brain (Pan et al., 2008). 
After crossing the blood-brain barrier, leptin acts on diverse brain regions and 
circuits to regulate a wide range of physiological functions such as food intake, energy 
expenditure, thermogenesis, reproduction, lipid and glucose metabolism, cognition and 
behavior (Morrison, 2009). Specific neuronal populations in the hypothalamus, 
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hippocampus, brainstem and other brain nuclei are targeted by leptin which binds to 
LepRb expressed by these neurons and regulates their activity (Patterson et al., 2011).  
i. Hypothalamus 
Leptin action in the hypothalamus regulates energy balance by acting in specific 
neuronal populations (table X). Several different hypothalamic nuclei have been 
identified to contain populations of neurons which express LepRb as well as projections 
of neurons that express LepRb (Patterson et al., 2011). The highest levels of LepR 
expression detected with IHC and ISH are found in the Retrochiasmatic area, the Arcuate 
nucleus (ARC), the Ventromedial nucleus (VMH), the Lateral hypothalamic area (LHA), the 
Dorsomedial nucleus (DMH) and the Ventral premammillary nucleus (Scott et al., 2009).  
Region Cell type 
Food 
Intake 
Body 
weight 
Energy 
expenditure 
Glucose 
homeostasis 
References 
ARC POMC no yes no yes (Balthasar et al., 2004) 
ARC NPY-AGRP no yes no no (van de Wall et al., 2008) 
ARC NOS-1 yes yes yes yes (Leshan et al., 2012) 
VMH SF-1 yes yes yes yes (Dhillon et al., 2006) 
LHA neurotensin no yes yes no (Leinninger et al., 2011) 
Table 3: Leptin-targeted hypothalamic neurons which regulate energy homeostasis. 
ii. Hippocampus 
Besides maintaining energy homeostasis and body weight, leptin’s action in the brain 
plays an important role in cognitive function, behavior and mood as well as in protection 
against cognitive decline and stress. These brain functions are regulated, at least in part, 
through leptin action in the hippocampus (Lu, 2007; Morrison, 2009). In addition, 
hippocampal leptin action regulates food intake by inhibiting food related memories 
(Kanoski et al., 2011).  
The expression levels of LepRb in the hippocampus are higher in the granular area of 
the dentate gyrus (DG) whereas in Ammon’s horn (CA1-3) are quite low or undetectable 
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as evidenced by immunoreactivity and ISH (Scott et al., 2009). However, projections of 
LepRb expressing neurons have been found to be more dense in the CA1-3 regions than 
in the DG (Patterson et al., 2011). 
Leptin action in the hippocampal neurons directly regulates synaptic functions and 
synaptic plasticity, neurogenesis and neuronal survival (Morrison, 2009).  
Leptin positively (Oomura et al., 2006) and negatively (Moult et al., 2009) regulates 
the induction of long term potentiation (LTP) in CA1 hippocampal cells and leptin 
signaling in this region is necessary for this process (Li et al., 2002). In addition, it has 
been demonstrated that leptin regulates glutamatergic neurotransmission, via the AMPA 
(α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid), NMDA (N-methyl-D-
aspartate) and GluR1receptors, and  modulates synaptic function (Durakoglugil et al., 
2005; Irving et al., 2006; Moult et al., 2010; Shanley et al., 2001). Finally, leptin-induced 
PI3K signaling inhibits hippocampal neurons by activating large conductance Ca2+-
activated K+ (BK) channels (O'Malley et al., 2005; Shanley et al., 2002a; Shanley et al., 
2002b). 
The subgranular zone (SGZ) of the dentate gyrus of the hippocampus is one of the 
three sites in the brain, along with subventricular zones of the lateral and third ventricle, 
where adult neurogenesis takes place (Hsieh, 2012; Lee et al., 2012). Leptin acts in the 
SGZ as a proliferation factor to enhance adult neurogenesis in vivo and in vitro via 
activation of STAT3 and Akt signaling pathways (Garza et al., 2008) as well as to restore 
stress-induced decrease of neural progenitor cell proliferation (Garza et al., 2012). A 
neuroprotective role of leptin in the hippocampus has been demonstrated to be 
mediated via JAK/STAT3, PI3K/Akt and MAPK/ERK1/2 signaling pathways (Guo et al., 
2008; Zhang and Chen, 2008). 
Finally, hippocampal action of leptin has been associated to anti-depressant like 
effects in behavioral tests such as forced swim test (FST), tail suspension test (TST) and 
sucrose (or saccharine) preference test (SPT). Brain infusion of leptin decreases 
depressive-like behavior in rats subjected to chronic stress, as addressed by FST and SPT, 
only when administered at the hippocampus (Lu et al., 2006). Mice lacking leptin 
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receptor in their dentate gyrus exhibit more depressive like behavior than control 
animals as evaluated with TST and SPT (Guo et al., 2012). 
4.4.5. Leptin Resistance 
Despite the fact that the term “leptin resistance” is widely used in an increasing 
number of publications, no universal, quantifiable or clinically useful term can be 
attributed (Myers et al., 2012). This term is used to describe a broad spectrum of 
conditions including hyperleptinemia (Frederich et al., 1995) or lack of responsiveness to 
leptin in inducing an anorexic effect and increasing energy expenditure (Tam et al., 
2012). At the cellular level, “leptin resistance” is used for describing the impairment of 
leptin ability to activate a number of signaling pathways such as JAK2/STAT3 (Bjorbaek 
et al., 1999), PI3K/Akt (Benomar et al., 2005a) which is due to the increased action of 
negative modulators including SOSCS3 (Bjorbaek et al., 1999) and PTP1B (Benomar et al., 
2009; Cheng et al., 2002). 
 
45 
 
CHAPTER 5 
The PI3K/ Akt signaling pathway 
 
5.1. General 
The phosphatidylinositol 3-kinases (PI3K)/Akt signaling pathway is one of the most 
extensively studied intracellular signaling cascades and is involved in signal transduction 
of numerous tyrosine kinase receptors as well as several cytokine receptors..  Activation 
of the PI3K/ Akt pathway triggers a cataract of processes that control cellular functions 
including proliferation, growth, survival, migration, trafficking and metabolism. The 
dysfunction of PI3K/Akt signaling pathway has been reported in numerous diseases such 
as metabolic syndrome and cancers, revealing thus this signaling cascade as a potential 
therapeutic target (Bartholomeusz and Gonzalez-Angulo, 2012; Braccini et al., 2012; 
Chen et al., 2012b; Ciraolo et al., 2008; Knight et al., 2006; Vucenik and Stains, 2012) 
5.2. The phosphatidylinositol 3-kinases  
The phosphatidylinositol 3-kinases (PI3Ks) form a family of intracellular kinases that 
catalyze the phosphorylation of the membrane-associated phospholipid 
phosphatidylinositol and its products, the phosphoinositides (PtdIns), at the 3′‑hydroxyl 
group/ring. In turn, the products of this reaction activate downstream effector proteins 
and their respective signaling cascades. Consequently, PI3Ks regulate a number of 
functions including cell metabolism, polarity, proliferation and survival.(Di Paolo and De 
Camilli, 2006). 
The eight different mammalian PI3K protein isoforms are divided in three Classes (I, II 
and III) according to their homology, structure and biochemical action. They all comprise 
common structural motifs including C2, helical and catalytic domains (Vanhaesebroeck 
et al., 2010).  
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Figure 9: Structure of PI3K isoforms (Vanhaesebroeck et al., 2012). 
5.2.1. Class I PI3Ks 
The best characterized group of PI3Ks is the Class I and it is divided into two 
subgroups, IA and IB. The members of both subgroups catalyze the production of 
PtdIns(4,5)P2 from PtdIns(3,4,5)P3 (Hawkins et al., 1992; Vanhaesebroeck et al., 2010; 
Vanhaesebroeck et al., 2012). 
a. Class IA  
Class IA PI3Ks are heterodimeric structures formed by one regulatory subunit (p85α, 
p85β, p55γ, p55α or p50α) and one catalytic subunit (p110α, p110β or p110δ) which 
catalyzes the production of PtdIns(3,4,5)P3 from PtdIns(4,5)P2 (Geering et al., 2007; 
Vanhaesebroeck et al., 1997). The p85α subunit contains two Src homology 2 (SH2) 
domains (nSH2 and cSH2) which serve as docking sites with very high affinity for 
phosphorylated tyrosine-containing  motifs (pY) that belong to membrane receptors and 
their substrates or other membrane-proximal proteins (Felder et al., 1993; McGlade et al., 
1992). A third SH2 (iSH2) domain interacts with the ABD and C2 domains of p110 (Dhand 
et al., 1994; Wu et al., 2009). In basal conditions,  the p85 subunit stabilizes and blocks 
the catalytic action p110 (Yu et al., 1998). RTKs,  GPCRs and their substrates are the main 
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type of receptors which interact with and activate Class IA PI3Ks (Vanhaesebroeck et al., 
2012). Upon p85 binding to the pY residues in the sequence context pYxxM (Songyang 
et al., 1993) of activated RTKs or adaptor proteins via its SH2 domains, the enzymatic 
activity of p110 is enabled due to abolition of the p85-mediated inhibition and the 
affinity of the p85/p110 complex to lipid membranes is increased (Burke et al., 2011; 
Shoelson et al., 1993; Zhang et al., 2011) The action of p85 can be inhibited by 
phosphorylation of two serine residues (Ser361 and Ser652) at analogous sites on both SH2 
domains of p85α (Foukas et al., 2004; Lee et al., 2011). Phosphorylation state of the Tyr688 
amino acid residue is also involved in the regulation of p85 and thus PI3K activity 
(Cuevas et al., 2001; Tsuboi et al., 2008). p110α is involved in the insulin signaling 
pathway (Knight et al., 2006) and plays an essential role in metabolism and growth due 
to increased interaction with and activation of IRS proteins (Foukas et al., 2006). The 
p110β subunit has been also demonstrated to be involved in the signal transduction of 
insulin and leptin (Al-Qassab et al., 2009) and to regulate metabolism and cell growth 
(Ciraolo et al., 2008). Finally, the p110δ subunit regulates many the development and 
activation of immune cells (So and Fruman, 2012). 
 
Figure 10: Class I PI3K activation and enzymatic action (Vadas et al., 2011). 
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b. Class IB 
Class IB PI3Ks contains the catalytic subunit p110γ which complexes with one of the 
regulatory subunits, p101, p84 or p87PIKAP which, in contrast to p85, do not contain 
SH2 domains (Engelman et al., 2006). Upon GPCR activation, the Gβγ subunits recruit to 
the cell membrane and activate the p101/p110γ complex (Brock et al., 2003; Stephens et 
al., 1997). The p101 subunit is required for full activation of p110γ by Gβγ and for 
directing its enzymatic preference towards PtdIns(4,5)P2 (Maier et al., 1999; Stephens et 
al., 1997). Ras-GTP is essential for the membrane recruitment and activation of 
p87/p110γ but it also facilitates the activation of p110γ alone or p101/p110γ complex 
(Kurig et al., 2009). In cardiac cells p110γ is activated by phosphodiesterase 3B (PDE3B) 
and reduces β-adrenergic receptor density which results in heart failure, an effect that is 
blocked by PKA (Perino et al., 2011). In addition, PDE3B-induced activation of p110γ 
regulates angiogenesis (Wilson et al., 2011). 
5.2.2. Class II PI3Ks  
In contrast to Class I PI3Ks which are heterodimers, Class II PI3Ks (or PI3K-C2) are 
monomers. PI3K-C2α, PI3K-C2β and PI3K-C2γ are the three different isoforms 
characterized in mammals (Falasca and Maffucci, 2007; Vanhaesebroeck et al., 2010). 
These isoforms possess a Ras-binding domain and a Phox domain (Stahelin et al., 2006; 
Vanhaesebroeck et al., 2010). PI3K-C2α activation, which can be induced by several 
stimuli, including hormones, chemokines and cytokines, regulates glucose transport, 
insulin secretion, neuronal secretion and endocytosis (Falasca and Maffucci, 2007). Cell 
growth and survival, cell migration and K+ channels activation are promoted by PI3K-C2β 
which can be activated by growth factors and phospholipids (Falasca and Maffucci, 2007; 
Falasca and Maffucci, 2012). So far there is no study that demonstrates a specific 
activator, product or mechanism of action for PI3K-C2γ (Falasca and Maffucci, 2007). 
PtdIns(3)P has been found to be the only product of Class II PI3Ks in cell cultures and in 
vivo (Domin et al., 2005; Falasca et al., 2007). 
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Figure 11: Activation and action of Class II PI3Ks. (Falasca and Maffucci, 2012). 
5.2.3. Class III PI3Ks 
This class contains only one isoform, the vacuolar protein sorting 34 (Vps34) (Backer, 
2008). The mammalian homologous protein, hVps34, is ubiquitously expressed (Volinia 
et al., 1995). Vps34 is constitutively associated with and the Vps15 protein kinase which 
contains a membrane-targeting myristoylated domain (Stack et al., 1993). Vps34 
signaling requires membrane-recruitment of other intracellular partners, including 
proteins with FYVE [Fab1p, YOTB, Vac1p, EEA1 (early endosomal antigen 1)] or PX (Phox 
homology domain) catalytic domains which bind PtdIns3P (Backer, 2008). The hVps34 
interacts with beclin-1 together they create complexes which play an important role in 
autophagy and cell growth with other proteins such as UVRAG (Liang et al., 2006), 
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Atg14L and Rubicon (Matsunaga et al., 2009), MTM and mTORC1 (Blondeau et al., 2000; 
Fetalvero et al., 2013)as well as in endocytosis by interaction with Rab5 and Rab7 
(Kinchen et al., 2008; Kitano et al., 2008). 
 
Figure 12: Class III PI3K complexes and action in mammals (Backer, 2008). 
5.3. Phosphoinositides 
Phosphoinositids (PtdIns) or Inositol phospholipids, derive from the phosphorylation 
of their precursor molecule phosphatidylinositol (Pins), or other PtdIns, on the inositol 
ring at positions 3, 4 and 5. The PI3K family enzymes catalyze this kind of 
phosphorylation which can be reversed by a number of phosphatases (INPP, MTM, PTEN, 
SHIP). These reactions give rise to seven phosphoinositide species (figure X). (Di Paolo 
and De Camilli, 2006; Vanhaesebroeck et al., 2012). The phosphorylated PtdIns, PtdIns-3-
P, PtdIns(3,4)P2 and  PtdIns(3,4,5)P3, serve as docking sites for downstream kinase that 
carry lipid-binding domains (i.e. the pleckstrin homology (PH) domain, the phox 
homology (PX) domain and the FYVE domain), which translocate to the cell membrane. 
This co-localization and binding leads to activation of these proteins and triggers their 
various downstream signaling cascades (DiNitto et al., 2003; Vanhaesebroeck et al., 
2010). 
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Figure 13: Action of PI3Ks and phosphatases on phosphoinositide transformation 
(Vanhaesebroeck et al., 2012). 
5.4. Negative regulation of PI3Ks 
5.4.1. Phosphatase and tensin homologue - PTEN 
PTEN was first identified as the product of a tumor suppressor gene responsible 
for diverse types of cancer (Li et al., 1997). The product of this gene is a 403 amino-acid 
protein which contains an N-terminal domain (190 amino acids) which is homologous to 
the cytoskeletal protein tensin 1 and encloses a protein phosphatase domain with the 
motif HCXXGXXR (Lee et al., 1999). Moreover, a C-terminal C2 domain facilitates the 
interaction of PTEN with cell membranes (Lee et al., 1999). PTEN can dephosphorylate 
serine-, threonine- and tyrosine-phosphorylated peptides with higher specificity for 
acidic substrates (Myers et al., 1997). In addition, this phosphatase has been 
demonstrated to dephosphorylate the PtdIns(3,4,5)P3 specifically at position 3 on the 
inositol ring via the same enzymatic site opposing the activity of PI3K (Maehama and 
Dixon, 1998). 
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5.4.2. Inositol polyphosphate 4- phosphatase  – INPP4 
INPP4 interacts with the p85 subunit of PI3K to approach PtdIns(3,4)P2 and 
dephosphorylate the D4 group to produce PtdIns(3)P (Munday et al., 1999), a process 
that is essential for tumor suppression in several kinds of cancer such as  breast cancers 
and ovarian cancers (Gewinner et al., 2009).  
5.4.3. Inositol polyphosphate 5- phosphatases (5-ptases) 
The 5-ptase family contains ten mammalian members which all contain a 300 
amino acid catalytic domain. These enzymes dissociate the 5-position phosphate from 
the inositol ring of PtdIns(4,5)P2, PtdIns(3,4,5)P3 and/or PtdIns(3,5)P2 (Ooms et al., 2009). 
The Src homology 2-domain-containing inositol phosphatase or SHIP2 (also 
known as inositol polyphosphate 5′-phosphatase-like protein-1 or INPPL1) is a 142 kDa 
protein which contains an SH2 domain on the N-terminal, 5-ptase domain in the center 
and a proline rich domain (PRD) followed by a sterile alpha-motif (SAM) domain on the 
C-terminal (Suwa et al., 2010). SHIP2 dephosphorylates of PtdIns(3,4,5)P3 and 
Ins(1,3,4,5)P4 to negatively regulate PI3K-mediated activation of downstream pathways 
(Pesesse et al., 1998). SHIP2 has been shown to be an essential regulator of various 
pathologies including insulin sensitivity/ diabetes (Clement et al., 2001), obesity (Sleeman 
et al., 2005), neurodegeneration (Soeda et al., 2010), cancer (Wisniewski et al., 1999) and 
atherosclerosis (DeKroon et al., 2006).  
Haemopoietic-specific 5-ptase (SHIP1) is a 145 kDa protein that has not only a 
highly homologous structure to SHIP2 (with the exception of the SAM domain) but also 
the same enzymatic function to hydrolyze PtdIns(3,4,5)P3 and Ins(1,3,4,5)P4 (Damen et al., 
1996; Rohrschneider et al., 2000). SHIP1 action negatively regulates proliferation of 
haematopoietic cells to prevent different types of leukemia (Fukuda et al., 2005; Horn et 
al., 2004).    
Inositol polyphosphate 5-phosphatase B (also known as Type II 5-phosphatase) or 
INPP5b and the 72 kDa inositol polyphosphate 5-phosphatase or INPP5e 
dephosphorylate PtdIns(3,4,5)P3 and PtdIns(4,5)P2 into PtdIns(3,4,)P2 and PtdIns(4)P 
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respectively (Bielas et al., 2009; Jefferson and Majerus, 1995). Mutations of the INPP5E 
gene have been shown to cause different kinds of ciliopathies (Bielas et al., 2009). 
5.5. Phosphoinositide dependent protein kinases 
5.5.1. Akt/PKB protein kinase 
The Akt/PKB protein kinase family belongs to the AGC group of protein kinases 
(named after PKA, PKG, and PKC).  This serine/threonine kinase family is composed of 
three members in mammals: AKT1/PKBα (480 amino acids, MW: 55.7 kDa), AKT2/PKBβ 
(481 amino acids, MW: 55.8 kDa) and AKT3/PKBγ (479 amino acids, MW: 55.8 kDa). They 
share more than 80% common amino-acid sequence and they are products of three 
distinct genes, located in different chromosomes. All three isoforms have a PH domain 
on the N-terminal, a catalytic domain in the center and a hydrophobic domain on their 
C-terminal. This structure is conserved among species from fly, worm, mouse, to human. 
AKT1 and AKT2 are ubiquitously expressed and this expression is more remarkable in 
insulin targeted tissues. AKT3 expression is mainly observed in lipid-rich tissues including 
brain, testis, adipose tissue and liver. (Fayard et al., 2010; Hanada et al., 2004; Schultze et 
al., 2011).  
 
Figure 14: Protein structure of  Akt isoforms (Hanada et al., 2004). 
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The Akt gene was first described as v-akt oncogene of the AKT8 murine retrovirus 
where it was first isolated (Staal et al., 1977) and ten years later the human AKT1 and 
AKT2 homologues were cloned by the same group. (Staal, 1987). Two other groups 
cloned the akt gene from human cells in 1991 and named it rac (related to the A and C 
kinases)(Jones et al., 1991) and PKB(protein kinase B)(Coffer and Woodgett, 1991). The 
last family member AKT3/PKBγ was cloned few years later (Brodbeck et al., 1999). 
Akt is located downstream of PI3Ks.  After translocation to the membrane, this 
kinase binds through its PH domain to PtdIns(3,4,5)P3 and PtdIns(3,4)P2. This binding 
facilitates the positioning of Akt in proximity to the membrane and its subsequent 
phosphorylation by upstream kinases (Calleja et al., 2007; Milburn et al., 2003). Both Akt1 
phosphorylation sites, Thr308 and Ser473 (Thr309 and Ser474 for AKT2, Thr305 and Ser472 for 
AKT3), situated in the activation loop of the catalytic domain and the hydrophobic 
regulatory domain respectively, need to be phosphorylated in order to achieve full 
kinase activity and dissociation from the cell membrane (Alessi et al., 1996). 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 levels positively correlate with Thr
308 and Ser473 
phosphorylation respectively (Ma et al., 2008). Phosphorylation of the Thr308 residue is 
mediated by PDK1 (3-phosphoinositide-dependent protein kinase-1) which is also 
recruited to the membrane by PIP3 through its PH domain (Alessi et al., 1997). Multiple 
candidate PDK-2 (or S473K) kinases, such as DNA-PK, ATM and mTORC2, have been 
proposed to catalyze the phosphorylation of Akt (Fayard et al., 2005). Besides, its role in 
the phosphorylation and activation of Akt, mTORC2 has been reported to regulate Akt 
conformation and stability by phosphorylating the Thr450 site of the TM (turn motif) 
domain (Facchinetti et al., 2008; Sarbassov et al., 2005). Recently, a study has 
demonstrated that PI3K-mediated Akt phosphorylation on Ser473 is through direct 
activation of mTORC2 by PtdIns(3,4,5)P3, indicating that mTORC2 is the most successful 
candidate to be called PDK2 (Gan et al., 2011). 
Akt activation can be blocked by phosphatases either directly or indirectly. Protein 
phosphatase 2A (PP2A) acts directly on Akt and dephosphorylates both Thr308 and 
Ser473leading to full inactivation of its kinase activity (Ugi et al., 2004). Phosphatase and 
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tensin homologue (PTEN) and SH2 domain-containing inositol polyphosphate 5-
phosphatase (SHIP) prevent indirectly Akt activation by counter-acting on PI3K action. 
These two phosphatases dephosphorylate PIP3 and produce PI(4,5)P2 and PI(3,4)P2, 
respectively (Ooms et al., 2009; Song et al., 2012). 
Following activation, Akt changes conformation, detaches from the cell 
membrane and translocates to the cytoplasm or the nucleus(Calleja et al., 2007). 
Consequently, Akt regulates numerous signaling molecules (see table 4) involved in a 
broad range of cellular functions in response to extracellular stimuli (Fayard et al., 2005). 
Indeed, upon phosphorylation Akt substrates regulate a large spectrum of cell processes 
including metabolism, glucose uptake, angiogenesis as well as cellular proliferation, 
survival and growth. Activation of each downstream protein can induce either a single 
specific effect or pleiotropic effect depending on the cell processes that it controls. In 
table 4 the list of the most well studied substrates is presented and their respective 
function/s. 
Protein 
name 
Phospho- 
residues 
Protein 
effect 
Cellular 
Function 
Cellular Effect References 
FOXO 
(1,3,4,6) 
T24, S256, 
S319 
Inhibition 
Transcription 
factors 
Metabolism, 
proliferation, survival 
(Tzivion et al., 2011) 
GSK3α/β S9/ S21 Inhibition Kinase 
Metabolism, 
proliferation, survival 
(Manning and Cantley, 
2007) 
BAD S99 Inhibition 
Apoptotic 
protein 
Survival (Datta et al., 1997) 
IKK T23 Activation Kinase Inflammation, cell stress (Ozes et al., 1999) 
Mdm2 S166,S186 Activation Ligase Cell survival, proliferation 
(Mayo and Donner, 
2001) 
TSC2 S939, T1462 Inhibition 
mTORC 
blocker 
Cell growth, proliferation 
(Huang and Manning, 
2009) 
eNOS S1177 Activation Synthase angiogenesis (Dimmeler et al., 1999) 
Casp9 S196 Inhibition Protease survival (Cardone et al., 1998) 
Table 4: Akt protein kinase substrates and their functions.  
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5.5.2. GSK3 protein kinase 
Glycogen synthase kinase 3 has been named after its earliest discovered role as 
inhibitor of the glycogen synthase (Embi et al., 1980).This serine/threonine kinase exists 
in two isoforms, α and β, which share a 97% homology in the kinase domain. GSKα (51 
kDa) and GSK3β (47 kDa) are ubiquitously expressed, with higher levels in the brain 
(Woodgett, 1990). In addition, GSK3α and β present similar structure and substrate 
preference and their function is not redundant as shown by gene deletion studies (Li and 
Jope, 2010). 
 
Figure 15: Protein structure of GSK3 isoforms (Doble and Woodgett, 2003). 
 GSK3 is constitutively active even in non-stimulated states and is inhibited when 
upstream signaling pathways are activated (Sutherland et al., 1993). GSK3 activity is 
regulated by phosphorylation, translocation, protein-protein interactions and substrate 
phosphorylation state (Doble and Woodgett, 2003). Phosphorylation of the Ser9 residue 
of GSK3β or Ser21 residue of GSK3α, located at the N-terminal of the protein, is mediated 
by a number of upstream kinases such as Akt/PKB (Cross et al., 1995), PKA (Tanji et al., 
2002), PKC (Fang et al., 2002), p70 ribosomal S6 kinase (Terruzzi et al., 2002), and p90 
ribosomal S6 kinase (Roseweir et al., 2012). This phosphorylation leads to the inhibition 
of GSK3 and consequently to the production of glycogen (Doble and Woodgett, 2003). 
GSKβ, but not GSKα, is also deactivated by phosphorylation of the C-terminal Thr390 
residue by p38 mitogen-activated protein kinase (Thornton et al., 2008). Finally, tyrosine 
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phosphorylation at Tyr279 of GSK3α and Tyr216 of GSK3β induces their activation 
(Buescher and Phiel, 2010). 
GSK is involved in a wide range of biological processes as witnessed by numerous 
studies performed at the molecular and cellular levels. This occurs through the multiple 
substrates targeted by GSK3. The substrate motif recognized by GSK-3 is Ser/Thr–X–X–X-
Ser/Thr-P (Roach, 1991). The effects of GSK3 on its substrates are mediated by either 
kinase activity or protein binding. Inhibitory phosphorylation occurs on primed (already 
phosphorylated, e.g. GS, eIF2B) or non-primed substrates (e.g PS-1).  These effects 
regulate multiple cellular processes that are implicated in pathologies such as Type II 
Diabetes and Alzheimer’s disease (Gao et al., 2012), mood disorders (Li and Jope, 2010)  
development and cancer (Rayasam et al., 2009). 
 
Protein 
name 
Phosphorylated 
residues 
Protein 
effect 
Protein 
Function 
Cellular Effect References 
GS 
S641, S645, S649, 
S653 
Inhibition 
Synthetic 
enzyme 
Metabolism, 
proliferation, survival 
(Rylatt et al., 1980) 
IRS1 S332 Inhibition 
Binding 
molecule 
Metabolism, 
proliferation, survival 
(Liberman and Eldar-
Finkelman, 2005) 
IRS2 S484/S488 Inhibition 
Binding 
molecule 
Metabolism, 
proliferation, survival 
(Sharfi and Eldar-
Finkelman, 2008) 
PTEN S362, T366 
Activation, 
Stability 
Phosphatase 
Growth, proliferation, 
survival 
(Al-Khouri et al., 2005) 
PS1 S397 Inhibition Protease Proteolysis 
(Twomey and 
McCarthy, 2006) 
eIF-2B S535, S539 Inhibition 
Translation 
factor 
Translation 
(Mohammad-Qureshi 
et al., 2008) 
5HT1B - Activation GPCR Neurotransmission (Polter and Li, 2011) 
TAU >20 
Misfolding 
and 
fibrilation 
microtubule
-associated 
Microtubule stability (Hanger et al., 2009) 
 
Table 5: GSK3 protein kinase substrates and their functions. 
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Serotonin and insulin are key regulators of homeostatic mechanisms in the hypothalamus. However, in
type 2 diabetes, the hypothalamic responsiveness to serotonin is not clearly established. We used a dia-
betic model, the Goto Kakizaki (GK) rats, to explore insulin receptor expression, insulin and serotonin
efﬁciency in the hypothalamus and liver by means of Akt phosphorylation. Insulin or dexfenﬂuramine
(stimulator of serotonin) treatment induced Akt phosphorylation in Wistar rats but not in GK rats that
exhibit down-regulated insulin receptor. Studies in a neuroblastoma cell line showed that serotonin-
induced Akt phosphorylation is PI3-kinase dependent. Finally, in response to food intake, hypothalamic
serotonin release was reduced in GK rats, indicating impaired responsiveness of this neurotransmitter. In
conclusion, hypothalamic serotonin as insulin efﬁciency is impaired in diabetic GK rats. The insulin–
serotonin cross-talk and impairment observed is one potential key modiﬁcation in the brain during
the onset of diabetes.
 2011 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Insulin acts in the brain and more precisely at the hypothalamic
level to regulate energy and glucose homeostasis (Bruning et al.,
2000; Gerozissis 2008, 2010; Plum et al., 2005). An efﬁcient insulin
action in the brain is a pivotal element in maintaining numerous
physiological functions. Thus, the combination of defective pancre-
atic beta-cell function associated to impaired insulin signaling at
the peripheral and central levels contribute to the onset of diabetes
(Accili, 2004; Farese et al., 2005; Lin et al.; 2004; Standaert et al.,
2004).
The action of insulin in the brain is modulated by several hor-
mones and neurotransmitters of particular interest among those
factors is the neurotransmitter serotonin (5-HT) that controls food
intake and energy homeostasis (Leibowitz and Alexander, 1998;
Wade et al., 2008) through the same type of neurons as insulin
(Xu et al., 2010; Zhou et al., 2007). Furthermore, increasing evi-
dences have shown that serotonin regulates energy and glucosed Ltd. All rights reserved.
docrinologie Moléculaire de
versité Paris Sud IBAIC, Bât.
08; fax: +33 1 69 15 70 74.
Taouis).balance through 5HT-2C receptors in the brain (Xu et al., 2010).
Serotonin also improves type 2 diabetes and obesity through the
same receptors (Zhou et al., 2007). These receptors are expressed
by POMC neurons and their activation promotes insulin sensitivity
in liver. POMC hypothalamic neurons also express insulin receptor.
However, the cross-talk between serotonin and insulin signaling
pathways at the hypothalamic level has received little attention
speciﬁcally in type 2 diabetes models. Previous own studies have
brought evidence that insulin administration in the median hypo-
thalamus increases hypothalamic serotonin release, whereas cen-
tral stimulation of the serotonergic system with dexfenﬂuramine,
a reuptake inhibitor and enhancer of serotonin release in synapses,
increases the extracellular hypothalamic insulin concentration
(Orosco and Gerozissis, 2001; Orosco et al., 2000). Thus, it is plau-
sible to hypothesize that diminished efﬁciency or responsiveness
of the serotonergic system in the brain may promote the onset of
insulin-resistance and the progress of diabetes.
To address the issue of a potential link between serotonin and
brain insulin signaling in diabetes, we performed in vivo studies
in the Goto-Kakizaki (GK) rat, a non-obese spontaneous type 2 dia-
betic model. This polygenic model of diabetes, produced by selec-
tive inbreeding of Wistar rats expressing glucose intolerance,
presents the main features of the metabolic and hormonal disor-
ders usually described in diabetic patients (Movassat et al., 2008;
Table 1
Body weight, food intake, visceral adipose tissue, blood glucose, plasma hormones
and basal hypothalamic serotonin (5-HT) release.
Wistar GK
Body weight (g) 335 ± 22.3 234 ± 4.4⁄⁄⁄
Food consumption (g/24 h) 25.0 ± 1.1 18.5 ± 1.6⁄⁄
Relative food consumption (g/24 h/kg) 74.6 ± 3.3 79.1 ± 6.8
Visceral adipose tissue (g) 4.0 ± 0.6 5.4 ± 0.6⁄⁄
Glucose levels (mmol/l) 4.8 ± 0.3 6.3 ± 0.8⁄⁄⁄
Insulin levels (lU/ml) 23.3 ± 1.2 41.9 ± 3.6⁄⁄⁄
Leptin levels (ng/ml) 1.5 ± 0.37 2.3 ± 0.5⁄⁄⁄
Basal 5-HT levels (pg/20 ml) 2.4 ± 0.1 2.3 ± 0.4
Data are expressed as mean ± SEM. ⁄⁄, ⁄⁄⁄indicate p < 0.01 and p < 0.001 respectively,
when GK rats were compared to Wistar rats.
n = 6  8 (for 5-HT levels, n = 4  6).
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I. Papazoglou et al. /Molecular and Cellular Endocrinology 350 (2012) 136–144 137Portha, 2005; Yamashita et al., 1996). In addition to peripheral
deviations, GK rats, similarly to other type 2 diabetes models, pres-
ent a number of brain dysfunctions such as leptin resistance or
modiﬁcation of neuropeptide Y (NPY) production, interfering with
the action of insulin in energy and glucose homeostasis (Gyte et al.,
2007; Maekawa et al., 2006).
In the present paper we showed that GK rats exhibited a lower
insulin receptor expression levels in both hypothalamus and liver.
In addition, the hypothalamic insulin-induced Akt phosphoryla-
tion, a major component of insulin signaling, is completely abol-
ished in GK rats as compared to Wistar rats. Interestingly, we
found that dexfenﬂuramine acute treatment induced Akt phos-
phorylation in the liver and hypothalamus of control but not in
GK rats, linking then the inefﬁciency of insulin to that of
dexfenﬂuramine. The impact of insulin-resistance on serotonin-
dependent phosphorylation of Akt was conﬁrmed in human neuro-
blastoma cells.
Finally, to analyze whether the serotonergic responsiveness was
affected in GK rats, we investigated the hypothalamic serotonin re-
lease in response to food intake, by means of microdialysis studies.
Signiﬁcant differences in food intake-induced serotonin release be-
tween GK and Wistar rats were observed. le
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2. Research design and methods
2.1. Animals
Rat studies were carried out in agreement with the French leg-
islation on animal experimentation and with the authorization of
the French Ministry of Agriculture (Animal Health and Protection
Directorate, authorization number: 91–519). Animals were main-
tained on a 12 h light-dark cycle. Adult male Wistar and GK rats
(issued from the Paris colony, B2PE, BFA University Paris 7) aged
between 8 and 12 weeks, fed standard laboratory chow (113,
UAR, Epinay sur Orge, France) developed under the same condi-
tions, were used. Food and water were available ad libitum.Pl
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###2.2. Chemicals
Cell culture reagents from Invitrogen (Cergy-Pontoise, France),
human insulin solution, serotonin creatinine sulfate complex and
Wortmannin from Sigma–Aldrich (France). Antibodies directed to-
ward Akt and phospho-(Ser 473)-Akt antibodies were from Cell
Signaling (Ozyme, St Quentin en Yvelines, France). All other chem-
icals are from Sigma (St-Louis, USA).Pl
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* 2.3. Intraperitoneal insulin or dexfenﬂuramine injection
To test the impact of insulin or endogenous serotonin on insulin
signaling, overnight fasted rats received, 30 min prior to euthana-
sia, an intraperitoneal (ip) injection either of saline, human insulin
(1 U/kg body weight, Actrapid, Novo Nordisk, Denmark) or dexfen-
ﬂuramine (5 mg/kg, Sigma–Aldrich, USA). The chosen doses of
insulin and dexfenﬂuramine were based on previous own studies
demonstrating their efﬁciency (Benomar et al., 2005b; Gerozissis,
2007).Fig. 1. Effect of dexfenﬂuramine or insulin injection on plasma glucose, insulin and
leptin levels. Wistar (W) rats, white bars and Goto-Kakizaki (GK) rats, black bars,
were injected ip 30 min before euthanasia with either saline (Con), dexfenﬂuramine
(Dex, 5 mg/kg body weight) or human insulin (Ins, 1 U/kg body weight). Blood
glucose levels (A) were immediately measured using a blood monitoring system
(Accu-Chek, Roche) and plasma leptin (B) and insulin (C) levels were determined by
RIA. The results are presented as means ± SEM (n = 4  5). ⁄, ⁄⁄, ⁄⁄⁄ indicate p < 0.05,
p < 0.01 and p < 0.001, respectively, when GK rats were compared to W rats.#, ###
indicate p < 0.05 and p < 0.001 when dexfenﬂuramine or insulin injected animals
were compared to saline injected rats of the same group.2.4. Determination of plasma glucose, insulin and leptin levels
At the end of the experiment, the animals were killed by decap-
itation and trunk blood was collected in heparinized tubes on ice.
Glucose levels were measured immediately with a blood monitor-
ing system (Accu-Chek, Roche). The plasma was isolated and stored
at 20 C.
138 I. Papazoglou et al. /Molecular and Cellular Endocrinology 350 (2012) 136–144Insulin was measured by a sensitive two-step RIA (3 h preincu-
bation, in the absence of the tracer, followed by 1 h and 30 min of
incubation with tracer), using commercially available reagents
(DiaSorin, Sallugia, Italy). Assay sensitivity was 2.3 ± 0.1 and
6.3 ± 0.5 lU/ml at 80% and 50%, respectively; coefﬁcients of varia-
tion within and between assays were 5–10% and 6–10%, respec-
tively; non-speciﬁc binding, deﬁned as the proportion of tracer
bound in the absence of antibody, was <6%. Leptin was determined
by a two-step RIA, using Linco’s rat leptin [125I] assay system (Linco
Research, St. Charles, MO, USA). Assay sensitivity was 0.44 ± 0.01
and 1.32 ± 0.04 ng/ml at 80% and 50% respectively; coefﬁcients of
variation within and between assays 2–4.6% and 3.0–5.7%, respec-
tively; non-speciﬁc binding was <2% (Banas et al., 2009).2.5. Tissue sampling and Western blot analyses
Following euthanasia, hypothalami and livers were removed,
immediately frozen in liquid nitrogen and stored at 80 C. Frozen
tissues were homogenized in the solubilization buffer containing
20 mM Tris–HCl (pH 7.5), 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2,
1% nonidet-P40, 10% glycerol, proteases inhibitors (0.35 mg/ml
PMSF, 2 lg/ml leupeptin, 2 lg/ml aprotinin) and phosphatases
inhibitors (10 mM sodium ﬂuoride, 1 mM sodium orthovanadate,
20 mM sodium b-glycerophosphate, 10 mM benzamidine). Tissues
were broken in a lysis (homogenization) apparatus (Precellys 24,
Bertin technology, France). After agitation for 90 min at 4 C, insol-
uble material was removed by centrifugation at 14 000 rpm, for
60 min at 4 C. Protein concentrations of the resulting supernatant
were determined using a protein assay kit (BCA) (Pierce, Perbio
Science, France). Proteins, 70 lg/sample, were resolved by SDS-
PAGE electrophoresis and electrotransfered to a nitrocellulose
membrane. Immunoblots were blocked with 3% Bovine Serum
Albumin and they were then incubated with the appropriate pri-
mary and secondary antibodies. Targeted proteins were visualized
by enhanced chemiluminescence reagents (ECL detection kit,
Amersham Biosciences) followed by autoradiography. Bands wereA W 
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Fig. 2. Effect of dexfenﬂuramine or insulin injection on Akt phosphorylation in the hypot
were injected ip, 30 minutes before euthanasia with either saline (Con), dexfenﬂura
Hypothalamus lysates were subjected to Western blot analysis. Membranes were probed
All blots were revealed by ECL and bands quantiﬁed by BIO1D software (Molecular Imag
the histogram. The ﬁgure contains grouped images from representative parts of the
means ± SEM (n = 6  10). ##, ### indicate p < 0.01 and p < 0.001 when dexfenﬂuraminequantiﬁed by densitometry, using Bio-1D software (Vilber Lour-
mat, France).
2.6. Surgery
Each animal was anesthetized with pentobarbital (50 mg/kg,
Sanoﬁ-Aventis, Libourne, France), pre-treated with the muscle
relaxant xylasine (Rompun, Bayer Puteaux, France) and placed in
a stereotaxic frame (Kopf Instruments, Tujunga, CA). A guide can-
nula (CMA, Carnegie Medicin AB, Stockholm, Sweden) was aimed
at the space lining the paraventricular (PVN) and ventromedian
(VMH) nuclei (coordinates: 1.9 mm anterior, 0.5 mm lateral,
and 7 mm ventral to bregma). The dialysis probe protruded
2 mm beyond the guide tube, the tip reaching a point 9 mm ventral
to dura. The guide was ﬁxed to the skull with stainless steel screws
and dental cement. One week was allowed for postoperative recov-
ery from brain surgery, necessary for a normal sleep, feeding, and
body weight gain patterns (Banas et al., 2009; Gerozissis et al.,
2001). All experiments were performed in the animals’ own home
cages.
2.7. Microdialysis procedure
The microdialysis membranes (CMA) were 2 mm long, with a
diameter of 0.5 mm and a 20 kD cut off. According to our in vitro
calibration test, the relative recovery for serotonin was around
10% (Banas et al, 2009.). An artiﬁcial cerebrospinal ﬂuid (Ringer
type solution containing 147 mM Na+, 2.3 mM Ca2+, 4 mM K+, and
155.6 mM Cl) was infused at a ﬂow rate of 2 ll/min. Thirty micro-
liters samples were collected every 15 min.
Brain microdialysis was performed in awake Wistar and GK
rats, one week after stereotaxic implantation of the guide cannula.
The animals, deprived of food at 06.00 pm the day before the
experiment, had ad libitum access to water. The probe was inserted
through the guide the next day at 09.00 am. To achieve stable sero-
tonin levels, samples were collected following an acclimationGK
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Fig. 3. Effect of dexfenﬂuramine or insulin injection on Akt phosphorylation in the liver. Wistar (W) rats, white bars (A,B) and Goto-Kakizaki (GK) rats, black bars (C), were
injected ip 30 minutes before euthanasia with either saline (Con), dexfenﬂuramine (Dex, 5 mg/kg body weight) or human insulin (Ins, 1 U/kg body weight). Liver lysates were
subjected to Western blot analysis. Membranes were probed sequentially with anti-phospho-Akt (p-Akt) followed by anti-Akt (t-Akt) antibodies. All blots were revealed by
ECL and bands quantiﬁed by BIO1D software (Molecular Imaging, Vilber Lourma, France). The blots are representative of mean results presented in the histogram. The
ﬁgure contains grouped images from representative parts of the same gel. The results are expressed as the ratio of p-Akt/t-Akt and presented as means ± SEM (n = 7  11).
##, ### indicate p < 0.01 and p < 0.001 when dexfenﬂuramine or insulin injected rats were compared to respective saline injected rats.
I. Papazoglou et al. /Molecular and Cellular Endocrinology 350 (2012) 136–144 139period of 4 h after insertion of the probe (Banas et al., 2009; Gero-
zissis et al., 2001). After collection of four 15 min baseline samples,
rats had access to ad libitum food intake between 03.00 and
03.30 pm. Two samples were collected during meal time and two
more samples after the end of the meal.
2.8. Analysis of hypothalamic serotonin
The dialysates were analyzed by means of reverse-phase liquid
chromatography (HPLC) with an electrochemical detection
(Decade, Antec) at a potential of 750 mV. The chromatographic sys-
tem consisted of a 20 ll sample loop leading to a 10 cm column
(Colochrom, 3.2 mm internal diameter, 3 l C-18 packing). The mo-
bile phase consisted of an acetate buffer containing 100 lM EDTA,
1 mM octanesulfonic acid, and 6% v/v acetonitrile at pH 3.1 (Banas
et al., 2009).2.9. Histology
Rats received a lethal dose of pentobarbital, brains were re-
moved, hardened in 10% formalin and sectioned. Probe track was
identiﬁed at low magniﬁcation. Only data from animals with cor-
rect probe placements were included in data analysis.2.10. SH-SY5Y cells stimulations
The human neuroblastoma cell line (SH-SY5Y) was obtained
from Dr. B. Dufy (UMR 5543, CNRS, Bordeaux-II University, Bor-
deaux, France). Cells were differentiated for 15 days with retinoic
acid as previously described (Benomar et al., 2005a). Serum-
starved cells were incubated in serum-free DMEM in absence or
presence of insulin (100 nM), serotonin (10 lM) or insulin and
serotonin, for 10 min at 37 C. To mimic insulin resistant state,
140 I. Papazoglou et al. /Molecular and Cellular Endocrinology 350 (2012) 136–144serum-starved cells were pre-incubated with insulin (100 nM) in
serum-free DMEM, for 16 h and then stimulated with insulin
and/ or serotonin as mentioned above. To inhibit PI3K, serum
starved cells were incubated in serum-free DMEM medium in the
presence of Wortmannin (100 nM), a PI3K inhibitor (Yano et al.,
1993), for 30 min at 37 C and then stimulated with insulin and/
or serotonin as mentioned above. After treatment, cells were solu-
bilized and lysates were subjected to Western blot using adequate
antibodies as above.2.11. Statistics
Multilevel analysis of variance (ANOVA, Statistica Software)
was applied for the comparisons between different treatments,
two way analysis of variance (ANOVA, Statistica Software) with
phenotype and treatment as the between-subjects factors was ap-
plied for the comparisons between Wistar and GK rats, received
either a saline (Con), dexfenﬂuramine (Dex) or insulin (Ins) injec-
tion. Values are expressed as means ± SEM. For microdialysis stud-
ies, the mean 5-HT basal levels (before the meal) were calculated
for each animal and the percentage of variation relative to the
mean of the four baseline samples was calculated. All results were
expressed as means of percentage variations ± SEM. The statistical
signiﬁcance for microdialysis was calculated by a one way and a
two way analysis of variance followed by a Fisher PLSD test to as-
sess the signiﬁcance at each time point. Signiﬁcance was set at
p < 0.05.IR
W GK
hypothalamus 
W GK
liver 3. Results
3.1. Body weight, food intake, visceral fat tissue, blood glucose,
hormonal concentrations and basal hypothalamic serotonin release
Compared to age matched Wistar, body weight and food intake
were signiﬁcantly lower in GK rats (Table 1). In contrast, visceral
adipose tissue weight was signiﬁcantly higher in GK as compared
to Wistar rats (Table 1). Furthermore, glycemia, insulinemia and
leptinemia were also signiﬁcantly increased in GK rats as com-
pared to control rats (Table 1). Brain basal serotonin release, deter-
mined following microdialysis as described in Section 2, was
similar between the two groups (Table 1).IR
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Fig. 4. Comparison of hypothalamic and hepatic IR protein expression in the two
models. Hypothalamus and liver lysates from Wistar (W), white bars and
Goto-Kakizaki (GK) rats, black bars, were subjected to Western blot analysis.
Membranes were probed with anti-insulin receptor (IR) antibodies. The expression
was normalized using b-tubulin. All blots were revealed by ECL and bands
quantiﬁed by BIO1D software (Molecular Imaging, Vilber Lourma, France). The blots
are representative of mean results presented in the histogram. The results are
expressed as the ratio of IR/b-tubulin and presented as means ± SEM (n = 5  9).
⁄, ⁄⁄⁄ indicate p < 0.05, p < 0.001, respectively, whenGK ratswere compared toW rats.3.2. Effect of dexfenﬂuramine or insulin acute treatment on glucose,
insulin and leptin plasma levels
A signiﬁcant difference for phenotype and treatment was ob-
served in blood glucose concentrations, [F(2,24) = 21.59;
p < 0.001], between groups and between treatments. As expected,
in saline treated rats, GK group showed a signiﬁcantly higher gly-
cemia than control group (Fig. 1A). An insulin ip injection signiﬁ-
cantly lowered glycemia in Wistar and GK rats. In opposition to
insulin, dexfenﬂuramine signiﬁcantly increased glycemia in GK
group and to a lesser extend in control group (Fig. 1A).
Two way analysis of variance shows a signiﬁcant difference for
phenotype (p < 0.001), but not between treatment on plasma leptin
levels. Thus, independently of treatment, GK rats exhibited signif-
icant increase in plasma leptin levels as compared to Wistar rats.
Insulin ip injection largely increased plasma insulin levels in the
two models by 23-fold and 8-fold in Wistar and GK rats, respec-
tively (Fig. 1C). A signiﬁcant difference for phenotype and treat-
ment was observed [F(1,14) = 1.60; p < 0.001]. Dexfenﬂuramine
treatment signiﬁcantly increased insulinemia in Wistar and GK
rats (Fig. 1C) as compared to saline treatment but this effect is sig-
niﬁcantly higher in GK rats.3.3. Effect of dexfenﬂuramine or insulin injection on Akt
phosphorylation in hypothalamus
To determine Wistar and GK rats’ insulin signaling pathway
responsiveness to insulin or dexfenﬂuramine treatment, Akt
phosphorylation was determined by Western blot analysis after
normalization with total Akt. In Wistar rats, both dexfenﬂuramine
and insulin signiﬁcantly increased Akt phosphorylation as com-
pared to saline treated rats (Fig. 2A). However, these effects were
completely abolished in GK rats (Fig. 2B).
3.4. Effect of dexfenﬂuramine or insulin injection on Akt
phosphorylation in liver
In liver of Wistar rats, dexfenﬂuramine (Fig. 3A) and insulin
(Fig. 3B) induced a signiﬁcant increase in Akt phosphorylation.
Dexfenﬂuramine did not signiﬁcantly affect Akt phosphorylation
in the liver of GK (Fig. 3C). On the contrary, insulin induced Akt
phosphorylation in GK rats (Fig. 3C). Notably, the amplitude of
insulin-induced Akt phosphorylation was 4-fold in Wistar and
1.9-fold in GK rats.
3.5. Comparison of insulin receptor protein expression in the two
models
To understand the altered efﬁciency of insulin on Akt phosphor-
ylation in GK rats, we compared insulin receptor (IR) protein
expression in the two groups. IR expression was signiﬁcantly de-
creased in GK rats as compared to Wistar rats with around 40% and
60% reduction in thehypothalamus and the liver, respectively (Fig4).
3.6. Serotonin activates Akt phosphorylation in differentiated human
neuronal cell line
To determine whether serotonin has a direct effect on Akt phos-
phorylation in a neuronal model, a dose response (Fig. 5A) and a
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Fig. 5. Effect of serotonin on Akt phosphorylation in differentiated neuronal cells in culture. Differentiated SH-SY5Y cells were stimulated with serotonin in different time (A)
and concentration (B) conditions. Differentiated SH-SY5Y cells were stimulated with insulin (100 nM), serotonin (5-HT, 10 lM) or insulin + serotonin for 10 min (C). The blots
(in C) are representative of mean results presented in the histogram. The results are expressed as the ratio of p-Akt/t-Akt and presented as means ± SEM (n = 3). ⁄⁄, indicate
p < 0.01 and p < 0.001, when insulin, serotonin or insulin + serotonin stimulated cells were compared to controls (Con). #, ## indicate p < 0.01 and p < 0.001 when insulin and
serotonin alone were compared with insulin + serotonin stimulated cells. (D) Differentiated cells without pretreatment, white bars, or pretreated with insulin (100 nM) for
16 h, black bars were washed and stimulated with insulin (100 nM), serotonin (5-HT, 10 lM) or insulin + serotonin for 10 min. (E) Differentiated SH-SY5Y cells without
pretreatment, white bars or treated with Wortmannin for 30 min, black bars, and were then stimulated with insulin (100 nM), serotonin (5-HT, 10 lM) or insulin + serotonin
for 10 min. Cell lysates were subjected toWestern blot analysis. Membranes were probed sequentially with anti-phospho-Akt (p-Akt) followed by anti-Akt (t-Akt) antibodies.
All blots were revealed by ECL and bands quantiﬁed by BIO1D software (Molecular Imaging, Vilber Lourma, France). The blots are representative of mean results presented in
the histogram. Figures (E) contain grouped images from representative parts of the same gel. The results are expressed as the ratio of p-Akt/t-Akt and presented as
means ± SEM (n = 3) where ⁄ indicates p < 0.05.
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SY5Y cells. Serotonin activates Akt phosphorylation from 10 lM
(Fig. 5A) and using this concentration serotonin stimulates Akt
phosphorylation since 10 min of treatment and increased until
60 min and then declines at 120 min (Fig. 5B). Based on literature
(Prosser et al., 2006) and on the indications obtained above (Fig. 5A
and B) for serotonin together with previous studies for insulin
(Benomar et al., 2005a), cells were then treated for 10 min with
10 lM serotonin or 100 nM insulin or both. Both insulin and sero-
tonin induced Akt phosphorylation (Fig. 5C). When insulin and
serotonin were applied simultaneously, the phosphorylation ofAkt was signiﬁcantly higher than that obtained by serotonin or
insulin alone (Fig 5C).
3.7. Effect of serotonin on Akt phosphorylation following overexposure
to insulin
To mimic insulin resistant state, differentiated SH-SY5Y cells
were pretreated with 100 nM insulin for 16 hours (Benomar
et al., 2005a). After several washes, cells were acutely challenged
with serotonin, insulin or both insulin and serotonin. As expected,
insulin pretreatment completely inhibited insulin acute effect, but
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Fig. 6. Hypothalamic serotonin response to food intake. Serotonin concentrations
were measured in 15 min samples of microdialysis, before (4 samples), during
(2 samples) and after (2 samples) the meal presentation. White triangles represent
Wistar and black triangles GK rats. The percentage of variation relative to the mean
of the four baseline samples was calculated. All results were expressed as means of
percentage variations ± SEM (n = 4). ⁄indicates p < 0.05, a difference towards
baseline levels (0 level). ##indicates p < 0.01, a difference within Wistar and Goto
Kakizaki groups.
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(Fig 5D).
3.8. Serotonin activates Akt phosphorylation through a PI3K
dependent mechanism
Since we described above that the alteration of insulin signaling
impaired serotonin-dependent Akt phosphorylation we attempted
to determine whether serotonin activates Akt phosphorylation
through PI3K pathway. Thus, cells were pretreated with 100 nM
Wortmannin (inhibitor of PI3K) 30 minutes prior to treatment with
serotonin, insulin or both insulin and serotonin. Wortmannin pre-
treatment completely abolished both insulin and serotonin effect
on Akt phosphorylation (Fig. 5E).
3.9. Reduced hypothalamic serotonin response to food intake in GK
rats
To evaluate the responsiveness of serotonin to food intake and
to determine if this response is altered in a type 2 diabetes model,
extracellular hypothalamic release using microdialysis technique
was measured as described in materials and methods. The meal
signiﬁcantly increased serotonin release in Wistar and GK rats dur-
ing meal time (Fig6). However, the time course of serotonin release
during and after the meal was signiﬁcantly different between the
two models [F(1,40) = 20,97; p < 0,01], with a signiﬁcantly lower
serotonin release in GK rats as compared to Wistar.4. Discussion
There are strong evidences that inefﬁciency of brain insulin ac-
tion may be involved in the initiation and the progress of type 2
diabetes (Accili, 2004; Gerozissis, 2010; Konner et al., 2007; Obici
et al., 2002; Schwartz and Porte, 2005). To address this issue, we
compared the efﬁciency of insulin signaling, as mirrored by Akt
phosphorylation, in GK (type 2 diabetes model) and Wistar rats.
This study demonstrates that insulin failed to phosphorylate Akt
in the hypothalamus of the diabetic phenotype. Further, we have
looked for a potential association between alteration of centralinsulin and serotonin action in the diabetic model. Therefore, to
stimulate the serotonergic system, we performed an acute injec-
tion of dexfenﬂuramine, 30 min before sacriﬁce, in a dose known
to induce hypophagia (Gerozissis, 2007). To investigate the effect
of serotonin on insulin signaling pathways we have extended our
study to a human neuronal cell line.
We showed that serotonin, as insulin, activates Akt phosphory-
lation in the hypothalamus of Wistar rats, but not in diabetic GK
rats indicating an alteration of the responsiveness and the efﬁ-
ciency of the serotonergic system. In non-diabetic rats, dexfenﬂur-
amine-induced Akt phosphorylation could be attributed to either a
direct effect of serotonin in the hypothalamus as previously sug-
gested (Orosco and Gerozissis, 2001; Orosco et al., 2000) or to a
subsequent insulinemia increase in response to dexfenﬂuramine
treatment. However, in GK rats even if dexfenﬂuramine increased
insulinemia more than in Wistar rats, it did not induce hypotha-
lamic Akt phosphorylation, suggesting an insulin resistant state
and/or alteration of serotonergic efﬁciency (Fig. 7). Supporting this
notion, the regulation of speciﬁc serotonergic receptors is altered
in the brain of streptozotocin induced diabetic rats (Abraham
et al., 2010).
In the liver and as expected, insulin induced a 4-fold Akt phos-
phorylation in Wistar rats. Similarly to the hypothalamus, dexfen-
ﬂuramine induced Akt phosphorylation in the liver of Wistar rats
and was ineffective in GK, favoring the hypothesis that the effect
of serotonin is not associated to increased peripheral insulinemia.
In opposition to serotonin, insulin was still effective in GK rats,
inducing a 2-fold Akt phosphorylation above basal, indicating a
partial peripheral insulin resistance.
In an attempt to check whether serotonin acts directly on Akt
phosphorylation, we have used a human neuroblastoma cell line
(SH-SY5Y). These cells express endogenous insulin and serotonin
receptors (Benomar et al., 2005a; Schmuck et al., 1994). Here, we
demonstrated that serotonin per se was able to activate the phos-
phorylation of Akt conﬁrming our observations in the hypothala-
mus. Using a PI3K inhibitor, we show that serotonin activates
Akt phosphorylation through a PI3K dependent mechanism. To mi-
mic a dysfunction such as hyperinsulinemia, neuronal cells were
overexposed to insulin during 16 h, condition that we have previ-
ously demonstrated to induce insulin resistance (Benomar et al.,
2005a), and then subjected to serotonin treatment. In line with
the results obtained in the hypothalamus of GK rats and reinforc-
ing this ﬁnding, our data indicate that, in neuronal cells, serotonin
is unable to phosphorylate Akt after chronic insulin pre-treatment.
To assess mechanisms involved in the altered insulin efﬁciency
in the diabetic rat, insulin receptor expression was determined at
the protein level. Compared to Wistar rats, diminished insulin
receptor expression was found in the liver and the hypothalamus
of GK rats. Consequently, the alterations on Akt phosphorylation
of the diabetic model could be associated to lower insulin receptor
expression probably due to the hyperinsulinemia of GK rats. Inter-
estingly, the insulin receptor decrease in the diabetic model is
higher in the liver (55%) than in the hypothalamus (36%). Altered
insulin transport of plasma insulin in the brain, known to occur
in metabolic dysfunctions (Israel et al., 1993; Reger and Craft,
2006; Schwartz and Porte, 2005), could explain the difference of
the impairment between the periphery and the brain. Additional
modiﬁcations of negative regulators of insulin signaling pathways
or/and other factors might be involved in hypothalamic insulin
responsiveness impairment (Dadke et al., 2000). Altered endoge-
nous hypothalamic serotonergic efﬁciency might be one of them.
Although insulin signaling was affected in both the brain and the
liver of the GK rat, the sensitivity of exogenous insulin to lower ba-
sal glycemia was maintained. The gluco-regulatory efﬁciency of
insulin in GK could depend on differential effects of insulin in
organs not investigated in the present study, such as the muscle
PI3K
pAkt pAkt 
PI3K
Efficient Metabolism 
Hypothalamus Hypothalamus 
IR 5-HTRs IR 5-HTRs 
Impaired Metabolism 
Normal Physiology Diabetic state 
Ins 5-HT Ins 5-HT
Fig. 7. A summary model. This model summarizes the serotonin–insulin cross-talk in non-diabetic and diabetic state in the hypothalamus. In normal physiology, both insulin
(Ins) and serotonin (5-HT) activate PI3-kinase (PI3K)/Akt signaling pathway through their insulin receptor (IR) and serotonin receptors (5-HTRs). Food intake (FI) increased 5-
HT release in the hypothalamus less in GK than in normal rats. In diabetic state, IR is down-regulated leading to reduced PI3K/Akt activation promoting then, together with
altered serotonergic responsiveness, the impairment of metabolism.
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elements or pathways that are differentially responding in diabetes
(Lin et al., 2004; Sajan et al., 2009; Standaert et al., 2004).
Peripheral insulin injection lowered circulating glucose without
signiﬁcant change in plasma leptin levels in the two phenotypes.
Dexfenﬂuramine increased plasma insulin in both Wistar and GK
rats. Dexfenﬂuramine injection increased slightly but signiﬁcantly
blood glucose in Wistar rats, in line with observations obtained in
mice following serotonin treatment (Watanabe et al., 2010). Inter-
estingly, dexfenﬂuramine dramatically increased glycaemia in GK
diabetic rats, suggesting perturbation of serotonergic efﬁcacy.
The above results obtained by a single acute stimulation of the
serotonergic system, differ from observations on long-term treated
diabetic patients or insulin resistant rats with serotonin reuptake
inhibitors shown to lower glycaemia or hepatic glucose production
(Buhl et al., 2010; Proietto et al., 1994; Xu et al., 2010; Zhou et al.,
2007). Furthermore, the effect of dexfenﬂuramine in GK rats
regarding hyperglycemia could be, at least in part, attributed to a
potential increase of noradrenalin since dexfenﬂuramine has been
described as potent substrate for norepinephrine transporters
(Rothman et al., 2003). Furthermore despite the alteration of the
serotonergic system in GK rats, the relative food intake was not af-
fected as compared to Wistar rats. This could be attributed to in-
creased leptinemia and insulinemia that may still partially
regulate food intake even if a relative resistance to these hormones
was reported in GK rats and we cannot exclude other compensa-
tory mechanisms not yet identiﬁed.
To explore eventual endogenous alterations of the serotonergic
system in diabetes, we performed brain microdialysis in vigilant
rats. Under chow diet, basal hypothalamic serotonin release before
the chow meal was identical in Wistar and GK rats. Food intake in-
creased hypothalamic serotonin release in the two groups. How-
ever, the amplitude of food-induced neurotransmitter release in
the diabetic rats was signiﬁcantly lower than that of healthy con-
trols, suggesting a diminished responsiveness of the serotonergic
system in the hypothalamus of GK rats, following physiological
stimuli. In line with previous indirect observations in patients with
metabolic syndrome (Muldoon et al., 2004), altogether the present
data and previous own observations for increased insulin concen-
trations in the hypothalamus after stimulation of the serotonergicsystem (Orosco and Gerozissis, 2001; Orosco et al., 2000) suggest
that reduced brain serotonin release might have a negative impact
on brain insulin efﬁciency.
Globally, the present study demonstrates that insulin- and
serotonin-dependent Akt phosphorylation is altered in the hypo-
thalamus and liver of diabetic GK rats and the effect of serotonin
on Akt phosphorylation could be direct as evidenced in a human
neuronal cell line. The impairment of hypothalamic insulin efﬁ-
ciency in GK rats could be attributed, at least in part, to modiﬁca-
tions of nutrition-depended serotonin responsiveness or/and
altered efﬁciency of the neurotransmitter (Fig. 7). Our ﬁndings on
the central insulin and serotonin communication in normal func-
tion and metabolic dysfunctions are reinforced by recent loose of
function and pharmacological studies (Xu et al., 2010; Zhou
et al., 2007). Whether the alterations of insulin and serotonin sig-
naling observed in the type 2 diabetes phenotype are a conse-
quence or a starting point for the development of metabolic
dysfunctions are major issues for further investigation. Nonethe-
less, our work reveals an unexplored aspect of the central mecha-
nisms involved in insulin–serotonin cross-talk.Acknowledgements
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Abstract 
Accumulating studies show that the metabolic syndrome, including obesity and type 2 
diabetes, increases the risk of mood disorders such as depression. Nevertheless, the 
mechanisms underlying this association are not clearly understood. In the current study, we 
hypothesized that leptin- and insulin-resistance impair the activation of serotonin signaling in 
the dentate gyrus (DG). To address, this question, we analyzed the behavioral and brain-
signaling consequences of a high fat (HF) diet on adult Wistar rats. We first showed that 8-9-
week long HF diet induced significant overweight and hyperglycemia as well as depressive-
like behavior compared with control chow diet, as evidenced in saccharin preference and 
swim forced tests. By using an ex vivo approach on brain slices, we demonstrated that leptin, 
insulin and serotonin activate the PI3K/Akt/GSK3β signaling pathway in the DG and that a 
16-week HF-diet feeding results in a decrease of this activation. Furthermore, our data 
demonstrated a significantly negative correlation between depressive-like behavior and 
serotonin-induced phosphorylation of GSK3β in the subgranular cells of the DG. 
Interestingly, a standard food substitution for 6 extra-weeks induced a total loss of depressive 
symptoms, whereas physiological parameters (body weight and glycemia) remained 
significantly higher than normal. In addition, food restoration reversed the activation of the 
PI3K/Akt/GSK3β signaling pathway by leptin, insulin and serotonin in the DG. In conclusion, 
our data by providing evidence for the existence of a cross-talk between leptin, insulin and 
serotonin signaling in the brain, suggest novel molecular mechanisms linking metabolic 
syndrome and depression, and open new avenues in the understanding and management of 
these pathologies. 
Keywords 
obesity; depression; serotonin; GSK3β; dentate gyrus; ex vivo  
Introduction 
Obesity and type 2 diabetes represent two of the most rapidly increasing worldwide 
epidemics
1, 2
. These two pathologies, usually associated to the metabolic syndrome, correlate 
in both symptoms and mechanistic patterns
3, 4
, and raise the risk of developing depression
5, 6
, 
the third most frequent mental disorder in Europe
7
. Reciprocally, depressive symptoms have 
been identified as risk factors for the development of type 2 diabetes and/or obesity
8-10
. More 
globally, a recent large-scale meta-analysis of earlier studies has confirmed the two-way 
relationship between metabolic syndrome and depression 
11
.  
Metabolic syndrome includes a resistance to insulin and leptin 
4
, two hormones produced by 
pancreatic beta cells and white adipocytes, respectively, which play a crucial role in the 
regulation of energy homeostasis notably by modulating the activity of various specialized 
neuronal circuits in the central nervous system
12
. These hormones activate common signaling 
pathways
4
 and as a result they can alter the neuronal response of each other in vitro
13
 and in 
vivo
14
. This cross-talk involves the insulin receptor substrate/phosphatidylinositol-3 
kinase/Akt (IRS/PI3K/Akt) signaling pathway, which is essential for the initiation of the 
majority of neuronal functions induced by insulin
15
 and leptin
16
, and may contribute to the 
reciprocal link existing between type 2 diabetes and obesity.  
The neurotransmitter serotonin (5-HT) is a major key player in the regulation of mood and the 
impairment of its production, reuptake and action contributes essentially to depressive 
syndromes
17
. Importantly, one of the initial actions of 5-HT mediating its mood enhancing 
properties is the inhibition of glycogen synthase kinase 3β (GSK3β) by phosphorylation on 
Ser9 residue 
18-20
, an important downstream target of the PI3K/Akt pathway
21
. Analogous 
properties in blocking the activity of GSK3β are exhibited by insulin22 and leptin23, which 
assign them as candidates for direct anti-depressive action and interaction with the 
serotonergic signal transduction.  
It has been suggested that the association between depression and obesity may be due to 
impaired leptin activity in the hippocampus, a brain region involved in mood disorders
24
. In 
addition, putative biochemical and cellular mechanisms have been proposed by studies that 
describe how the dietary
24-26
 (e.g. high fat diet) or the genetic (e.g. under-expression of the 
insulin receptor
27
 or leptin receptor
28
) manipulation, which decrease the sensitivity and 
efficiency of these hormones, can further induce or exacerbate depressive-like symptoms in 
rodents. However, the precise mechanisms underlying this link remained unknown. 
Considering that we have previously demonstrated that insulin and 5-HT signaling pathways 
can interact via PI3K/Akt in neurons
29
, we hypothesized that insulin and leptin resistance may 
affect 5-HT signaling in the dentate gyrus of the hippocampus, and in particular the 
subgranular layer. Indeed, this area highly expresses the receptors of insulin 
30
 and leptin 
31, 32
 
and their substrates 
30, 33
, and is considered as an important target of antidepressant action, 
notably due to its intense serotonergic innervations 
34, 35
. 
The aim of this study was thus to gain evidence about how leptin- and insulin-resistance 
contribute to a depressive like behavior by interacting with the serotonergic system. To 
address this question, we submitted rats to a high fat (HF) diet and we studied the correlations 
between diet-induced obesity, type 2 diabetes, depression, and the sensitivity to leptin, insulin 
and 5-HT in subgranular neurons. Here we validated that rats fed a high fat diet (HF) exhibit a 
reversible higher risk of developing depressive syndrome, as attested by behavioral tests such 
as the forced swimming test (FST) and the sucrose preference test (SPT). Furthermore, we 
demonstrated that this may be due, at least in part, to a cross-desensitization of the 
subgranular neurons to leptin, insulin and 5-HT at the level of the PI3K/Akt/GSK3β signaling 
pathway.  
  
Materials and Methods 
Animals and diets 
Eight weeks old male Wistar rats (RjHan:WI) were obtained from Janvier (Saint-Berthevin, 
France). The rats were pair-housed and kept under a 12-h light/dark cycle in a temperature-
controlled environment at 22 °C. After one week of acclimatization, the animals received ad 
libitum experimental diets: either standard chows (#113 Safe, Augy, France) (C group) or a 
purified high fat diet (#235 version 2 Safe) (HF group). In the HF diet, 46% of the energy 
content derived from lipids versus 17% in the standard diet. Furthermore, the respective 
caloric intake differed between both diets: 4397 kcal/kg in the HF diet versus 3 000 kcal/kg in 
the standard one. After 10 weeks of experimental diets, half of the HF group was subjected to 
a restoration of the standard diet for 6 extra-weeks (HF/C group), whereas the second half of 
this group was kept under a HF diet (Fig. 1). Body weight and food intake were recorded 
throughout the experiments. Rats were always killed at the same time of the day (4-5 h after 
lights on). Experiments were performed according to European legal requirements (Decree 
86/609/EEC). 
 
Brain slice experiments 
Ex vivo experiments were modified from previous studies
36, 37
. Rats fed a control or a HF diet 
were decapitated under isofluorane anaesthesia, and their brain immediately removed and 
transferred into ice-cold oxygenated Krebs-Henseleit bicarbonate buffer (K3753, Sigma, 
Lyon, France) supplemented with 24.9 mM NaHCO3, 2 mM CaCl2, 11 mM ascorbic acid and 
315 mM thiourea (Sigma). Three hundred µm-thick slices of hippocampus were prepared 
caudally from Bregma -1.8 mm to -4.8 mm with the help of a stereotaxic atlas (Paxinos and 
Watson, 5
th
 edition). Slices were halved with a razor blade through the medial line and left for 
a 1 h recovery at RT in oxygenated buffer. Hemislices were then transferred and immersed in 
the chamber system (Campden Instruments Ltd, Leicester, UK) continuously oxygenated and 
perfused with Krebs buffer with a flow rate of 2 mL/min, and slowly warmed to 35 °C. Slices 
were incubated for 5 min with 5-HT (10 µM; Sigma), insulin (100 nM; Actrapid®, Novo 
Nordisk, La Défense, France), or leptin (10 nM; Protein Laboratories Rehovot, Rehovot, 
Israel). Control slices were incubated with buffer alone. 
 
Immunohistochemistry 
Tissue preparation. After the 5-min stimulation in the perfusion system, slices were directly 
fixed by immersion in cold 4% paraformaldehyde in PBS for 2 hours before being 
cryoprotected in 20% sucrose for 2 hours at 4 °C. They were then frozen and cut coronally 
with a cryostat at -16°C into 20 µm thick sections. The sections were thawed onto Superfrost 
Plus slides (Thermo Scientific) so that all the conditions (control and treated) were present on 
the same slide, and finally stored at -20 °C until use. 
Immunofluorescence. Multiple immunofluorescent stainings including the detection of pAkt, 
pGSK3β, Ki67, Hu protein and calretinin were performed on brain sections. The main lines of 
the immunohistochemical protocol were the same as those previously described with slight 
adaptations
38
. Briefly, hippocampal sections were incubated overnight at 4 °C with a 
combination of rabbit anti-pAkt (Ser473) (D9E) XP
TM
 (1:100; Cell Signaling Technology, 
Beverly, MA, USA), rabbit anti-pGSK3β (Ser9) (D85E12) XP® (1:100; Cell Signaling 
Technology), rabbit monoclonal anti-Ki67 (1:100, Novus Biologicals, Cambridge, UK) and 
mouse anti-HuC/D (1:50, Molecular Probes, Life Technologies, Saint-Aubin, France). 
Primary antibodies were visualized by incubating the sections for 1 h at RT with Alexa-488, 
Alexa-546 or Alexa 633 (Life Technologies) conjugated donkey anti-goat, rabbit, or mouse 
antibodies (1:400). Sections were finally counterstained with DAPI. 
Confocal microscopy and quantification. Immunofluorescence was examined by confocal 
microscopy (Zeiss LSM 700 system; Zeiss microscopy, Jena, Germany). Series of optical 
sections were collected through the Z axis at 1 µm intervals and averaged four times. Four 
diode lasers at 405 nm, 488 nm, 555 nm and 639 nm were used for the excitation of DAPI, 
Alexa-488, Alexa-546 and Alexa-633, respectively. Images were taken through a 10× or a 20× 
objective. Quantifications were performed with ImageJ 1.36b software (NIH, USA). Briefly, 
pAkt levels were assessed by measuring the integrated fluorescence densities after background 
subtraction within nine reproductive contours of dentate gyrus throughout the rostro-caudal and 
medio-lateral axes of the brain. All the values were normalized with that of the control 
condition of the same animal and final data represented as the mean percentage of the control ± 
SEM. Besides, the number of pGSK3β-, Hu- and/or Ki67-positive cells was counted manually 
in the whole subgranular zone of each dentate gyrus. The data represent the average of the sum 
of 3 sections distributed homogeneously on the rostro-caudal axis ± SEM.  
 
Measure of depression-like behavior  
Anhedonia. Anhedonia was evaluated by performing a saccharin preference test modified 
from
39
. In order to prevent a possible bias induced by the consumption of a high calorie and 
low carbohydrate HF diet on the appeal to a high sugar beverage, and to limit the impact of 
such a beverage on glycaemia, we used saccharin, a palatable sweetener for rats 
40
, instead of 
sucrose. Prior to the preference test, rats were submitted to two successive habituations of 2 
days each. The first one consisted in training the rats to drink water from two bottles, and the 
second one aimed to prevent novelty-dependent preference to sweetener by exposing the rats 
to two bottles filled with 0.025% saccharin. Then the rats were given a choice between water 
and increasing concentrations (0.025% and 0.05%) saccharin for 2 days per concentration. To 
avoid placement-dependent preferences, the position of the two bottles was randomly changed 
every day. The relative daily saccharin intake was calculated as absolute intake (g) per rat 
body weight. 
 
Forced swim test (FST). Our protocol was adapted from
41
. Rats were subjected to two 
swimming sessions, a pre-test of 15 min followed by a 5-min long test 24 h later. Rats were 
placed individually in a clear, vertical cylindrical container in Plexiglas (height: 60 cm, 
diameter: 40 cm) filled to a depth of 45 cm with water at 25 °C. The cylinder was rinsed and 
filled with clean water before each trial. Rats were dried and warmed up immediately after the 
swim period, and placed into a temporary dry cage so that pre-swim rats are not in direct 
contact with post-swim rats. The swimming sessions were recorded from the side using a 
video camera. The latency and duration of climbing, swimming and immobility, as well as the 
frequency of head shaking, were measured by using ethological software (Observador®, 
Behavior Scoring Program, Athens, Greece). The higher body weight of HF rats has not 
biased the swim performance of the rats since individual body weights did not correlate with 
either immobility, swimming or climbing. 
Circular corridor. The general locomotor activity of the rats was evaluated in the following 
day. This test was used to rule out the possibility that an increase in the immobility time in the 
FST was due to a general decrease in ambulatory activity of the HF rats. The apparatus 
consisted of a circular corridor (Imetronic, Pessac, France) in which the outside radius of the 
inner wall was 32 cm and the inside radius of the outer wall was 60 cm, providing a 14-cm 
wide running area. Four infrared beams were placed every 90° at a height of 5 cm above the 
running platform. The locomotor activity was counted when animals interrupted two 
successive beams and thus had traveled a quarter of the circular corridor. The number of 
quarter turns, recorded via a computer equipped with appropriate software, was used as an 
index of the locomotor activity. The activity scores were recorded every 10 min for a period 
of one hour. 
 
Statistics 
The data are represented as mean ± standard error of the mean (SEM). Statistical analysis was 
performed using InVivoStat (invivostat.co.uk) and data was tested for outliers using predicted 
vs. residuals plot test. Data were statistically analyzed using one-way ANOVA (post hoc 
Bonferroni), repeated measures parametric analysis or paired Student’s t-test. Statistical 
significance was set at p<0.05.  
Results 
Effects of the diets on metabolic parameters 
A significant overweight in rats fed a HF diet became established from the second week of 
regimen (+4.7% in HF compared with C rats; p<0.05; Fig. 1A). During the 16 weeks of HF 
feeding, the mean body weight progressively increased from 377.9 ± 2.5 to 720.5 ± 21.3 g. By 
comparison, control animals exhibited a lesser augmentation of their body weight (from 368.8 
± 5.1 g to 639.1 ± 9.3 g) (Fig. 1A). The average body weight was significantly increased in 
HF rats compared with C animals by 8.9% and by 12.7% after 9 and 16 weeks of regimen, 
respectively (p<0.001) (Fig. 1A). The establishment of overweight in HF rats was associated 
with a significant 13.6% increase in mean energy intake after 8 weeks of diet (p<0.001), 
which persists at 15 weeks (Fig. 1B).  
The diet substitution of HF with C food from the tenth to the sixteenth week (HF/C group) 
was associated with a significant slowdown of the body weight gain curve compared with 
non-restored HF animals (p<0.05). Nevertheless, HF/C rats remained significantly bigger than 
C animals after 6 weeks of C food restoration (p<0.001; Fig. 1B). The mean energy intake of 
HF/C rats was similar to that of C animals (Fig. 1B). 
In comparison to C group, rats fed a HF diet for 8 weeks exhibited a significant 
hyperglycaemia (116.9 ± 1.9 mg/dL in HF vs 109.0 ± 1.8 mg/dL in C; p<0.05) (Fig. 1C). 
After 16 weeks of diet, HF rats and HF/C were significantly hyperglycaemic in comparison to 
control animals (Fig. 1C). 
 
HF feeding promotes a reversible depressive-like behavior 
In order to determine the functional consequences of a HF diet on the development of 
depressive symptoms, we used two different behavioral tests: the preference to saccharin and 
the FST. A significant reduction in the consumption of 0.025% saccharin solution over the 
first 24 hrs was observed in rats receiving the HF diet for 8 weeks compared to their controls 
(p<0.05; Fig. 2A). This difference was no more significant on the two following days (not 
shown). During the FST, rats fed a HF diet for 9 weeks exhibited a significant decrease in 
swimming time (p<0.05) and a significant increase in immobility time (p<0.05) compared to 
their controls (Fig. 2B). The climbing time was similar between HF and C rats. Six weeks of 
diet substitution led to a total normalization of the swimming and the immobility times in the 
FST (Fig. 2C). It is noteworthy that the HF diet decreased the immobility latency (not shown), 
and that this behavioural characteristic was reversed by control diet restoration (238.8 s in C 
vs 38.7 s in HF and 227.8 s in HF/C; p<0.001). The general locomotor activity of the rats was 
assessed in a circular corridor. No difference was evidenced between C, HF and HF/C groups 
(Fig. S1). The number of head shakes during the FST was significantly decreased in HF 
animals in comparison to C (p<0.05; Fig. 2D).  
 
HF feeding impairs serotonin, insulin and leptin signaling in the subgranular neurons of 
the dentate gyrus 
The immunohistochemical detection of p(Ser9)GSK3β and p(Ser473)Akt after a 5-min-
stimulation of hippocampal slices with 5-HT (10 µM), leptin (10 nM) or insulin (100 nM) was 
used to compare the sensitivity of dentate gyrus cells to these factors in C, HF and HF/C rats. 
In C rats, the incubation of hippocampal slices with 5-HT, leptin or insulin 
significantly increased the general level of pGSK3β-immunofluorescence in the molecular 
and granular layers of the dentate gyrus (Fig. 3A-D). Moreover, the number of pGSK3β-
positive cell bodies increased, mostly in the subgranular layer (Fig. 3E-F). The augmentation 
of pGSK3β-positive cells was estimated to 56% ± 7 (p<0.01), 33% ± 2 (p<0.05) and 25% ± 
12 (p<0.05) with 5-HT, leptin or insulin, respectively, as compared with basal (not 
stimulated) conditions (Fig. 3L). The majority of these cells (70%) were neurons (Fig. S2AB), 
as shown by co-detecting pGSK3β and HuC/D proteins (arrowheads; Fig. 3E-G). This 
indicates that 5-HT, leptin and insulin stimulations increased the absolute number of 
pGSK3β-positive neurons in the subgranular zone of the dentate gyrus (Fig. S2B). The 
number of non-neuronal (Hu-negative) pGSK3β-positive cells remained unchanged after the 
treatments (Fig. S2A). Serotonin, leptin and insulin were no more capable of inducing 
phosphorylation of GSK3β in the dentate gyrus of HF animals (Fig. 3H-L). On the contrary, 
the response to these factors of dentate gyrus coming from HF/C rats was not significantly 
different to that of C rats. Indeed, the average number of pGSK3β cells was significantly 
increased by 40% ± 18 (p<0.01), 46% ± 28 (p<0.05) and 41% ± 20 (p<0.05) after incubation 
with 5-HT, leptin or insulin respectively, as compared with basal conditions (Fig. 3L). 
The perfusion of hippocampal slices obtained from C rats with 5-HT, leptin or insulin 
almost trebled pAkt levels in the dentate gyrus (Fig. 4A-D, L). This effect was mainly 
observed in the subgranular zone of the dentate gyrus. It is noteworthy that some scattered 
pAkt-positive cells were also located in the hilus. PhosphoAkt was mainly found in neurons, 
as indicated by co-detecting HuC/D protein (arrowheads; Fig. 4E-G). Hippocampal slices 
obtained from HF rats exhibited no phosphorylation of Akt in the dentate gyrus after 
stimulation with 5-HT, leptin or insulin (Fig. 4H-L). The restoration of a C diet for 6 weeks 
tended to normalize the sensitivity of dentate gyrus cells to 5-HT, leptin and insulin, since 
these factors induced an augmentation of pAkt levels estimated to 72% ± 16 (p<0.01), 127% 
± 40 (p<0.001) and 160% ± 32 (p<0.001), respectively, compared to non-stimulated condition 
(Fig. 4L). These values were not significantly different to those of C rats.  
 
 
 
Depressive-like behavior correlates negatively with serotonin-induced GSK3β 
phosphorylation in the subgranular neurons of the dentate gyrus. 
Taking all the groups into account, the 5-HT-induced phosphorylation of GSK3β in the 
subgranular cells was correlated positively with the swimming time and negatively with the 
immobility time (Fig. 5A,D; p<0.05). Likewise, the response of subgranular cells to leptin 
positively correlated with the swimming time (Fig. 5B; p<0.05). However, no correlation was 
found between any behavioural parameters and the insulin-induced phosphorylation of 
GSK3β (Fig. 5C,F). Similarly, no correlation was evidenced between phosphorylation levels 
of Akt and FST parameters (Fig. 5G-L). Finally, no correlation was found between 
phosphorylation of GSK3β/Akt in the subgranular cells with the climbing times (not shown). 
  
Discussion 
The current study demonstrates that HF diet-induced metabolic syndrome promotes a 
reversible depressive-like behavior in rats, which occurs, at least in part, due to an impairment 
of the Akt/GSK3β pathway activation in the hippocampus. Indeed, we show that, in 
physiological conditions, leptin and insulin increase the phosphorylation of Akt and GSK3β 
in the subgranular neurons of the dentate gyrus, and that the activation of this pathway is 
prevented by a 16-week-long HF diet. Moreover, this HF-induced leptin- and insulin-
resistance was associated with a blockade of the serotonin-induced activation of the 
Akt/GSK3β pathway in the same area, suggesting a possible cross-talk between leptin, insulin 
and serotonin signaling in the subgranular neurons. These data enrich the understanding of the 
neurobiological links between metabolic pathologies and depression and propose an 
alternative mechanism to the ones described previously
24, 25
. 
GSK3β, a serine/threonine protein kinase and downstream substrate of the PI3K/Akt 
pathway 
21
, plays an important role in mood regulation 
42
, notably in the physiopathology of 
depression. For instance, heterozygous GSK3β+/- mice are less prone to depression since they 
exhibit decreased immobility time in the FST 
43, 44
, and selective GSK3 inhibitors exert 
antidepressant action in the FST in mice and rats 
45, 46
. In addition, GSK3 is an important 
target of mood stabilizers and antidepressants 
42
. It is inhibited by lithium 
47
, and mice 
overexpressing mutant forms of GSK3α and/or β on Ser21 and/or Ser9 residues exhibit 
increased immobility time in the FST after administration of fluoxetine, revealing that the 
antidepressant action of fluoxetine occurs via GSK3 inhibition in mice 
18, 48
.  
Our experiments indicate for the first time to our knowledge an alteration of serotonin 
signaling in HF-induced depression, as evidenced by the accurate analysis of the FST. Indeed, 
in our study, the HF diet induced an increased immobility time and a decreased swimming 
time whereas the climbing time was unchanged in comparison to C and HF/C groups, 
reflecting a reduced action of the serotonergic system 
49, 50
. Furthermore, swimming and 
immobility times correlated with serotonin-dependent GSK3β phosphorylation levels. These 
findings suggest that serotonin-induced phosphorylation (namely inhibition) of GSK3β in the 
dentate gyrus is an essential step for the manifestation of reduced depressive behavior and a 
process that could represent a molecular link between depression and insulin-/leptin-
resistance conditions. Besides, a behavioral aspect linked to serotonergic action that has not 
been detected in previous studies is the number of head shakes in the forced swim test. We 
have shown that this behavior, which indicates search for an escape and is associated with the 
activation of the serotonin receptors 1A, 2 and cAMP activation
51, 52
, is also decreased in HF 
rats when compared with control animals.  Finally, we report for the first time to our 
knowledge a decreased immobility latency in HF-induced depressive-like behavior
53
. 
Feeding rats a HF diet (40% kcal fat) for 8 weeks caused a depressive-like behavior, 
as attested by two complementary behavioral experiments, the saccharine preference test and 
the FST. Indeed, the HF fed animals exhibited a lower relative consumption of saccharine as 
well as a significant increased immobility time paralleled to a decrease in swimming and 
immobility latency time in the FST. This indicates that a milder protocol than the ones 
published earlier (~60% kcal fat for 12
1
 to 16
2
 weeks) is sufficient to trigger depressive-like 
behavior. The HF diet primarily induced an overweight and a hyperglycemia, two respective 
indicators of resistance to leptin and insulin. This resistant state was corroborated in the brain 
at the cellular level since the HF diet totally prevented the phosphorylation of Akt and GSK3β 
by these hormones on brain slices.  
Previous studies have suggested antidepressant effects of leptin and insulin, as well as 
a potential involvement of the Akt/GSK3β pathway in this process. For instance, leptin 
receptor deletion from the hippocampus results in depressive-like behaviors in mice 
28
. In 
addition, i.p. injections of leptin reduce depressive-like symptoms and inhibit hippocampal 
GSK3β via phosphorylation on Ser9 in rats 23. In our experiments, the positive correlation 
between leptin-induced GSK3β phosphorylation levels and the immobility time in the FST 
provides the missing link between depression and leptin signaling in the dentate gyrus. It is to 
note that the involvement of the JAK2/STAT3 pathway in the aforementioned effects of leptin 
is unlikely, as suggested by Scott and colleagues (Elmquist et al., 2009). Besides, the 
streptozotocin-treated or db/db diabetic mice exhibit lengthened immobility in the FST, which 
can be partially reversed by insulin treatment 
54
. In addition, it has been shown that 
rosiglitazone, an anti-diabetic compound improving insulin sensitivity by up-regulation of 
PI3K/Akt pathway 
55
, exhibits antidepressant properties in control and diabetic (db/db) mice 
56
. However, an impairment of locomotor activity has been observed in these models, limiting 
the interpretation of the results. Further, we evidenced no significant correlation between 
insulin-induced Akt/GSK3β phosphorylation levels and the immobility time in the FST. This 
could reflect a not exclusive but synergistic effect of insulin with other factors, such as leptin 
and serotonin, yet other effects unrelated to depression are possibly mediated by insulin in this 
region or elsewhere. Altogether, our data show for the first time that in HF-induced leptin-
/insulin-resistance, the impaired activation of the Akt/GSK3β pathway in the dentate gyrus 
may contribute to the onset of depressive-like behavior.  
The phosphorylation of Akt and GSK3β induced by incubation of brain slices with 
leptin, insulin and serotonin in control and HF/C rats mainly occurred in neurons of the 
subgranular layer, as evidenced by anti-Hu staining. Moreover, the behavioral parameters 
correlated with the phosphorylation levels of GSK3β specifically in the subgranular zone, but 
not in the whole dentate gyrus (including the hilus and the other cellular layers). Thus our 
study indicates that leptin, insulin and serotonin activate the Akt/GSK3β pathway in the 
subgranular neurons, and that the impact of the HF diet on depression may involve, at least in 
part, this area. This is in accordance with a previous study showing that injection of lentiviral 
GSK3β shRNA in this region that decrease the level of this protein in the subgranular cells 
decreased immobility times in FST and tail suspension test
57
.  Whereas it was known that 
subgranular neurons express leptin 
31, 32
, insulin 
30
 and serotonin receptors 
58
, we show here 
for the first time a possible cross-talk could exist between these factors in this area, which 
would underlie the link between metabolic syndrome and depression. Several brain regions 
have been proposed to contribute to mood disorders. However, the subgranular layer of the 
dentate gyrus has been thought to play a major role in the physiopathology of depression. 
Indeed, this region is submitted to a continuous neurogenesis through lifespan, which is 
required for the behavioral effects of antidepressants
59
. Such a neurogenesis is modulated by a 
variety of factors, including serotonin 
60
, insulin 
61
 and leptin 
23
 and involves GSK3β 62, 63.  
 
Taken together, our data indicate that a HF-induced leptin- and/or insulin-resistance 
may alter mood directly or indirectly through the impairment of serotonin signaling at the 
level of GSK3β in the dentate gyrus. Such a cross-talk between serotonin and insulin 
signaling has already been observed in the hypothalamus and in neuroblastoma cells via 
PI3K/Akt 
29
. Moreover, the fact that we (and others) evidenced a molecular link between 
obesity and depression in rodent strongly indicates that the social and psychological aspects 
are not the only links between these pathologies. A molecular neurobiological substrate 
underlies this interaction and should be taken into consideration in treating patients suffering 
from at least one these pathologies. Finally, the deleterious impact of the HF diet on mood 
and brain signaling could be reversed after six weeks of standard food restoration. This is in 
agreement with a meta-analysis by Fabricatore et al., where it is suggested that weight loss 
leads to a decrease of depressive symptoms in obese individuals 
64
. Nevertheless, the fact that 
glycaemia and body weight remained elevated in HF/C animals indicates that the brain 
responds faster than peripheral organs to food restoration. This could be of great importance 
for clinical aspects of psychological disorders related to metabolic disease. 
In conclusion, our study shows that in HF-induced metabolic syndrome, leptin and 
insulin resistance may impact on the serotonin-dependent phosphorylation of GSK3β in the 
subgranular neurons of the dentate gyrus, which contributes to the onset of depression. Such 
an alteration is reversible at the molecular and behavioral levels with an appropriate diet. 
Taken together, our data suggest the existence of a signaling cross-talk between serotonin, 
leptin and insulin converging on GSK3β, which may underlie the link between metabolic 
syndrome (including obesity and type 2 diabetes) and depression. The bidirectional 
association between these pathologies deserves further investigation. More generally, our 
study suggests that metabolic syndrome and depression should be incorporated into clinical 
decisions as symptoms of a common pathology. 
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 Figure legends 
Figure 1: Experimental schedule and effect of high-fat diet on body weight, energy intake 
and glycemia in male Wistar rats. (A) Body weight curves of rats exposed to chow diet (C, 
closed boxes), high-fat diet (HF, open circles) or high-fat diet reversed to chow diet (HF/C, 
closed circles). Data are presented as mean ± SEM. C vs HF: *p<0.05, ***p<0.001, HF vs 
HF/C: 
#
p<0.05, C vs HF/C: 
†††
p<0.001 (assessed by repeated measures parametric analysis 
test). The dashed line indicates the starting time of diet restoration. The bars indicate the time 
of performance of each test. SPT, Saccharin Preference Test; FST, Forced Swim Test. (B) 
Energy intake curves of rats exposed to chow diet (C, closed boxes), high-fat diet (HF, open 
circles) or high-fat diet reversed to chow diet (HF/C, closed circles). Mean individual food 
intake in week 8 and week 15. Data are presented as mean ± SEM. C vs HF: ***p<0.001, HF 
vs HF/C: **p<0.01, C vs HF/HF: **p<0.01 (assessed by repeated measures parametric 
analysis test) C: n=10, HF: n=9, HF/HF: n=4, HF/C: n=5 (C) Blood glucose levels of rats 
exposed to chow diet (C, black), high-fat diet (HF, white) or high-fat diet reversed to chow 
diet (HF/C, striped) at 8 and 16 weeks. C: n=10, HF: n=9, HF/HF: n=4, HF/C: n=5. Data are 
represented as mean ± SEM. *p<0.05 vs C. 
Figure 2: Effect of high-fat diet on depressive-like behavior in male Wistar rats. (A) 
Saccharin preference test in rats exposed for 8 weeks to chow diet (C, black) or high-fat diet 
(HF, white). (B) Climbing, swimming and immobility times of rats exposed to chow diet (C, 
black) or high-fat diet (HF, white) for 9 weeks. (C) Climbing, swimming and immobility 
times of rats exposed to chow diet (C, black), high-fat diet (HF, white) or high-fat diet 
reversed to chow diet (C, striped) after 16 weeks of experiment. (D) Number of head shakes 
of rats in the FST exposed to chow diet, high-fat diet or high-fat diet after 8 weeks of 
experiment. C: n=10, HF: n=9, HF/HF: n=4, HF/C: n=5. All data are presented as mean ± 
SEM. *p<0.05 vs C. Assessed by one-way ANOVA. 
Figure 3: Immunohistochemical detection of p(Ser9)GSK3β (green) and HuC/D (red) in the 
dentate gyrus. (A-D) Immunofluorescent staining of pGSK3β in rats fed a chow diet after 
stimulation of brain slices with 5-HT (10 µM), leptin (10 nM) and insulin (100 nM) for 5 min. 
(E-G) Colocalization of pGSK3β (green) and HuC/D (red) in subgranular cells are shown 
with arrowheads. (H-K) pGSK3β immunofluorescence in the dentate gyrus of rats fed a HF 
diet after stimulation of brain slices with 5-HT (10 µM), leptin (10 nM) and insulin (100 nM). 
For 5 min (L) Quantification. Effect of stimulation with 5-HT, leptin and insulin on the 
number of pGSK3β-positive cells in the dentate gyrus of rats fed a chow diet (C), high fat 
(HF) or high-fat diet reversed to chow diet (HF/C). n=3-4 per group. All data are presented as 
% of control (not stimulated) ± SEM. *p< 0.05; **p< 0.01 vs control (not stimulated). 
Corresponding DAPI counterstained sections (blue) are shown on the right top corner of each 
picture. Confocal laser scanning. Focal planes. Scale bars=135 µm (A-D;H-K); 225 µm (E-
G). 
Figure 4: Immunohistochemical detection of p(Ser473)Akt (green) and HuC/D (red) in the 
dentate gyrus (A-D) Immunofluorescent staining of pAkt in rats fed a chow diet after 
stimulation of brain slices with 5-HT (10 µM), leptin (10 nM) and insulin (100 nM) for 5 min. 
(E-G) Colocalization of pAkt (green) and HuC/D (red) in subgranular cells are shown with 
arrowheads. (H-K) pAkt immunofluorescence in the dentate gyrus of rats fed a HF diet after 
stimulation of brain slices with 5-HT (10 µM), leptin (10 nM) and insulin (100 nM) for 5 min. 
(L) Quantification. Effect of stimulation with 5-HT, leptin and insulin on the integrated 
density of pAkt immunofluorescence in the dentate gyrus of rats fed a chow diet (C), high fat 
(HF) or high-fat diet reversed to chow diet (HF/C). n=4 per group. All data are presented as % 
of control (not stimulated) ± SEM. *p< 0.05; **p< 0.01 vs control (not stimulated). 
Corresponding DAPI counterstained sections (blue) are shown on the right top corner of each 
picture. Confocal laser scanning. Focal planes. Scale bars=135 µm (A-D;H-K); 225 µm (E-
G). 
Figure 5: Correlation graphs of swimming and immobility times in the FST with GSK3β and 
Akt phosphorylation in rats after 16 weeks of experiment. Significant correlations of 5-HT-
induced GSK3β phosphorylation with (A) swimming time, (B) immobility time, (C) leptin-
induced pGSK3β.  
 
Fig. S1. Locomotor activity analysis. Number of quarter turns in the circular corridor over 60 
min of rats exposed to chow diet (C, closed boxes), high-fat diet (HF, open circles) or high-fat 
diet reversed to chow diet (HF/C, closed circles) after 16 weeks of experiment. 
Fig. S2. (A) Repartition of HuC/D-positive (Hu+) and negative (Hu-) cells among pGSK3β 
positive cells in the dentate gyrus of rats (all groups included), after stimulation with 5-HT 
(10 µM), leptin (10 nM) and insulin (100 nM) for 5 min. (B) Percentage of HuC/D-positive 
(Hu+) and negative (Hu-) cells among pGSK3β-positive cells in the dentate gyrus of rats (all 
groups and stimulations included). 
 
500
600
700
800
week 8 week 15
300
350
400
450
500
550
600
650
700
750
800
0 1 2 3 4 5 6 7 8 9 10111213141516
B
o
d
y
 w
e
ig
h
t 
(g
) 
Time (weeks) 
Figure 1 
 
* 
 
* 
 
* 
0
20
40
60
80
100
120
140
week 8 week 16
B
lo
o
d
 g
lu
c
o
s
e
 (
m
g
/d
L
) 
* 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** *** 
*** *** 
*** 
# 
# 
# 
††† 
††† ††† 
††† ††† ††† 
B 
C 
C 
HF 
HF/C 
C 
HF 
HF/C 
C 
HF 
HF/C 
A 
0
100
200
300
400
500
600
700
800
900
1000
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
E
n
e
rg
y
 i
n
ta
k
e
  
(k
c
a
l/
w
e
e
k
) 
Time (weeks) 
*** 
 **  ** 
SPT 
FST 
Slices 
050
100
150
200
250
Climbing Swimming Immobility
T
im
e
 (
s
e
c
o
n
d
s
) 
0
50
100
150
200
250
Climbing Swimming Immobility
T
im
e
 (
s
e
c
o
n
d
s
) 
0
10
20
30
40
50
60
70
80
90
100
C HF
%
 o
f 
s
a
c
c
h
a
ri
n
e
 c
o
n
s
u
m
p
ti
o
n
 
Figure 2 
B A 
C D 
 * 
 * 
 * 
 *  * 
 *  * 
C 
HF 
HF/C 
C 
HF 
0
10
20
30
40
50
60
C HF
N
u
m
b
e
r 
o
f 
h
e
a
d
 s
h
a
k
e
s
 
* 
050
100
150
200
C HF/HF HF/C
Figure 3 
A B C D 
E F G 
H I J K 
Control 5HT Lep Ins 
Control 5HT Lep Ins 
 ** 
N
u
m
b
e
r 
o
f 
p
G
S
K
3
b
-p
o
s
it
iv
e
 
c
e
ll
s
 (
%
 o
f 
c
o
n
tr
o
l)
 
L 
Control 
5-HT 
Leptin 
Insulin 
 *  * 
 ** 
 * 
 * 
pGSK3b Hu pGSK3b/Hu 
Figure 4 
A B C D 
E F G 
H I J K 
Control 5HT Lep Ins 
Control 5HT Lep Ins 
0
100
200
300
400
C HF/HF HF/C
 ** 
p
A
k
t 
In
t.
 D
e
n
s
it
y
  
(%
 o
f 
c
o
n
tr
o
l)
 
L 
Control 
5-HT 
Leptin 
Insulin 
 **  ** 
 ** 
 *** 
 *** 
pAKT Hu pAKT/Hu 
R² = 0.1547 
50
100
150
200
250
0 200 400 600
S
w
im
m
in
g
 (
s
) 
pAkt (5-HT) 
Figure 5 
A B C R² = 0.3532 
50
100
150
200
250
50 100 150 200
S
w
im
m
in
g
 (
s
) 
pGSK3β (5-HT) 
R² = 0.4021 
50
100
150
200
250
50 100 150 200 250
S
w
im
m
in
g
 (
s
) 
pGSK3β (leptin) 
R² = 0.2389 
50
100
150
200
250
50 100 150 200 250
S
w
im
m
in
g
 (
s
) 
pGSK3β (insulin) 
D E F R² = 0.3663 
0
50
100
150
200
250
50 100 150 200
Im
m
o
b
il
it
y
 (
s
) 
pGSK3β (5-HT) 
R² = 0.1949 
0
50
100
150
200
250
50 100 150 200 250
Im
m
o
b
il
it
y
 (
s
) 
pGSK3β (leptin) 
R² = 0.1908 
0
50
100
150
200
250
50 100 150 200 250
Im
m
o
b
il
it
y
 (
s
) 
pGSK3β (insulin) 
R² = 0.1112 
50
100
150
200
250
0 200 400 600 800
S
w
im
m
in
g
 (
s
) 
pAkt (leptin) 
R² = 0.2296 
50
100
150
200
250
0 200 400 600
S
w
im
m
in
g
 (
s
) 
pAkt (insulin) 
G H I 
J K L R² = 0.2562 
0
50
100
150
200
250
0 200 400 600
Im
m
o
b
il
it
y
 (
s
) 
pAkt (5-HT) 
R² = 0.0971 
0
50
100
150
200
250
0 200 400 600 800
Im
m
o
b
il
it
y
 (
s
) 
pAkt (leptin) 
R² = 0.2953 
0
50
100
150
200
250
0 200 400 600
Im
m
o
b
il
it
y
 (
s
) 
pAkt (insulin) 
 *  * 
 * 
Supplemental data 
Figure S1 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60
n
u
m
b
e
r 
o
f 
q
u
a
rt
e
r 
tu
rn
s
 
Time (minutes) 
C 
HF 
HF/C 
010
20
30
40
50
60
70
80
Hu+ Hu-
0
5
10
15
20
25
30
35
Hu+ Hu-
N
u
m
b
e
r 
o
f 
p
G
S
K
3
b
-p
o
s
it
iv
e
 c
e
ll
s
 
Figure S2 
 *** 
 *** 
 ** 
 *** 
  
 
DISCUSSION 
 
 
100 
 
Discussion 
 
Serotonin activates the PI3K/Akt pathway in the hypothalamus 
One of our major findings was that dexfenfluramine injection induces an increase 
in Akt phosphorylation levels in the hypothalamus. Therefore, elevated concentration of 
serotonin in the hypothalamus results in the stimulation of one or more of its numerous 
receptors that trigger signaling cascades involving Akt as one of their downstream 
molecules. As previously reported, several 5-HT receptors are able to initiate the 
activation of Akt in neuronal cells (Cowen, 2007). However, so far there was no evidence 
of this serotonergic effect in the hypothalamus. Serotonin release in the rat 
hypothalamus is well-acknowledged since serotonergic projections from the dorsal 
raphe reach numerous hypothalamic nuclei such as ARC, PVN, VMH and SCN (Azmitia 
and Segal, 1978; Willoughby and Blessing, 1987).   
Hypothalamic action of serotonin plays an important role in the regulation of 
energy homeostasis, mainly by modulating feeding behavior (Donovan and Tecott, 2013; 
Leibowitz et al., 1990). Indeed, a majority of anti-obesity drugs that target the brain 
stimulate the serotonergic system (e.g. dexfenfluramine, norfenfluramine, benfluorex and 
sibutramine). They induce an anorectic effect in animals (Rowland, 1986) and humans 
(Hill and Blundell, 1990). Thus, we hypothesize that the effect of increased serotonin 
levels on food intake could, at least in part, occur through the activation of PI3K/Akt 
signaling pathway in appetite regulating neurons. In addition, regulation of peripheral 
functions such as hepatic insulin sensitivity (Storlien et al., 1989) , hepatic glucose 
production(Picarel-Blanchot et al., 1994) and energy expenditure (Rothwell and Stock, 
1987) by hypothalamic serotonin action, could be possibly initiated via this pathway. 
Akt exerts its kinase activity on a plethora of downstream molecules (Manning 
and Cantley, 2007). One of its substrates involved in hypothalamic energy regulation is 
the Forkhead box protein O1 (FOXO1),  a transcription factor, that down-regulates  
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POMC and up-regulates AgRP in the ARC (Iskandar et al., 2010; Kim et al., 2006; Sasaki 
and Kitamura, 2010).In mice,  5-HT has been reported to induce FOXO1 phosphorylation 
and its translocation from the nucleus to the cytoplasm in the cortex, the hippocampus 
and the striatum in a PI3K/Akt-dependent manner (Polter et al., 2009). In addition, 5-
HT2C receptor activation results in an increase of POMC expression in the ARC (Lam et al., 
2008). However, 5-HT does not alter the expression of hypothalamic AgRP (Li et al., 
2000). Thus, hypothalamic 5-HT2C/PI3K/Akt/FOXO1 pathway could be a possible 
mediator of the 5-HT action in the regulation of energy homeostasis, and this needs 
more investigations to decipher the implicated molecular mechanisms in this regulation. 
Another Akt direct substrate that plays an important role in the control of energy 
homeostasis by acting in the hypothalamus is glycogen synthase kinase-3β (GSK3β) 
(Benzler et al., 2012; Manning and Cantley, 2007). GSK3β inhibitor delivered by i.c.v. 
ameliorates  hypothalamic Akt signaling and glucose tolerance in obese ob/ob mice 
while overexpression of GSK3β in the mediobasal hypothalamus of wild type mice results 
in increased food intake and body weight and aggravates the toxic effects of high-fat 
diet (Benzler et al., 2012). Similar outcomes have been described from mice treated with 
a 5-HT2C receptor agonist (Zhou et al., 2007)  and in 5-HT2C KO/mutant mice respectively 
(Nonogaki et al., 1998; Tecott et al., 1995). 5-HT is a major regulator of GSK3β in the 
brain via the activation of different receptors with equivalent or opposing actions, 
demonstrated with administration of dexfenfluramine, agonists and antagonists of 5-HT 
receptors (1A,2A/2C) (Li et al., 2004). These data suggest that Akt phosphorylation by 5-
HT could play an important role in the overall glucose metabolism and the regulation of 
feeding behavior.  
However, to clearly demonstrate the importance of neural Akt signaling pathway 
in serotonin-dependent energy homeostasis regulation it is necessary to develop Akt 
genetic models with specific KO in the whole brain or distinguished neurons. So far, 
these models are not yet available.  The only Akt genetic models available concern single 
or double global Akt1 or Akt2 knockouts (Hay, 2011). Fortunately, valuable data were 
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obtained from studies with deletions, mutations,  overexpression  or repression of other  
insulin signaling pathway components e.g. receptors (Balthasar et al., 2004; Konner et al., 
2007; Xu et al., 2010), PI3K isoforms (Al-Qassab et al., 2009), PDK (Iskandar et al., 2010),  
TSC1 (Yang et al., 2012), FOXO1 (Fukuda et al., 2008). 
The hypothalamic suprachiasmatic nucleus (SCN) receives robust serotonergic 
innervation, from both dorsal and median raphe, and could account for the response 
that we observed after the administration of dexfenfluramine (Steinbusch, 1981). In 
mammals, this region is considered as the “master clock” due to its crucial role in the 
orchestration of circadian rhythms and hormone secretion (Kriegsfeld and Silver, 2006). 
5-HT is an important regulator of the circadian cycles in the SCN mainly through the 
activation of 5-HT1A and 5-HT7 receptors (Moriya et al., 1998). 5-HT1A agonist 8-OH-
DPAT also induces an increase of melatonin receptors which is reversed by the 
antagonist NAN-190 (Recio et al., 1996). Melatonin receptor stimulation in the rat SCN 
activates the insulin signaling cascade including IRS1, PI3K, Akt and ERK1/2 (Anhe et al., 
2004). Recently, it was demonstrated that when high fat diet feeding is restricted during 
the dark phase in mice, it prevents from diet-induced obesity and insulin resistance, 
suggesting the significance of the circadian rhythms in the regulation of metabolism 
(Hatori et al., 2012).  Direct activation of Akt by 5-HT has not been reported in the SCN. 
However, a similar mechanism to melatonin GPCR could, at least partially, explain the 
increase in Akt phosphorylation that we observed and the impairment of this effect in 
the hypothalamus of diabetic rats. The activation of Akt by 5-HT and insulin using brain 
slices would elucidate the potential role of this pathway in the metabolism regulation by 
the SCN. 
Conclusively, a further dissection of the Akt activation by 5-HT in the 
hypothalamus is necessary for unraveling the roles of this function in the brain nuclei 
mediating serotonergic signals of energy homeostasis and feeding regulation.  
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Serotonin activates PI3K/Akt pathway in SH-SY5Y cells 
In the human neuronal cell line SH-SY5Y, we demonstrated that the serotonin 
induces PI3K-dependent Akt phosphorylation (Papazoglou et al., 2012). Serotonin-
induced activation of Akt has been demonstrated to occur in both neuronal and non-
neuronal cells (Cowen, 2007).  
Cross talk between serotonin and insulin in the SH-SY5Y human neuroblastoma 
cells 
In one of the principal studies we demonstrated the possibility of a cross-talk 
between insulin and serotonin signaling pathways. More precisely in differentiated SH-
SY5Y neuroblastoma cells that underwent insulin-pretreatment in order to mimic insulin 
resistance conditions, serotonin-induced Akt phosphorylation was impaired (Papazoglou 
et al., 2012). In this case, insulin signaling pathways are down-regulated leading to the 
loss of both insulin and leptin responsiveness (Benomar et al., 2005a). On the other hand, 
chronic treatment with 5-HT (Li et al., 2012) or SSRIs (Levkovitz et al., 2007) induces 
insulin resistance in 3T3-L1 cells and rat hepatoma Fao cells respectively.  
Interestingly, we noticed also that when administered together, 5-HT and insulin, 
introduce an additive effect in terms of Akt phosphorylation. This result could be 
explained either by direct interactions of the 5-HT receptors with the insulin receptor as 
mentioned earlier or by 5-HT-induced inhibition of protein kinases that down-regulate 
the insulin signaling pathway. Such protein is GSK3β which is constantly active and 
phosphorylates IRS1 (Liberman and Eldar-Finkelman, 2005) and IRS2 (Sharfi and Eldar-
Finkelman, 2008) on Ser332 and Ser484, 488 respectively, resulting in decreased IRS/PI3K 
association and insulin signaling activation (Summers et al., 1999). 5-HT-induced 
phosphorylation of GSK3β (Polter and Li, 2011) can thus enhance the initiation of insulin 
signals leading to Akt phosphorylation. Equally, insulin-induced GSK3β inhibition (van 
Weeren et al., 1998) can enhance the activation and cell surface deposition of 5-HT1B 
(Chen et al., 2009), one of the receptors found to activate Akt (Leone et al., 2000). In 
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addition, the phosphatase PP2A that dephosphorylates Akt on Thr308 leading to its 
inactivation could also be involved in insulin/5HT cross-talk. Indeed, PP2A is inhibited by 
insulin (Srinivasan and Begum, 1994). On the other hand, 5-HT activates the β-
arrestin2/Src/Akt via 5-HT2A (Schmid and Bohn, 2010), a pathway that is negatively 
regulated by PP2A (Beaulieu et al., 2005). Thus, both sides can improve reciprocal 
sensitivities to activation of this pathway.   
Cross-talk between serotonin and insulin in the hypothalamus of rat 
In my first article we described the attenuated ability of dexfenfluramine to 
activate Akt in the hypothalamus of diabetic GK rats. As stated already, one possible 
interpretation is the transactivation of insulin receptor by 5-HT receptor/s which is 
decreased in the diabetic rat in comparison to the control. 
A direct Akt substrate, FOXO1, is phosphorylated in neurons by administration of 
both insulin (Fukuda et al., 2008)  and dexfenfluramine (Polter et al., 2009) suggesting it 
as a candidate of common action. FOXO1 is rapidly phosphorylated by Akt and 
translocated out of the nucleus (Biggs et al., 1999). In the hypothalamus, nuclear FOXO1 
plays an essential role in the regulation of energy homeostasis (Kim et al., 2012; Ren et 
al., 2012; Ropelle et al., 2009). The regulation of food intake requires the activation of the 
PI3K/Akt/FOXO1 pathway in both POMC (Belgardt et al., 2008; Iskandar et al., 2010) and 
AgRP (Cao et al., 2011) neurons of the ARC. FOXO1 activation in POMC and AgRP 
neurons by 5-HT might explain why animal models with specific deletions of IR, LepRb or 
both receptors in these neurons do not display the predicted phenotype (Balthasar et al., 
2004; Hill et al., 2010; Konner et al., 2007). Mice with specific deletion of 5-HT receptors 
in these neurons are required in order to elucidate if indeed the activation of FOXO1 by 
5-HT is an important step for the control of food intake. 
In the VMN, infusion of serotonin (Fetissov and Meguid, 2010) or mCPP (Hikiji et 
al., 2004) regulates food intake while injection of anti-insulin antibodies induce 
hyperphagia in rats (Strubbe and Mein, 1977). However, mice with selective deletion of 
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insulin receptor from a group of neurons in this area (SF-1) resulted in decreased 
deleterious effects of high fat diet (Klockener et al., 2011). This indicates that other 
neurons are also responsible for the anorexic effect of insulin in this brain region which 
will probably be targeted by 5-HT too. FOXO1 deletion from the same neurons resulted 
in decreased body weight, due to increased energy expenditure, and improved glucose 
tolerance, suggesting that the 5-HT-induced hypophagia in the VMN is not mediated by 
these neurons or this pathway simultaneously (Kim et al., 2012).   
Moreover, mice lacking the serotonin transporter gene (SERT), inferring a chronic 
increase in serotonin levels both centrally and peripherally, exhibited decreased insulin 
sensitivity in peripheral tissues and eventually obesity (Chen et al., 2012). This finding 
suggests that extended activation of the PI3K/Akt pathway by 5-HT in the brain and 
probably peripheral insulin-sensitive tissues, leads to feedback down-regulation of this 
pathway in a manner similar to hyperinsulinemia conditions. This existence of a cross-
talk between serotonin and insulin is also supported by studies evidencing a long-term 
synergistic effect of drugs targeting the serotonergic system, such as sibutramine, and 
the improvement of insulin sensitivity through lifestyle modifications and structured diet 
(Albu et al., 2010; Ryan, 2004). 
Another debatable notion is the co-expression of the receptors in the same 
neurons in order to be able to have an interaction of signaling pathways. As previously 
reported in the arcuate nucleus, the effects of insulin and leptin occur in two distinct 
subpopulations of POMC neurons, demonstrating the lack of crosstalk between these 
hormones in these cells (Williams et al., 2010). Similarly, POMC neurons expressing 5HT2C 
receptors compose a population that does not express leptin receptors increasing this 
way the diversity of properties and function of these anorexigenic neuronal groups 
(Sohn et al., 2011). However, it is yet to be clarified if insulin and 5HT2C receptors are 
located in the same POMC neurons.   
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5-HT, Insulin and Leptin activate the PI3K/Akt/GSK3β in the dentate gyrus  
 In the second study included in this thesis, we demonstrated that 5-HT, insulin 
and leptin stimulation increased the phosphorylation levels of Akt and GSK3β in the 
dentate gyrus of the hippocampus ex vivo on rat brain slices.   
Hippocampal GSK3β inhibition by Ser9 phosphorylation has been shown to be 
directly induced by serotonin (Li et al., 2004), leptin (Garza et al., 2012) and insulin 
(Clodfelder-Miller et al., 2005). Serotonin activates Akt and deactivates GSK3β by 
phosphorylation in rat hippocampal neuron cultures in a PI3K-dependent manner (Chen 
et al., 2007; Cowen et al., 2005). Moreover, administration of dexfenfluramine resulted in 
analogous effects in the hippocampus of mice (Li et al., 2004; Polter et al., 2009). 
However, the anatomical distribution of this activation in the different regions of 
hippocampus has not been demonstrated yet. Only one recent study by Polter and 
colleagues presented the phosphorylated Akt immunoreactivity, in the hippocampus of 
mice, after i.p. injection with the 5-HT1A agonist 8-OH-DPAT but no quantification was 
available in the article. In the same article, levels of phosphorylated GSK3β were also 
displayed and it was reported that immunoreactivity was increased significantly in the 
CA3 and DG regions (Polter et al., 2012). In another study, it was reported that i.p. 
administration of fluoxetine induced an increase of pGSK3β immunostaining in hilar cells 
of the DG (and CA3 pyramidal cells which are not shown) but without any quantification 
given (Li et al., 2007). In both articles, the lack of good magnification and quantification 
respectively, suggested that new experiments need to be done in order to clarify this 
effect and its localization. Similarly, regarding leptin and insulin, there are no studies to 
date that describe quantified changes in the levels of phosphorylation of Akt and/or 
GSK3β. Elmquist and colleagues in a neuroanatomical study detected immunoreactivity 
of LepRb only in the granular area of the DG and in no other hippocampal area. In 
addition, leptin failed to activate the JAK/STAT pathway and it was suggested that the 
effects of leptin in this area should be mediated through another pathway such as the 
PI3K/Akt pathway (Scott et al., 2009). In our study, we clearly demonstrated that the 
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effects of these three hormones on pGSK3β levels occur primarily in neuronal cells of the 
subgranular layer of the DG. pAkt immunoreactivity was more scattered, intense and less 
concentrated in the cell bodies, so we measured the total optical density of the same 
region. Finally, we observed that in the DG, the area with the most elevated numbers of 
pGSK3β was the superior arm suggesting that this area is of great importance for the 
initiation of antidepressant action.  Concluding, this is the first study wherein the 5-HT-, 
insulin-, leptin-induced immunoreactivity of phosphorylated Akt and GSK3β is 
demonstrated so plainly in the rodent hippocampus. 
In order to better characterize the action of 5-HT, insulin and leptin in the 
hippocampus, we used in this study an ex vivo approach on brain slices. This technique 
allowed us to compare the individual sensitivities to each neural modulator and to assess 
any possible correlation/s with physiological and behavioral parameters. Moreover, it 
gives us the facilitation of using each animal as its own control and thus wipes out all the 
variability noise induced by the individuality of each animal. In parallel, it allows us to 
reduce the absolute number of experimental animals, assigning it as a more 
ethologically correct method. In addition, the use of brain slices gives the advantage of 
avoiding indirect actions of the administrated substance via endocrine, paracrine or 
polysynaptic intermediates.  
The fact that cellular insulin resistance and/or leptin resistance induce reciprocally 
decreased sensitivity of these two hormones has been suggested to occur in the brain 
too in our laboratory (Benomar et al., 2005a; Benomar et al., 2005b). Similarly, as 
previously mentioned, we have reported the existence of a cross-talk between insulin 
and serotonin the hypothalamus and in neuronal cells (Papazoglou et al., 2012). Here, we 
also demonstrated that in the subgranular zone of the DG, insulin and leptin resistance 
impairs the activation of the PI3K/Akt/GSK3β pathway by insulin and leptin as expected, 
but also by serotonin, suggesting a cross-talk among all the three of them. This cross-
talk could take place in calretinin-positive cells, as suggested by a double 
immunohistochemical detection of the calcium binding protein and pAkt (Annex 2). The 
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activation of this pathway by 5-HT in the DG may be initiated by the receptor 5-HT1A. 
Indeed, it has been clearly demonstrated, with the use of SSRIs and antagonists or 
agonists of 5-HT1A receptor, that serotonin GSK3β inhibition in the hippocampus occurs 
after stimulation of postsynaptic 5-HT1A (Li et al., 2004; Polter et al., 2012). In addition, 5-
HT1A-mediated inhibition of GSK3β in the hippocampus is blocked by LY294000, 
indicating that this action of serotonin requires the activation of PI3K/Akt pathway 
(Polter et al., 2012). Furthermore, the possibility that the 5-HT-induced phosphorylation 
of Akt in the subgranular neurons depends on PI3K activation and involves 5-HT1A 
receptor is strengthened by preliminary experiments showing that 5-HT-dependent 
phosphorylation of Akt was prevented by a pre-treatment with LY294000, a PI3K 
inhibitor (Annex 3A-C), or NAD 299, a 5-HT1A antagonist (Annex 3AB,D). However, these 
data have to be confirmed in future experiments. 
High-fat diet induces a depressive-like behavior in adult male Wistar rats 
One of our major findings was that high-fat diet consumption by rats not only 
results in obesity and its parallel metabolic comorbidities, but also generates mood 
disturbances. This has been already demonstrated in mice by two studies (Sharma and 
Fulton, 2012; Yamada et al., 2011). Yamada et al. suggested that leptin exerts 
antidepressant action via the stimulation of BDNF expression in the hippocampus, which 
is impaired by a HF diet (Yamada et al., 2011). Besides, Sharma and Fulton demonstrated 
that HF diet alters the expression of several molecules (BDNF, D1R, D2R, ΔFos, phospho-
CREB) in the reward circuit including nucleus accumbens, dorsolateral striatum and 
ventral tegmental area (Sharma and Fulton, 2012). Here we show that a direct effect of 
the HF diet on the neuronal sensitivity to 5-HT, the main neuromodulator of mood, may 
underlie the causal link between metabolic syndrome and depression. More precisely, 
our results indicate that the resistance to leptin and/or insulin induced by a HF diet alters 
5-HT signaling in the subgranular neurons of the dentate gyrus. These neurons are of 
particular interest because they can derive from adult neurogenesis, which is required for 
antidepressants’ action (Santarelli et al., 2003). Interestingly, by detecting 
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immunohistochemically Ki-67, a cell proliferation marker, we found that the HF diet 
decreased the cell proliferation rate in the subgranular zone, and that this effect was 
partially reversed after 6 weeks of food substitution (Annexes 4-5). Furthermore, we 
noticed that the number of Ki-67-positive cells in the subgranular zone negatively 
correlated with the body weight of animals. Taken together, these data reinforce the link 
between metabolic syndrome and adult neurogenesis in our model.  
It is interesting that the nature of nutrition received by an animal can affect its 
psychological state in such a short time. The toxicity of a hypercaloric diet is beyond the 
metabolic defects that were provoking our interest until recently and reaches the 
spectrum of psychological disorders. This problem arises also from the fact that obesity 
is an obvious effect of this diet whereas the depressive–like symptoms are not that 
noticeable and a battery of behavioral test is needed in order to reveal such evidences. 
Likewise, in human beings, obesity and depression are powerfully linked according to 
recent epidemiological and clinical studies (Faith et al., 2011). Equally noteworthy is the 
finding that diet reversion restores not only food intake but also behavioral aspects such 
as depressive-like behavior before reaching the body weight and the glycemia of control 
animals. Moreover, sensitivity to insulin, leptin and serotonin was reestablished too in 
the dentate gyrus of HF/C rats. This is in accordance with a recent study showing that 
diet reversion restores insulin sensitivity and transport in rat brain (Begg et al., 2013). 
Thus, these data suggest that food quality is an important factor not only for the 
introduction of metabolic syndrome but also for the rescue from these effects. 
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Conclusion 
 
In this thesis, we aimed to investigate the consequences of insulin-resistance 
states on the serotonin signaling in the brain. We hypothesized that the PI3K/Akt 
signaling pathway could be shared by both serotonin and insulin in several regions, 
including the hypothalamus, a key center of the control of energy balance, and the 
hippocampus, which is widely involved in the mood regulation. Indeed, these regions 
express high levels of insulin and serotonin receptors. To address this question, we used 
two rat models of insulin resistance, the Goto-Kakizaki rats, which exhibit spontaneous 
type 2 diabetes, and a diet-induced obesity model, which is characterized by joint 
insulin- and leptin-resistance. Moreover, we mimicked insulin-resistance in a human 
neuroblastoma cell line (the SH-SY5Y cells) to further dissect the interactions between 
insulin and serotonin signaling. Interestingly, we evidenced a serotonin-dependent 
activation of the PI3K/Akt pathway in the hypothalamus, the hippocampus and the 
neuroblastoma cells, which was altered in insulin resistant models. These observations 
suggest the existence of a cross-talk between serotonin and insulin in these brain 
regions, which could putatively occur in other areas of the central nervous system too. 
Consequently, an impairment of the serotonergic signaling in the hypothalamus 
due to insulin resistance can exacerbate a number of dysfunctions in the control of 
energy homeostasis. Moreover, hypothalamic impairment of the PI3K/Akt pathway can 
signify many modifications to downstream signaling cascades and result in some of the 
symptoms of type 2 diabetes. Thus, we propose that serotonin-induced Akt activation in 
the various hypothalamic nuclei should be investigated as well as the physiological 
outcomes of this action in different neuronal subgroups. Furthermore, the putative 
serotonin receptors that are responsible for the initiation of the PI3K/Akt pathway 
stimulation in the hypothalamus should be tested. The modulation of other metabolism-
related signaling pathways such as the JAK2/STAT3 pathway should be investigated in 
this region. Finally, a study of downstream targets of Akt, such as FOXO1 and GSK3β, 
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which are key players in the regulation of energy balance, would provide a better 
understanding of the effects of serotonin.  
Likewise, insulin resistance in the high-fat diet model decreased activation of Akt 
and increased the activation of the Akt substrate GSK3β by serotonin in the 
hippocampus. In parallel, this model displayed depressive-like behavior, associated to 
impaired inhibition of GSK3β by serotonin in the dentate gyrus. This observation allows 
us to conclude that the alteration of serotonin signaling in insulin-resistant states 
accounts for the depressive behavior evidenced in these animals. Thus, the cross-talk 
between insulin and serotonin signaling could represent a neurobiological mechanism 
underlying the association between metabolic syndrome and depression. In addition, the 
alteration of the antidepressant serotoninergic effects in diabetic and/or obese models 
should be tested in order to confirm the causal relationship between insulin-resistance 
and depression. Finally, the complete mechanism of this cross-talk remains to be further 
clarified. The type of 5-HT receptor through which PI3K/Akt/GSK3β is stimulated needs 
to be investigated in future studies. In addition, the cellular components that are 
involved in the interaction between serotonin and insulin signaling should be 
characterized.  
Taken the information provided by this thesis all together, we can conclude that a 
cross-talk between serotonin and insulin (and leptin in the DG) signaling pathways exists 
in the hypothalamus and the hippocampus (Figure 16). 
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Figure 16: Cross-talk between serotonin, insulin and leptin in the  
brain through the PI3K/Akt/GSK3β signaling pathway. 
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Annex 1 
 “Extracellular progranulin protects cortical neurons from 
toxic insults by activating survival signaling.” 
Neurobiol Aging. 32(12):2326.e5-16.  
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activating survival signaling
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Abstract
To reduce damage from toxic insults such as glutamate excitotoxicity and oxidative stresses, neurons may deploy an array of neuroprotective
mechanisms. Recent reports show that progranulin (PGRN) gene null or missense mutations leading to inactive protein, are linked to frontotem-
poral lobar degeneration (FTLD), suggesting that survival of certain neuronal populations needs full expression of functional PGRN. Here we show
that extracellular PGRN stimulates phosphorylation/activation of the neuronal MEK/extracellular regulated kinase (ERK)/p90 ribosomal S6 kinase
p90RSK) and phosphatidylinositol-3 kinase (PI3K)/Akt cell survival pathways and rescues cortical neurons from cell death induced by glutamate
r oxidative stress. Pharmacological inhibition of MEK/ERK/p90RSK signaling blocks the PGRN-induced phosphorylation and neuroprotection
gainst glutamate toxicity while inhibition of either MEK/ERK/p90RSK or PI3K/Akt blocks PGRN protection against neurotoxin MPP.
nhibition of both pathways had synergistic effects on PGRN-dependent neuroprotection against MPP toxicity suggesting both pathways
contribute to the neuroprotective activities of PGRN. Extracellular PGRN is remarkably stable in neuronal cultures indicating neuroprotective
activities are associated with full-length protein. Together, our data show that extracellular PGRN acts as a neuroprotective factor and support the
hypothesis that in FTLD reduction of functional brain PGRN results in reduced survival signaling and decreased neuronal protection against
excitotoxicity and oxidative stress leading to accelerated neuronal cell death. That extracellular PGRN has neuroprotective functions against toxic
insults suggests that in vitro preparations of this protein may be used therapeutically.
© 2011 Elsevier Inc. All rights reserved.
Keywords: Progranulin; Neuroprotection; Neurodegeneration; Frontotemporal lobar degeneration; Excitotoxicity; Oxidative stress; ERK; Akt
Abbreviations: BDNF: brain-derived neurotrophic factor; BSA: bovine serum albumin; DMEM: Dulbecco’s modified Eagle’s medium; EDTA: ethylene-
diaminetetraacetic acid; ERK: extracellular signal-regulated kinase; FBS: fetal bovine serum; MEK: MAPK/ERK kinases; MPP: 1-methyl-4-phenylpyri-
inium; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MTT: methylthiazolyldiphenyl-tetrazolium bromide; p-: phosphorylated-; PAGE: polyacryl-
mide gel electrophoresis; PBS: phosphate buffer saline; PC: pheochromocytoma; PCDGF: S6 kinase; SDS: sodium dodecyl sulfate; TAR: trans-activation
esponse element; LDH: lactate dehydrogenase.
www.elsevier.com/locate/neuaging1. Introduction
Progranulin (PGRN), also identified in literature as PC
cell-derived growth factor (PCDGF), acrogranin, or proepi-
* Corresponding author at: Center for Molecular Biology and Genetics of
Neurodegeneration, Departments of Psychiatry and Neuroscience, Mount
Sinai School of Medicine, One Gustave Levy Place, Box 1229, New York,
NY 10029, USA. Tel.: 1 212 241 9380; fax: 1 212 241 0760.E-mail address: nikos.robakis@mssm.edu (N.K. Robakis).
0197-4580/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.neurobiolaging.2011.06.017thelin, is a 593 residue polypeptide that contains a signal
sequence and 7.5 homologous cysteine-rich granulin do-
mains separated by linker sequences (Bateman and Bennett,
2009). Mature PGRN is secreted as a highly glycosylated
1 Current address: McKnight Brain Institute and Department of Neu-
rology, University of Florida College of Medicine, 100 S. Newell Drive,
Gainesville, FL 32611, USA.2 These authors contributed equally to this work.
i
c
B
b
d
a
d
s
2
c
r
d
2
a
l
p
n
l
d
P
s
s
D
c
d
p
t
r
p
o
S
f
m
s
s
a
d
2
c
s
a
2
M
m
r
t
A
2
E
a
o
m
m
O
2326.e6 J. Xu et al. / Neurobiology of Aging 32 (2011) 2326.e5–2326.e16protein of approximately 88–95 kDa that under certain
conditions is processed in the linker regions by elastase or
other proteases to produce biologically active peptides re-
ferred to as granulins or epithelins (Butler et al., 2008;
Kessenbrock et al., 2008; Zhu et al., 2002). Processing of
secreted PGRN is inhibited by the secretory leukocyte pro-
tease inhibitor (SLPI) (Zhu et al., 2002). PGRN and its
derivatives, granulin peptides, are expressed in many tissues
including epithelial cells, the gastrointestinal tract and he-
matopoietic cells (Daniel et al., 2000) and have been asso-
ciated with multiple biological functions such as regulation
of cell growth, cell cycle progression, embryonic develop-
ment, and tissue repair (Bateman and Bennett, 2009; He and
Bateman, 2003). Studies in nonneuronal systems indicate
that PGRN activates cell signaling pathways including the
extracellular regulated kinase (ERK1/2) and the phosphati-
dylinositol-3 kinase (PI3K)/Akt cell survival pathways (He
et al., 2002; Lu and Serrero, 2001; Monami et al., 2006;
Zanocco-Marani et al., 1999). During inflammation and
wound healing, cells secrete the protease elastase that con-
verts PGRN to granulin peptides which may have different,
overlapping, or even opposite functions from the parent
protein (Plowman et al., 1992; Tolkatchev et al., 2008; Zhu
et al., 2002). For example, while full length PGRN acts as
an anti-inflammatory agent, individual granulin peptides
have been shown to stimulate production of proinflamma-
tory cytokines (Zhu et al., 2002). These observations sug-
gest that a carefully maintained equilibrium between PGRN
and granulin peptides may be important to tissue homeo-
stasis.
In the central nervous system (CNS), PGRN is expressed
in both neurons and microglia (Daniel et al., 2000; Matsu-
waki et al., 2011; Ryan et al., 2009). Importantly, recent
genetic studies showed that PGRN mutations are linked to
frontotemporal lobar degeneration (FTLD), a form of de-
mentia characterized by severe neuronal loss in the frontal
and temporal brain regions of adult patients (Baker et al.,
2006; Cruts et al., 2006). These findings renewed interest in
the brain functions of this protein. To date, more than 70
FTLD-linked PGRN mutations have been detected with
most of them causing functional null alleles (Sleegers et al.,
2010). Although the autosomal dominant mode of inheri-
tance of PGRN-linked familial FTLD might suggest gain of
a toxic function, many PGRN mutants encode incomplete or
nactive peptides indicating that PGRN haploinsufficiency
an result in dominant transmission of neurodegeneration.
ased on these findings, decreased plasma PGRN levels has
een proposed as a biomarker for early diagnosis of this
isorder (Finch et al., 2009; Ghidoni et al., 2008; Sleegers et
l., 2009). Besides the null FTLD mutations that lead to
ecreased PGRN levels, there are at least 17 PGRN mis-
ense mutations linked to FTLD families (Gijselinck et al.,
008). The pathogenetic nature of these mutations is less
lear than the PGRN null mutations, but it was recently
eported that at least some missense mutations also cause aecrease in the levels of functional PGRN (Shankaran et al.,
008; Wang et al., 2010). Thus, there is strong evidence that
50% reduction of functional PGRN (haploinsufficiency)
eads to increased neuronal cell death in adult brains sup-
orting the hypothesis that PGRN or its derivatives promote
euronal survival.
Recently, it was reported that secreted PGRN binds sorti-
in and is subsequently delivered to lysosome through en-
ocytosis (Hu et al., 2010). Additional studies suggest that
GRN functions as a neurotrophic agent that may promote
urvival of primary neuronal cultures under conditions of
erum withdrawal (Gao et al., 2010; Ryan et al., 2009; Van
amme et al., 2008). Furthermore, PGRN knockdown de-
reases axonal outgrowth in zebra fish embryos and PGRN-
eficient hippocampal slices are susceptible to glucose de-
rivation (Laird et al., 2010; Yin et al., 2010). Together,
hese reports indicate that PGRN functions as a neu-
otrophic factor and may play important roles in neuronal
hysiology.
That reduction of PGRN leads to increased degeneration
f cortical neurons in the CNS (Bateman and Bennett, 2009;
leegers et al., 2010), raises the possibility this protein
unctions as a neuroprotctive factor. For example, PGRN
ay protect brain neurons from exposure to toxic insults
uch as glutamate-associated excitotoxicity and oxidative
tress. Both processes are associated with neuronal activity
nd have been proposed to play important roles in the
evelopment neurodegenerative disorders (Fatokun et al.,
008; Lau and Tymianski, 2010). Here we show that extra-
ellular PGRN activates neuronal ERK1/2 and Akt cell
urvival signaling and protects neurons from toxic insults
ssociated with neurodegeneration.
. Methods
All chemicals were purchased from Sigma, (St. Louis,
O, USA) except where indicated. All animal experi-
ents were carried out in accordance with the rules and
egulations at the Mount Sinai School of Medicine and
he Biomedical Research Foundation of the Academy of
thens.
.1. Primary neuronal cultures
Cortical neuronal cultures from embryonic brains of
18.5 Wistar rats were prepared as described (Vogiatzi et
l., 2008; Xu et al., 2009). Dissociated cells were plated
nto poly-D-lysine-coated plates at a density of approxi-
ately 60,000/cm2. Cells were maintained in Neurobasal
edium supplemented with 1% B27 (Invitrogen, Eugene,
R, USA), L-glutamine (0.5 mM) and penicillin/streptomy-
cin (1% vol/vol) and used at 8 to 12 days in vitro (DIV).
Under these conditions postmitotic neurons represent more
than 98% of cultured cells (Paxinou et al., 2001).
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Human embryonic kidney (HEK293)T cells stably trans-
fected with vector pcDNA3.1/V5-His-TOPO expressing hu-
man PGRN (provided by Dr. Bateman, McGill University)
were grown in DMEM supplemented with 10% FBS and 0.5
mg/mL G418. At 100% cell confluency, the growth medium
was replaced with fresh DMEM and conditioned media
were collected 48 hours later. An approximately 90-kDa
protein corresponding to glycosylated full-length PGRN
was present in conditioned media of transfected, but not
control, cultures (see Supplementary Fig. 1). His-tagged
PGRN was bound to Ni-NTA agarose beads (Qiagen, Va-
lencia, CA, USA) overnight and collected beads were
washed with PBS containing 10 mM imidazole. PGRN was
then eluted with PBS containing 200 mM imidazole. Silver-
stained SDS gels showed purified full-length PGRN protein
with minimal degradation (Supplementary Fig. 1). For
PGRN stability experiments, PGRN was added to neuronal
cultures for various times as indicated in the text. Elastase
alone (0.3 U/mL) or elastase preincubated with protease
inhibitors for 30 minutes, was added to the media together
with PGRN. At the end of reaction, media were retrieved,
denatured and analyzed by Western blot using anti-V5 tag
antibody (Invitrogen).
2.3. Cell survival assays
Three independent assays were used to measure PGRN-
dependent neuroprotection against glutamate or H2O2 tox-
city as indicated in Results. Hoechst staining assay of
euronal viability (Arndt-Jovin and Jovin, 1977) was deter-
ined according to manufacturer’s instructions (Sigma).
riefly, neurons on poly-D-lysine-coated 24-well plates
ere treated with glutamate for 3 hours, fixed in 4% para-
ormaldehyde for 20 minutes at room temperature and
tained with Hoechst 33342 for 10 minutes. Neurons were
hen observed under a fluorescence microscope on ultravi-
let illumination. Numbers of viable neurons were counted
n 10 fields per well with at least 20 neurons per field.
esults are expressed as percent of control value. MTT cell
iability assay based on the cleavage of yellow tetrazolium
alt MTT to purple formazan (Denizot and Lang, 1986) was
erformed according to manufacturer’s instructions
Sigma). In summary, neurons at 8–12 DIV grown on
oly-D-lysine-coated 96-well plates were treated with toxic
gents for 3 hours and MTT solution (1 mg/mL) was added
o each well. Plates were incubated at 37 °C for 2 hours and
he reaction was terminated by 0.1 N HCl in isopropanol for
hour. Absorbance was then measured at 560 nm by spec-
rophotometric microplate reader (Thermo Scientific, Hud-
on, NH, USA) with background subtraction at 620 nm.
ata are expressed as a percentage of control value. Lactate
ehydrogenase (LDH) release assays (Koh and Choi, 1987),
ere performed using the cytotoxicity Detection Kit plusRoche, New Jersey, NJ, USA) according to manufacturer’snstruction. Results are expressed as the percentage of LDH
elease by nontreated cells.
.4. Assessment of MPP toxicity
Rat cortical neurons cultured on poly-D-lysine-coated
2-well plates for 5 days were treated with 35 nM progranu-
in or bovine serum albumin (BSA) (as control) for 24 hours
rior to addition of 40 M 1-methyl-4-phenylpyridinium
MPP). Twenty-four hours after MPP addition, culture
media were removed and cells were lysed in a detergent
containing solution that enables the quantification of viable
cells by counting the number of intact nuclei in a hemacy-
tometer as described (Farinelli et al., 1998; Stefanis et al.,
1999). Cell counts were performed in triplicate and are
reported as mean  standard error (SE). In experiments
with inhibitors of ERK and Akt MPP treatment was mod-
fied in order to achieve comparable death rates in shorter
ime periods. This was crucial because inhibitors are unsta-
le in culture and may exert nonspecific toxic effects when
sed for longer times. Titration experiments with or without
he inhibitors showed that 4-hour treatments with the com-
ounds was the optimal regimen. Axonal degeneration and
oss of neuritic processes were observed using phase-con-
rast microscopy.
.5. Western blot analysis
Western blot analysis was performed as described (Vo-
iatzi et al., 2008; Xu et al., 2009). Briefly, neurons were
ashed with cold PBS and solubilized in lysis buffer con-
aining 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 2 mM
DTA, 1% Triton X-100, phosphatase and protease inhib-
tor cocktail. Cell lysates were centrifuged at 16,000g for 40
inutes and 30 g of supernatant protein was loaded onto
ach well of 10% SDS-PAGE. The following antibodies
ere used for blotting analysis: anti-PGRN (Zymed, San
rancisco, CA, USA), anti-His (Qiagen), anti-V5 (Invitro-
en), anti-ERK1/2 and pERK Thr202/Tyr204 (Cell Signal-
ng, Beverly, MA, USA), anti-Akt and pAkt Ser473 (Cell
ignaling), anti-p90RSK and pRSK Thr359/Ser363 as well
s pRSK Ser380 (Cell Signaling).
.6. Statistical analysis
All data are expressed as mean  SE. All data were
ormalized to the control (100%) and Levene’s test (em-
edded in SPSS [IBM SPSS statistics, version 19]) was
sed to assess the homogeneity of variance. Accordingly,
tatistical significance of differences was evaluated either
ith paired t test or with one-way analysis of variance
ANOVA) followed by the Student-Newman-Keuls’ test
s post hoc multiple comparisons depending on the sig-
ificance of Levene’s test. p values  0.05 were consid-ered significant.
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3.1. Extracellular PGRN promotes neuronal survival
against toxic insults
Decreased expression of PGRN is associated with in-
creased degeneration of cortical neurons in the CNS (Bate-
man and Bennett, 2009; Sleegers et al., 2010), raising the
possibility this protein functions as a neuroprotective factor.
For example, PGRN may protect brain neuronal populations
from exposure to toxic insults such as glutamate-associated
excitotoxity and oxidative stress. To better understand the
effects of PGRN on neuronal survival, we generated ade-
quate amounts of purified protein using recombinant DNA
technology (see Methods) and asked whether exogenous
PGRN is able to protect rat cortical neuronal cultures from
glutamate toxicity. Treatment of our cultures with 50 M
lutamate reduced neuronal cell viability to 53%  4%,
determined by Hoechst staining, a commonly used protocol
that evaluates cell survival by counting intact cell nuclei
(see Methods). Pretreatment of the neuronal cultures with
recombinant PGRN however, significantly decreased the
glutamate-induced neuronal cell death (73% 5% survival)
(Fig. 1A). The neuroprotective effect of PGRN against
glutamate excitotoxicity was verified by employing the
MTT as well as the LDH assays, both of which are com-
monly used to evaluate cell toxicity and survival (Fig. 1B
and 1C, respectively). Glutamate toxicity, measured by the
amount of LDH released to the culture medium, was re-
duced by PGRN proportionally to its concentration and the
effect of PGRN at 35 nM was comparable to the neuropro-
tective effect induced by brain-derived neurotrophic factor
(BDNF) used as a positive control (Fig. 1C).
To explore whether PGRN is able to protect neurons
from oxidative stress, we treated rat cortical neuronal cul-
tures with hydrogen peroxide (H2O2), a commonly used
reagent for induction of oxidative stress. Addition of 25 M
H2O2 reduced neuronal viability, measured using the MTT
assay, to about 46%  4% of control while preincubation
with 35 nM PGRN significantly protected neurons from
oxidative damage increasing cell survival to approximately
54%  5% of control. BSA used at concentrations similar
to PGRN had no effect on neuronal cell viability (Fig. 1D).
MPP, the active derivative of 1-methyl-4-phenyl-1,2,3,6-
etrahydropyridine (MPTP), is known to exert neuronal tox-
city, in part, by releasing reactive oxygen species (ROS)
rom the mitochondria, as a result of Complex I inhibition
Przedborski and Vila, 2003). To study the PGRN effects
gainst MPP toxicity, we exposed cortical neurons to 40
M MPP for 24 hours and cell survival was evaluated by
ounting intact nuclei. MPP treatment decreased neuronal
survival to 47%  7% of control (Fig. 1E), while pretreat-
ment of these cultures with 35 nM of PGRN restored
survival to nearly control levels (Fig. 1E). In contrast, pre-
treatment with BSA had no effect on the MPP-induced
euronal death (Fig. 1E). Together, these results indicate ihat PGRN has a strong neuroprotective effect against
PP neurotoxicity. Furthermore, our data suggest that the
neuroprotective effect of PGRN depends on the toxic agent.
Thus, there is a significance difference between PGRN and
GluPGRN (p  0.016; Fig. 1A) but no significance be-
tween PGRN and MPP  PGRN (p  0.516; Fig. 1E)
suggesting PGRN almost completely reverses the toxic ef-
fects of MPP but not those of glutamate.
Depending on culture conditions and cell type, secreted
GRN can be processed by extracellular proteases, includ-
ng elastase and proteinase 3, to produce granulin peptides
hat have been proposed to have different functions from the
arent protein (He and Bateman, 2003; Kessenbrock et al.,
008; Zhu et al., 2002). To explore whether neurons secrete
roteases able to process PGRN, purified protein was added
o the medium of rat cortical neuronal cultures, and nonde-
raded PGRN was recovered and analyzed. Fig. 2 shows
hat PGRN is remarkably stable in the culture media of
rimary neurons even after overnight incubation (lanes 2, 3,
, and 9). In contrast, PGRN was quickly degraded in the
resence of exogenous elastase (lanes 4 and 7), a process
nhibited by inhibitors of elastase (lanes 5 and 8). These data
how that exogenous PGRN is not metabolized to any
ignificant extent by primary neuronal cultures in vitro and
uggest that it is unlikely that this protein is processed to
ranulins by cortical neurons in vivo. Furthermore, our
bservations suggest that the neuroprotective properties of
xogenous PGRN are most probably due to full-length
GRN protein rather than granulin peptides.
.2. Extracellular PGRN activates ERK and Akt signaling
n cortical neurons
To elucidate the mechanism by which PGRN exerts its
europrotective function, we examined its effects on cell sig-
aling pathways including those of ERK1/2 and Akt kinases.
oth pathways have been reported to be activated in response
o PGRN in nonneuronal cell lines (He et al., 2002; Lu and
errero, 2001; Monami et al., 2006; Zanocco-Marani et al.,
999) and we reasoned that these may also be activated in
rimary neurons. ERK1/2 and Akt kinases are involved in cell
urvival and activation of the corresponding signaling path-
ays is indicated by phosphorylation of ERK1/2 at residues
hr202/Tyr204 and of Akt at Ser473 (Fayard et al., 2005;
ayne et al., 1991). Fig. 3A shows that PGRN treatment leads
o a rapid increase in the phosphorylation of both ERK1/2 and
kt kinases at residues Thr202/Tyr204 and Ser473, respec-
ively. Interestingly, ERK1/2 phosphorylation peaked earlier
han Akt phosphorylation (Fig. 3A) and because there is no
vidence that Akt is downstream of ERK, these PGRN-in-
uced phosphorylation events may be independent of each
ther suggesting PGRN independently activates both survival
athways. To confirm the specificity of ERK and Akt activa-
ion by PGRN, we employed pharmacological agents that
pecifically target MEK/ERK1/2 and PI3K/Akt kinases. Pre-
ncubation of our cultures with MEK/ERK1/2 inhibitor U0126
d(
o
w
g
f
reatmen
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PI3K/Akt inhibitor LY-294002 abolished PGRN-induced Akt
phosphorylation. MEK/ERK1/2 inhibitor PD98059 and PI3K/
Akt inhibitor wortmannin gave results similar to those obtained
with U0126 and LY-294002 respectively (Fig. 3B and C).
An important downstream effector of ERK1/2 kinase is
the p90 ribosomal S6 kinase (p90RSK) which is activated
Fig. 1. Neuroprotective functions of extracellular progranulin (PGRN). (A)
supplement. At 8–12 days in vitro (DIV), neurons were pretreated with 35
Cells were then fixed with 4% paraformaldehyde and stained with Hoechs
the average of 4 wells. Cell survival was measured by counting the numbe
were calculated from 5 independent experiments. *** p  0.005 compari
(paired t test). (B) Cortical neurons as above cultured in 96-well plates w
(BDNF) for 18 hours followed by 50 M glutamate for 3 hours. Cell viabil
SE) were summarized from 5 independent experiments and in each exper
between cultures treated with glutamate in the presence or absence of PGR
ifferent concentrations (5 nM, 15 nM, or 35 nM) of PGRN or 50 ng/mL
cell-free culture supernatant was collected and LDH release was determine
7 independent experiments. * p  0.05; *** p  0.005 comparing betwee
paired t test). Numbers next to PGRN indicate concentrations in nM. (D)
r BSA for 24 hours followed by 25 M H2O2 treatment overnight. Cell v
ere summarized from 7 independent experiments and in each experim
lutamate-treated cultures in the presence or absence of PGRN (paired t tes
or 24 hours followed by 40 M MPP treatment for 24 hours. Cell surviv
lysis (see Methods). Results (mean  SE) were summarized from 6 ind
glutamate in the presence and absence of PGRN (paired t test). Ctrl, no tupon phosphorylation at residues Thr359/Ser363 andSer380. Following activation p90RSK travels to the nucleus
where it regulates gene expression (Anjum and Blenis,
2008). Fig. 4 shows that treatment of neuronal cultures with
PGRN induced a rapid increase in the phosphorylation of
p90RSK residues Thr359/Ser363 and Ser380. Furthermore,
the PGRN-induced phosphorylation of p90RSK was
blocked by MEK/ERK1/2 inhibitor U0126 indicating that
tical neurons were cultured in 24-well plates in neurobasal media plus B27
RN for 30 minutes followed by 50 M glutamate incubation for 3 hours.
. Five pictures were taken from each well and each condition represented
ls with normal nuclear morphology. Results (mean  standard error [SE])
een cultures treated with glutamate in the presence or absence of PGRN
reated with 35 nM PGRN or 50 ng/mL brain-derived neurotrophic factor
evaluated by MTT assay and normalized to control (ctrl). Results (mean 
ach condition is the average of 6 identical wells. * p  0.05 comparing
DNF (paired t test). (C) Neuronal cultures as above were pretreated with
for 2 hours followed by 50 M of glutamate treatment for 24 hours. The
manufacturer’s instructions. Results (mean  SE) were summarized from
es treated with glutamate in the presence and absence of PGRN or BDNF
tical neuronal cultures as in (B) were pretreated with either 35 nM PGRN
was evaluated as in (B) and normalized to control. Results (mean  SE)
h condition is the average of 6 identical wells. * p  0.05 comparing
eurons in 12-well plates were pretreated with either 35 nM PGRN or BSA
valuated by counting the number of intact nuclei in a hemacytometer after
t experiments. *** p  0.005 comparing between cultures treated with
t; Glu, glutamate.Rat cor
nM PG
t 33342
r of cel
ng betw
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ity was
iment e
N or B
BDNF
d as per
n cultur
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specifically activates the ERK1/2 and Akt cell survival
pathways in neuronal populations and suggest a mechanism
by which PGRN protects neurons from toxic insults.
3.3. Inhibition of ERK1/2 and Akt signaling abolishes the
neuroprotective effects of extracellular PGRN
To examine whether the PGRN-dependent neuroprotec-
tion is indeed mediated by ERK1/2 signaling, we used
MEK/ERK1/2 inhibitor U0126. Fig. 5A shows that the
PGRN-dependent neuronal survival of glutamate-treated
cultures is inhibited by U0126. Consistent with these results
obtained with the cell counting assay, U0126 also blocked
the PGRN-dependent decrease of LDH in the media of
glutamate-treated neuronal cultures (Fig. 5B). U0126 alone
had no effect on cell survival or LDH release (Fig. 5).
Despite the PGRN-induced increase in Akt phosphorylation
however, Akt inhibitors, including LY-294002, had no ef-
fect on the PGRN-dependent neuroprotection (Supplemen-
tary Fig. 2), suggesting that the Akt signaling has little or no
effect on the neuroprotective activities of PGRN against
glutamate toxicity and that MEK/ERK1/2 signaling may be
the main pathway mediating the PGRN neuroprotection
against glutamate excitotoxicity.
We then employed pharmacological inhibitors to ask
whether the ERK1/2 and Akt signaling pathways are
involved in the neuroprotective function of PGRN
against MPP-induced toxicity. Fig. 6A shows that
GRN significantly inhibited the neuronal cell death in-
uced by toxin MPP and this neuroprotective effect was
locked by MEK/ERK1/2 inhibitors including U0126
Fig. 2. Stability of extracellular PGRN in neuronal culture media. Thirty-five
nM of recombinant PGRN (see Methods) was added to neuronal cultures for
various time periods as indicated. Elastase (0.3 U/mL) or mixture of elastase
with protease inhibitor cocktail was added together with PGRN at the same
time. Protease inhibitors were preincubated with elastase for 30 minutes before
adding into culture media. At the end of reaction, 5 L of media were
retrieved, denatured and analyzed by Western blot with anti-V5 tag antibody.
Numbers to the left of the blots indicate the position and size (kDa) of
molecular mass markers. IB, immunoblot.nd PD98059. In contrast to the glutamate-induced tox-city however, the neuroprotective effect of PGRN
gainst MPP toxicity was partially blocked by inhibitors
f the PI3K/Akt cell survival signaling like LY-294002
nd wortmannin (Fig. 6A). These data suggest that both
he ERK1/2 and Akt signaling pathways contribute to the
europrotective activities of PGRN against MPP toxic-
ity. This suggestion is further supported by data that inhibition
of both MEK/ERK1/2 and PI3K/Akt pathways act synergisti-
cally suppressing further the PGRN-dependent neuronal sur-
vival of MPP-treated cultures (Fig. 6A). Furthermore, our
ata indicate that these pathways contribute independently to
he neuroprotective effects of PGRN against MPP toxicity.
Morphological examination of MPP-treated neuronal cul-
ures showed that PGRN decreases degeneration of neuritic
rocesses caused by exposure to MPP and this protective
process is blocked in the presence of inhibitors against both
MEK/ERK1/2 and PI3K/Akt kinases (Fig. 6B). Together, our
results reveal a novel neuroprotective function of PGRN
against toxic agents, such as neurotoxin MPP, and suggest
that this neuroprotective function of PGRN involves activation
of both ERK1/2 and Akt cell survival signaling pathways.
4. Discussion
Progranulin is a secreted protein that has been shown to
play important roles in many biological processes including
inflammation, wound repair, tumorgenesis, and embryonic
development (Bateman and Bennett, 2009). Genetic studies
show that PGRN mutations leading to reduced levels of
functional protein (haploinsufficiency) associate with spe-
cific neurodegeneration in the frontotemporal region of the
brain (Baker et al., 2006; Cruts et al., 2006) suggesting that
PGRN functions in neuronal physiology and survival, and
that specific cortical neuronal populations may need full
protein expression for sustained survival. Indeed, recent
studies indicate that PGRN has neurotrophic activities and
promotes neuronal survival under conditions of serum or
trophic factor withdrawal (Gao et al., 2010; Ryan et al.,
2009; Van Damme et al., 2008). Chronic exposure of brain
neurons to toxic insults such as glutamate excitotoxicity and
oxidative stress however, has been proposed as an important
factor contributing to neurodegenerative disorders charac-
terized by progressive loss of cortical neurons (Fatokun et
al., 2008; Lau and Tymianski, 2010). In addition, these
neurotoxic mechanisms may operate in acute conditions like
stroke where production of oxygen free radicals or hyper-
activity of glutamate receptors may compound neuronal
damage and death. We reason that to avoid or minimize
severe neuronal damage inflicted by toxic insults, neurons
may deploy an array of neuroprotective mechanisms and
that PGRN may be part of this neuronal defense against
toxic insults. Neurons deprived of the full protection of
PGRN, like in FTLD-linked PGRN mutations, may then be
more vulnerable to toxic conditions than neurons that ex-
press normal level of PGRN. Over the years this chronic
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loss and dementia.
PGRN is secreted as a glycosylated polypeptide indicat-
ing that it exerts at least some of its biological functions in
the extracellular space. To explore the neuroprotective
properties of extracellular PGRN and to preserve possible
modifications specific to mammalian cells, we produced and
purified PGRN protein from the culture media of human
embryonic kidney (HEK293) cells overexpressing human
PGRN. Purified protein was then tested in primary neuronal
cultures to ask whether PGRN protects neurons from spe-
Fig. 3. Extracellular PGRN activates extracellular regulated kinase (ERK) a
plates were treated at 8 DIV with 5 nM PGRN for the indicated time period
collected and assayed on Western blots for the proteins indicated to the rig
(B) ERK inhibitors U0126 (U0) and PD98059 (PD; 25 M each) blocked
inutes prior to addition of 5 nM PGRN. Neurons were subsequently coll
ensitometric analysis of the amounts of p-ERK in the presence of inhibito
white bar). Other bars represent phosphoprotein to protein ratios relative
wort; 1 M) or LY-294002 (LY; 25 M) blocks PGRN-induced Akt pho
were collected at indicated times and subjected to SDS-PAGE and Weste
of inhibitors is expressed as p-Akt to Akt ratio as above. Data were obtain
f variance (ANOVA) followed by the Student-Newman-Keuls’ test, com
.001, comparing between cultures treated with PGRN in the presence orcific toxic insults such as glutamate-associated excitotoxic- wity and oxidative stresses evoked by H2O2 and MPP. Our
esults show that extracellular PGRN has potent neuropro-
ective functions mediated, at least in part, by the activation
f neuronal MEK/ERK and PI3K/Akt signal transduction
athways both of which are stimulated by extracellular
GRN.
Under certain conditions including inflammation, PGRN
s processed by specific proteases, such as elastase, to
ranulin peptides proposed to mediate some of the functions
f the parent protein (Plowman et al., 1992; Tolkatchev et
l., 2008; Zhu et al., 2002). We thus examined the extent to
signaling pathways of cortical neurons. (A) Rat cortical neurons in 12-well
ated cultures were used as controls (ctrl). Following incubation, cells were
e blots. A representative blot out of 3 independent experiments is shown.
induced ERK1/2 phosphorylation. Inhibitors were added to cultures for 30
t indicated times and subjected to SDS-PAGE and Western blot as above.
essed as phospho-ERK (p-ERK) to ERK ratio that was set as 1 for control
trol. (C) Phosphatidylinositol-3 kinase (PI3K)/Akt inhibitors wortmannin
lation. Inhibitors and PGRN were added to cultures as in (B) and neurons
as above. Densitometric analysis of the amounts of p-Akt in the presence
3 separate experiments (** p  0.01, *** p  0.001, one-way analysis
etween cultures treated with PGRN and without treatment (ctrl); ### p 
e of inhibitors. Signal variability is indicated by error bars.nd Akt
s. Untre
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2326.e12 J. Xu et al. / Neurobiology of Aging 32 (2011) 2326.e5–2326.e16our neuronal cultures. Our data show that PGRN is remark-
ably stable in the media of neuronal cell cultures as we
failed to detect any significant degradation of PGRN even
after overnight incubation. Media PGRN was completely
degraded by exogenous elastase suggesting neurons secrete
little or no elastase or other PGRN processing enzymes to
the medium (Fig. 2). Our observations support the hypoth-
esis that the detected neuroprotective effects of exogenous
PGRN are due to the full-length protein rather than its
processing products granulins, although they do not exclude
similar or parallel neuronal functions of these peptides. Our
finding also suggests that secreted neuronal PGRN may act
as an autocrine signaling factor to stimulate neuroprotec-
tion. Recent reports identify sortilin as a cell surface binding
partner of PGRN indicating that this protein is internalized
Fig. 4. PGRN stimulates phosphorylation of p90 ribosomal S6 kinase
prepared as above were treated with 5 nM PGRN for the indicated tim
nd at the end of treatment, neurons were lysed and assayed by Western
,2,3 proteins. (B) Cortical neurons were treated as in (A) for the indica
roteins were assayed as above. (C) Densitometric analysis of p90RSK
erformed and analyzed as described in Fig. 3. Data were obtained from
y the Student-Newman-Keuls’ test, comparing between cultures treate
0.001, comparing between cultures treated with PGRN in the presencethrough sortilin-mediated endocytosis (Hu et al., 2010). It is dthus important to explore whether sortilin-mediated endo-
cytosis of PGRN is involved in neuroprotection. Although
our data show no decrease in the levels of extracellular
PGRN, we cannot exclude the possibility that small and
undetectable fractions of PGRN are endocytosed by neuro-
nal cell surface sortilin. Alternatively, sortilin may be
merely a regulator/controller of extracellular PGRN levels
by endocytosis destined for lysosomal degradation, and the
putative receptor for neuronal survival is yet to be found.
Exogenous PGRN rescued cell death in neuronal cultures
subjected to toxic insults such as glutamate, H2O2 and
MPP, but did not significantly alter the survival rate of
ultures in the absence of toxic insults. Interestingly, the
europrotective effects of PGRN, measured by different
ethodologies, were most pronounced against MPP-in-
SK) in primary cortical neuronal cultures. (A) Rat neuronal cultures
ds, in the absence or presence of MEK/ERK inhibitor U0126 (25 M)
for levels of p90RSK phosphorylated at Thr359/Ser363 and total RSK
ods and levels of phoshorylated p90RSK at Ser380 and total RSK 1,2,3
/Ser363 and p90RSK Ser380 in neuronal cultures treated as above was
rate experiments (* p  0.05, ** p  0.01, one-way ANOVA followed
PGRN and without treatment (ctrl); # p  0.05, ## p  0.01, ### p 
sence of U0126.(p90R
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2326.e13J. Xu et al. / Neurobiology of Aging 32 (2011) 2326.e5–2326.e16MPTP, a mitochondrial toxin that induces Parkinsonism in
humans and experimental animals (Przedborski and Vila,
2003). The primary event in MPP-induced cell death is
the production of ROS with subsequent mitochondrial dys-
function and apoptotic death. On the other hand, glutamate-
induced excitotoxicity is receptor-mediated and primarily
involves Ca2 overload followed by ROS generation and
ecrotic death. The differential effect of PGRN on neuronal
urvival of glutamate- or MPP-treated cultures suggests
hat the neuroprotective effect of PGRN may depend on the
pecific cell death mechanism involved in each condition
nd that PGRN may be more potent against apoptotic than
ecrotic death. Furthermore, the potent protective effect of
GRN against the MPP-induced neuronal cell death raises
he possibility that PGRN reduces the release of reactive
xygen species through the inhibition of Complex I in the
itochondria and may affect neurodegenerative mecha-
isms specific to Parkinson’s disease including degenera-
ion of substantia nigra neurons. In this respect, it is of
nterest that PGRN has been proposed to be involved in
arkinson’s disease (Brouwers et al., 2007; Sleegers et al.,
010).
Haploinsufficiency of PGRN in FTLD seems to neces-
itate a delicate mechanism to strictly maintain the extra-
ellular levels of PGRN and recent reports suggest that
Fig. 5. Inhibition of ERK1/2 kinase blocks the neuroprotective function of
extracellular PGRN against glutamate toxicity. (A) Rat cortical cultures of
8–12 DIV were pretreated for 1 hour with U0126 (10 M) and then with
35 nM PGRN for 2 hours, followed by 50 M glutamate for 24 hours.
ells were then fixed, stained and analyzed as described in the legend of
ig. 2A. Results (mean  SE) were summarized from 8 independent
experiments. *** p  0.001 comparing cultures treated with glutamate in
he presence and absence of PGRN (paired t test); ### p  0.001 between
ultures treated with PGRN/glutamate in the presence and absence of
0126 (paired t test). (B) Conditioned media of neuronal cultures prepared
s above was replaced with fresh media and neurons were treated with
0126, PGRN, and glutamate as described above. Cell-free supernatants
ere then collected and LDH release was determined as described in the
egend to Fig. 2C. Results (mean  SE) were summarized from 9 inde-
endent experiments. *** p  0.001 comparing between cultures treated
ith glutamate in the presence and absence of PGRN; ## p  0.01
omparing between cultures treated with PGRN/glutamate in the presence
nd absence of U0126 (paired t test).GRN-deficient hippocampal slices starved for glucose and Exygen show greater cell death compared with wild type
issues (Yin et al., 2010). Our data however, reveal specific
euronal signaling pathways regulated by PGRN. Further-
ore, that increasing extracellular PGRN increases neuro-
rotection indicates that reduction of extracellular PGRN
like in FTLD) will decrease protection from toxic insults.
n addition, our results reveal neuroprotective signaling
timulated by increased PGRN and this signaling should be
ess effective in conditions of reduced PGRN. Taken to-
ether, PGRN is not simply neurotrophic, but also neuro-
rotective against various noxious insults, a property that
ay be important to the survival of nonmitotic neuronal
ells throughout life. Accordingly, compared with wild type
eurons, neurons deficient in PGRN may be more vulnera-
le to chronic insults such as increased activity of the
lutamatergic system or oxidative stress. Similar mecha-
ism may apply to other neurodegenerative diseases as
GRN has been implicated in Alzheimer’s disease (AD),
arkinson’s disease (PD), and amyotrophic lateral sclerosis
ALS) (Sleegers et al., 2010).
Treatment of neuronal cultures with PGRN increased
hosphorylation of Akt and ERK kinases at epitopes asso-
iated with kinase activation and these phosphorylation
vents were sensitive to specific inhibitors of the MEK/
RK1/2 and PI3K/Akt signaling pathways (Fig. 3). To-
ether, these data indicate that exogenous PGRN activates
oth the MEK/ERK1/2 and PI3K/Akt cell survival path-
ays of neuronal cells and suggest that these pathways may
e involved in the PGRN-dependent neuroprotection
gainst toxic insults. A recent report indicates that treatment
f PGRN null (PGRN /) neurons with recombinant
GRN failed to stimulate phosphorylation of ERK1/2
Kleinberger et al., 2010). Presently it is unclear whether
his discrepancy is due to differences in the activities of the
GRN preparations used or to methodological differences
n the protocols employed.
An important downstream effector of ERK1/2 is protein
90 ribosomal S6 kinase (p90RSK) which is phosphory-
ated and activated by ERK in the cytoplasm. Following
ctivation, p90RSK translocates to the nucleus where it
ctivates the serum response factor (SRF). Treatment of
euronal cultures with PGRN leads to the phosphorylation
f specific p90RSK residues, a process inhibited by MEK/
RK inhibitor U0126 (Fig. 4). Because this inhibitor targets
EK, the upstream activator of ERK, our results indicate
hat exogenous PGRN stimulates the neuronal MEK/ERK/
90RSK cell signaling cascade and suggest that stimulation
f this pathway contributes to the neuroprotective properties
f PGRN. Indeed, inhibition of this cascade blocks the
europrotective activity of PGRN against glutamate excito-
oxicity (Fig. 5) further supporting the hypothesis that
GRN-induced activation of the MEK/ERK/p90RSK path-
ay plays important roles in the neuroprotective functions
f this protein. Pharmacological inhibition of the MEK/
RK/p90RSK pathway also blocked the PGRN-dependent
rp
s
M
M
o
2326.e14 J. Xu et al. / Neurobiology of Aging 32 (2011) 2326.e5–2326.e16neuroprotection against neurotoxic agent MPP (Fig. 6). In
addition, inhibition of the PI3K/Akt signaling pathway us-
ing LY-294002 or wortmannin also blocked the PGRN-
dependent neuroprotection against MPP. Interestingly,
combined pharmacological inhibition of both pathways had
a synergistic effect suppressing neuronal survival further
than did inhibition of either pathway alone, suggesting that
both pathways contribute to the neuroprotective activity of
PGRN against MPP. Notably, the PGRN-conferred neu-
oprotection against MPP was also characterized morpho-
logically by sparing of neuronal processes (Fig. 6B). This
PGRN effect is noteworthy especially in a postmitotic sys-
tem of primary cortical neuronal cultures older than 7 DIV
(Baki et al., 2008). Because MPP-induced death is char-
acterized by axonal degeneration which proceeds soma de-
mise (Przedborski and Vila, 2001), our results suggest that
PGRN not only induces neurite outgrowth (Gao et al., 2010;
Ryan et al., 2009; Van Damme et al., 2008) but also pre-
serves integrity of neuronal processes (Fig. 6B). Together,
our results support the hypothesis that reduction of func-
tional PGRN in FTLD patients with PGRN mutations re-
sults in reduced activity of neuronal cell survival pathways
such as MEK/ERK/p90RSK and PI3K/Akt thus decreasing
neuronal protection against chronic toxic insults and leading
to increased rates of neuronal cell death. That PGRN added
to growth media acts as a neuroprotective factor against
toxic insults suggests that cellular expression of PGRN may
not be necessary for neuroprotection and that in vitro prep-
Fig. 6. ERK1/2 and Akt signaling mediate the neuroprotective activities
reincubated with PGRN (15 nM) for 30 minutes with or without inhibito
ignaling as indicated and then treated with 40 M MPP for 4 hours. Follo
were counted in a hemacytometer. Data are presented as mean  SE
Student-Newman-Keuls’ test, *** p  0.001, comparing between cultur
### p  0.001, comparing between MPP and MPPPGRN-treated
PPPGRN in the presence and absence of MEK/ERK1/2 and P
MPPPGRNwortmannin in the presence and absence of PD98059 or U
PP treatment of neuronal cultures caused retraction of neuritic processe
f MPP-treated cultures (MPPPGRN) and this PGRN effect is abolished
respectively. Magnification is 20.arations of this protein may be used therapeutically if ap-propriately delivered to brain tissue, a hypothesis that needs
experimental verification.
FTLD patients with PGRN mutations are often charac-
terized by the presence of misfolded, polyubiquitinated, and
abnormally phosphorylated C-terminal fragments of TAR
DNA-binding protein 43 (TDP-43) in tau-negative and
ubiquitin-positive neuronal inclusion bodies (Neumann et
al., 2006; Sleegers et al., 2010). Recent reports suggest that
neurons derived from PGRN-deficient mice accumulate
phosphorylated TDP-43 fragments (Kleinberger et al.,
2010; Yin et al., 2010) while suppressing PGRN induces a
caspase-dependent cleavage of TDP-43, a process that may
be relevant to accumulation of TDP-43 fragments (Klein-
berger et al., 2010; Zhang et al., 2007). Thus, it would be
important to explore whether the MEK/ERK/p90RSK and
PI3K/Akt signaling pathways are involved in the molecular
modifications that promote formation and translocation of
TDP-43 aggregates. Deciphering the cellular signaling path-
ways that mediate the neuroprotective effects of PGRN and
its involvement in the accumulation of abnormal aggregates
common to the disease may lead to the development of new
therapeutic interventions for the treatment of FTLD and
related disorders.
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Annex 2 
Immunohistochemical detection of pAkt (green) and calretinin (red), a calcium 
binding protein, in the dentate gyrus of rats fed a chow diet after stimulation of 
brain slices with 5-HT (10 µM). Arrowheads indicate the colocalizations 
(orange/yellow). Counterstaining with DAPI (blue). 
Confocal laser scanning. Scale bar: 30 µm. 
CR, calretinin. 
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Annex 3 
Immunohistochemical detection of pAkt (green) in the dentate gyrus of rats fed a 
chow diet after stimulation of brain slices without (A) or with (B-D) 5-HT (10 µM). 
Some 5HT-stimulated slices were pre-treated for 20 min and then co-treated with 
either (C) NAD 299 hydrochloride (10 mM, Tocris bioscience, Bristol, UK), a 5-HT1A 
antagonist, or (D)  LY294002 (10 µM, Sigma), a PI3K inhibitor. Theses pre-
treatments prevented 5-HT from inducing the phosphorylation of Akt. Control 
slices were incubated with buffer alone (A). Corresponding DAPI counterstained 
sections (blue) are shown on the right top corner of each picture. 
Confocal laser scanning. Scale bar: 135 µm. 
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Annex 4 
A 
B 
C 
DAPI/Ki67 
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HF/C 
Immunohistochemical detection of Ki-67 (green), a nuclear cell proliferation  
marker, in the dentate gyrus of rats fed (A) a chow diet (C), (B) a HF diet (HF) or (C) 
HF reversed to chow diet (HF/C). Circles indicate the localizations of Ki-67-positive 
cells on DAPI (blue) counterstained sections. The HF diet decreased the number of 
Ki-67-positive cells in the dentate gyrus of rats, which was partially reversed with 
chow diet restoration. 
Confocal laser scanning. Scale bar: 150 µm. 
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Annex 5 
(A) Quantification of the immunohistochemical detection of Ki-67 in the dentate 
gyrus of rats fed a chow diet (C), a HF diet (HF) or HF reversed to chow diet 
(HF/C). Data are presented as average number of cells over 20-µm-thick dentate 
gyrus. The HF diet decreased the number of Ki-67-positive cells by ~40% in the 
dentate gyrus of rats, which was partially reversed with chow diet restoration. n.s., 
non significant; **p<0.01. (B) Inverse correlation between the average number of 
Ki-67-positive cells and the body weight of rats fed a chow diet (closed boxes), a 
HF diet (open circles) or HF reversed to chow diet (closed circles). p<0.05. 
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Résumé 
L’insuline et la sérotonine (5-HT) sont deux acteurs majeurs du maintien de l’homéostasie 
énergétique, fonction placée sous le contrôle de l’hypothalamus. En ciblant cette région, l’insuline 
remplit de nombreuses fonctions métaboliques via l’activation de la voie PI3K/Akt. La 5-HT 
exercent des effets biologiques similaires mais les voies de signalisation impliquées dans ces 
processus étaient jusqu’alors mal connues. De plus, il avait été démontré que la 5-HT est capable 
d’activer la voie PI3K/Akt/GSK3β dans l’hippocampe, mécanisme sous-tendant potentiellement les 
effets antidépresseurs du neurotransmetteur.  
Les principaux objectifs de cette thèse étaient d’étudier 1/ l’activation de la voie PI3K/Akt 
par la 5-HT dans l’hypothalamus de rats diabétiques (modèle Goto-Kakizaki) et chercher un 
potentiel dialogue avec l’insuline and 2/ les mécanismes sous-tendant l’induction de la dépression 
par une alimentation hyperlipidique, par l’analyse de la phosphorylation d’Akt et GSK3β sous 
l’action de l’insuline, de la leptine et de la 5-HT dans l’hippocampe de rat. 
Ici on montre que 1/ la 5-HT stimule la voie PI3K/Akt dans l’hypothalamus et que la 
phosphorylation d’Akt induite par la 5-HT est atténuée dans des conditions d’insulino-résistance, 
suggérant l’existence d’un dialogue entre les voies de signalisation de l’insuline et de la 5-HT. Par 
ailleurs, nos résultats indiquent qu’une alimentation hyperlipidique induit un comportement 
dépressif réversible chez le rat, qui pourrait impliquer la voie PI3K/Akt/GSK3β dans les neurones 
subgranulaires du gyrus denté.  
La mise en évidence d’un dialogue entre les voies de signalisation de la 5-HT, de la leptine 
et de l’insuline au niveau central enrichit nos connaissances sur le rôle de ces facteurs dans la 
régulation de l’homéostasie énergétique et de l’humeur, et propose un lien moléculaire entre 
diabète de type 2, obésité et dépression.  
 
Abstract 
Insulin and serotonin (5-HT) are two key players in the maintenance of energy homeostasis 
which is controlled by the hypothalamus. In this brain region, insulin mediates numerous metabolic 
effects via the activation of the PI3K/Akt signaling pathway. 5-HT exerts similar biological 
properties by acting in the hypothalamus but the signaling pathways accountable for these effects 
are still unclear. Moreover, it has been reported that 5-HT induces the activation of the PI3K/Akt 
pathway in the hippocampus and the inhibition of GSK3β, suggesting this action as a potential 
mechanism for the antidepressant effects of this neurotransmitter. 
The main objectives of this thesis were to study 1/ the serotonin-induced activation of the 
PI3K/Akt in the hypothalamus of wild type and diabetic rats (Goto-Kakizaki model) and search a 
potential cross-talk with insulin and, 2/ the mechanisms underlying the high-fat diet induced 
depression by investigating the role of the phosphorylation of Akt and GSK3β by 5-HT, insulin and 
leptin in the hippocampus of rats. 
Here, we show that 5-HT triggers the PI3K/Akt signaling pathway in the rat hypothalamus, 
and that this activation is attenuated in insulin-resistant conditions, suggesting a cross-talk 
between insulin and 5-HT. Moreover, we reported that high-fat diet feeding induces a reversible 
depressive-like behavior, which may involve the PI3K/Akt/GSK3β pathway in subgranular neurons 
of the dentate gyrus.  
In conclusion, the activation of the PI3K/Akt pathway and its target GSK3β by 5-HT in the 
hypothalamus and in the dentate gyrus, respectively, can be impaired in insulin-/leptin-resistant 
states, which may underlie a link between metabolic diseases and depression. 
